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Abstract 
Background: Prostate cancer is the most frequently diagnosed cancer in men (40.6% in 2010) in 
Puerto Rico and external beam radiation therapy (EBRT) is the preferred form of treatment for 
one third of newly diagnosed prostate cancer patients in Puerto Rico.  Puerto Ricans often 
experience ethnic disparities in cancer treatments and in their symptom experience. 
Purpose: This study will: (a) describe the trajectory of fatigue among Hispanic Puerto Rican 
men over the course of receiving EBRT for non-metastatic prostate cancer and compare these 
findings with historical data of fatigue symptoms of Caucasian men with prostate cancer during 
EBRT; (b) assess gene expression changes from baseline to midpoint of EBRT using microarray 
technology; and (c) determine the association between changes in genes expression and changes 
in fatigue score from baseline to midpoint of EBRT using an unbiased, hypothesis-generating 
approach.   
Methods: As a prospective exploratory and comparative design study, fatigue was measured 
using the Functional Assessment of Cancer-Therapy –fatigue from 26 Hispanic Puerto Rican 
men who were newly diagnosed with non-metastatic prostate cancer at three time points 
(baseline [prior to EBRT], midpoint [days 19-21], and end of EBRT [days 38-42]).  Whole-blood 
samples also were collected at baseline and at midpoint of EBRT to explore the differential 
expression of genes using microarray.  Functional networks of the differentially expressed genes 
were examined.  Descriptive data were analyzed using t-test, Wilcoxon, and Friedman test for 
repeated measures.  Gene expression data were analyzed using the LIMMA package in R and the 
functional network analysis was conducted using Ingenuity Pathway analysis.   
Findings: Subjects were ages 52-81 with fatigue scores that were unchanged during EBRT 
(baseline= 42.38, SD= 9.34; mid-point=42.11, SD= 8.93, endpoint= 43.04, SD= 8.62); 
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Friedman's test: χ21.20[df, 2], p=.55).  Three hundred seventy-three genes (130 up regulated and 
243 down regulated) were differentially expressed from baseline to mid-point of EBRT 
(FDR<0.01).  The top distinct canonical pathways of the differentially expressed probesets (p< 
0.0001) were: Phospholipase C Signaling, Role of NFAT in Regulation of the Immune 
Response, and Gαq Signaling. 
Conclusions: There were no changes in fatigue scores among Puerto Rican men during EBRT 
for prostate cancer.  However, differentially expressed genes during EBRT suggest activation of 
immune response, which is a mechanism proposed to explain cancer-related fatigue. Further 
investigation is warranted to explain the disparity in fatigue symptoms reporting of Puerto Rican 
men from other ethnicities receiving the same treatment. 
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CHAPTER I 
INTRODUCTION 
Background 
 Prostate cancer is the most frequently diagnosed cancer (40.6% in 2010) in Puerto Rico 
and the leading cause of cancer death among Puerto Rican men.1  Deaths from prostate cancer in 
Puerto Rico are higher than in all racial groups in the U.S.2  Hispanic Puerto Rican men are more 
likely to experience disparities in cancer treatments such as later stage diagnosis requiring more 
intense treatments, worse symptoms and poorer health-related quality of life (HRQOL) when 
compared to Caucasians in the U.S.3-7  Many newly diagnosed prostate cancer patients in Puerto 
Rico are not willing to undergo prostatectomy probably due to fears about possible side effects 
(e.g., chronic urinary incontinence and sexual dysfunction), making external beam radiation 
therapy (EBRT) a more popular option in the management of non-metastatic prostate cancer in 
Puerto Rico.1,4 
 While localized treatments like EBRT have led to higher cure rates,9 up to 71% of 
prostate cancer patients complain of fatigue during EBRT.10-11  This fatigue has been associated 
with alterations in employment, increased hospitalizations, non-compliance with treatment, and 
need for dose adjustment or interruption of treatments.13   Cancer-related fatigue (CRF) is a 
multidimensional symptom also influenced by psychological and physiological factors.  For 
example, a systematic review 8showed that depression was significantly correlated with fatigue 
(95% CI, 0.54 to 0.58) across the 51 studies.  Sleep disturbance also has been found to be 
positively correlated with fatigue and to be a significant predictor of fatigue.12  Similarly, 
increased general fatigue was found to be significantly associated with reduced vigorous physical 
activity and physical activity has been shown to have some benefit in the management of 
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fatigue.13  Nonetheless, recent studies suggest intrinsic biological vulnerabilities may contribute 
to, or explain the higher prevalence of cancer therapy-related symptoms in Hispanics than among 
Caucasians.7,14  The etiology and mechanism underlying this disparity remain elusive. 
 In vivo studies suggest that differential expression of genes activating several 
physiological pathways may explain the mechanisms in CRF.15-19  Recent research using 
microarray technology to identify possible biomarkers of CRF among Caucasian men receiving 
EBRT for non-metastatic prostate cancer found 11 mitochondrial-related differentially expressed 
genes, eight of which showed significant associations with changes in fatigue scores.16  Much 
remains to be investigated, including whether physiological evidence can explain the variability 
of fatigue responses to EBRT between ethnic groups, especially in the Hispanic Puerto Rican  
male population. 
Purpose of Study 
 The proposed study explored changes in self-reported fatigue and gene expression over 
the course of EBRT.  In order to capture the initial inflammatory response of EBRT that peaks at 
midpoint (day 21),15-19 we focused on determining the changes in expression of genes from 
whole blood samples that were collected at baseline and midpoint of EBRT only.  Functional 
networks of the differentially expressed genes were examined using Ingenuity Pathway Analysis 
to determine pathways that may explain the possible physiological mechanisms that influence 
fatigue intensification during EBRT in this population. 
Fatigue during EBRT 
 Cancer-related Fatigue (CRF) is one of the most unpleasant and distressing symptoms 
experienced during treatment.10,13,15   While CRF during EBRT appears unrelated to age, cancer 
stage, radiation dose or fraction, it is frequently associated with racial and ethnic differences, and 
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reduced health related quality of  life (HRQOL) and physical functioning.5-6,10-12  Further, it 
consistently has been reported that the occurrence and severity of CRF in Hispanics, of which 
Puerto Rican men are a sub-group, is higher than in Caucasians.14,20  As an example, Gonzalez 
and colleague’s preliminary study using the Therapy Related Symptom Checklist showed that 
Puerto Rican men with prostate cancer (N=13) have a high prevalence (80%) of fatigue at 
midpoint of EBRT.25  There is increasing recognition that variability in the symptom experience 
of fatigue may be explained by biological causal pathways.21-24  Recently, Saligan and colleagues 
found a significant association between fatigue intensification during EBRT of Caucasian men 
with non-metastatic prostate cancer and up regulation of IFI27 (expression value = 0.774, p < 
0.0001), a gene known to induce apoptosis that is highly induced by IFN-α/β, both cytokines that 
alter immune response.17   Not only is there a need for more exploration examining cultural 
differences in this area, but identifying whether or not there is a difference in physiologic profiles 
associated with fatigue intensification during EBRT among ethnic groups will contribute to 
symptom science.  Moreover, the Puerto Rico Comprehensive Cancer Control Plan (2008-2013)2 
and the 2013 Oncology Nursing Society Research Agenda26 have called for more investigations 
on the incidence and etiology of CRF.  There currently is no optimal pharmacologic therapy and 
little molecular evidence to guide the development of effective therapies for the management of 
CRF. 
Biological basis for EBRT-related Fatigue 
 Gene expression levels are known to change in response to genotoxic stress, such as 
ionizing radiation, including those involved in cell cycle control or deoxyribonucleic acid (DNA) 
repair, as well as transcription factors, growth factors and proteases.27  Furthermore, EBRT 
affects many biological networks, including those related to immune response and mitochondrial 
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function.16-19  Both of these mechanisms can contribute to the development of fatigue that 
compromises the quality of life of cancer survivors.  Therefore, a plausible etiology of EBRT-
related fatigue28 is based on the fact that in addition to reducing cell survival, ionizing radiation 
has been shown to simultaneously induce accelerated biological aging leading to cellular 
senescence containing dysfunctional mitochondria.  Dysfunctional mitochondria can impair 
energy conversion and increase the production of reactive oxygen species (ROS) and reactive 
nitrogen species.  These induce detrimental cellular damage to irradiated cells and cells of 
surrounding normal tissues, causing short and long term bystander effects through cytokine 
stimulation to respond to tissue damage.  Genomic changes could mediate some of the effects of 
ionizing radiation.16-19   Therefore, much interest in how variations in gene expression patterns 
can play a part in the genetic differences among patients that culminate in dissimilarity in the 
experience of fatigue has emerged.  Saligan’s group further observed a significant correlation 
between changes in fatigue and the upregulation of ApoE 18and α-synuclein during EBRT17, 
providing initial evidence of the role of inflammation, mitochondrial dysfunction and neuro-
metabolism behind fatigue intensification during EBRT of Caucasian men with non-metastatic 
prostate cancer.  
 The knowledge base of EBRT-related fatigue is increasing; yet, limited attention has 
been given to provide physiological evidence that can support or explain the disparity in the 
symptom experience of fatigue between ethnic groups, especially in the Hispanic Puerto Rican 
population.  This disparity in symptom experience influences treatment outcomes and clinical 
management of symptoms.5,7   Further investigations are needed. 
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Conceptual Framework 
 The proposed study is informed by an innovative conceptual framework that draws on the 
Theory of Unpleasant Symptoms (TUS).29-30  The TUS includes three major concepts: symptoms, 
influencing factors, and consequences of the symptom experience.29-30  The TUS posits that 
interactions among the influencing factors (physiological, psychological, and situational) affect 
predispositions to manifest unpleasant symptoms.  
Figure 1. Model of Gene Expression and Cancer-Related Fatigue 
Cancer Patient Under EBRT  Gene Expression   Self-reported Fatigue 
  
 
FatigueFatigue 
 
 
 
 
 
  
 
 In this model (see Figure 1), an interrelationship exists between psychological, 
physiological, and situational factors and the fatigue experience during EBRT.  A variety of 
physiological factors have been postulated to be associated with RT-associated fatigue.  
Radiation-related damage induces cellular responses manifested by differential expression of 
genes influencing activities of physiologic pathways including mitochondrial function, 
inflammation, DNA damage processing, inhibition of signal transduction, mutations, cell-cycle 
arrest, genomic instability, carcinogenesis, and cell death.28  Changes in levels of gene expression 
are posited as interacting with, and affecting, the person’s predisposition to develop fatigue 
Alteration in inflamma- 
tory response & 
energy production 
Physiologic Factors 
e.g. Age, Body Max 
Index (BMI)  
Psychological Factors 
e.g. Depression 
Situational Factors 
e.g. employment 
status 
Physiologic factor: 
Differential Expression of 
genes influencing 
inflammation and 
mitochondrial function 
 
 
         
Fatigue 
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through alterations in the individual’s response to inflammation and oxidative stress.  Evidence 
of CRF associated with age, body mass index (BMI) > 25 kg/m2, sleep disturbance, and low 
energy expenditures, have been reported and CRF impairment may be partially induced or 
exacerbated by psychological factors such as depression.12,31-34  Age, BMI, sleep disturbance, 
energy expenditure,  and depression will be measured in this study.  Other physiological factors 
(e.g. disease/treatment characteristics) and situational factors (e.g. employment status) will be 
used to describe the sample since such factors have not been associated with CRF.35-36  Changes 
in gene expression and self-reported CRF will be the main variables to be investigated. 
Study Aims 
The proposed study specific aims are: 
1: To describe the trajectory of fatigue among Hispanic Puerto Rican men over the course of 
receiving EBRT for non-metastatic prostate cancer and compare these findings with historical 
data of fatigue symptoms of Caucasian men with prostate cancer during EBRT. 
2: To assess gene expression changes from baseline to midpoint of EBRT among Hispanic 
Puerto Rican men receiving EBRT for non-metastatic prostate cancer. 
3: To determine the association between changes in genes expression with changes in fatigue 
scores from baseline to midpoint of EBRT in Hispanic Puerto Rican men with non-metastatic 
PC. 
Design Overview 
 In this study, the clinical fatigue experienced by 26 Hispanic Puerto Rican men over the 
course of EBRT was described.  Then, an unbiased hypothesis-generating approach using a 
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microarray platform was conducted to explore the differential expression of genes from 
peripheral whole blood RNA collected from Hispanic Puerto Rican men at baseline and at 
midpoint of EBRT.  Because of resource limitations and in order to capture the initial 
inflammatory response of EBRT which peaks at midpoint (day 21), only levels of the 
differentially expressed genes at baseline and at midpoint of EBRT were determined.  Functional 
networks of the differentially expressed genes were examined using Ingenuity Pathway Analysis 
to determine pathways that may explain the possible physiological mechanisms that influence 
fatigue intensification during EBRT in this population.   
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CHAPTER II 
 
Review of the Literature 
 The review of the literature begins with a detailed discussion of prostate cancer including 
pathophysiology, prevalence and mortality rates, and treatment options.  A general background 
on Puerto Rico (P.R.) including cancer mortality and morbidity rates as well as cancer disparities 
is presented next.  This is followed by a discussion of the concept of the symptom experience of 
Cancer Related Fatigue (CRF), including the pathophysiology and genetic basis for External 
Beam Radiation Therapy (EBRT)-associated fatigue, gene expression and prostate cancer 
therapeutics.  The Theory of Unpleasant Symptoms (TUS) will guide the consideration of 
variables discussed that may influence the person's ability to perceive CRF symptoms.  Finally, 
biological vulnerability to disparity in the experience of symptoms will be discussed.  
Prostate Cancer 
 The prostate is a gland that is part of the male reproductive system.  A healthy adult 
prostate measures approximately 4 x 2 x 3 centimeters and weighs about 20–25 grams (the size 
of a "large walnut"); size is usually maintained constant throughout early adulthood and the 
middle years.37  Figure 2 shows the location of the prostate that is beneath the bladder, 
surrounding the upper part of the urethra, and in front of the rectum.  The main function of the 
prostate is to produce the seminal fluid, a white substance that nourishes and transports the 
sperm.  
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 Figure 2. Location of the Prostate 
 
  
 
 
In order to keep the prostate healthy and functioning properly gland cells grow, divide, 
and produce more cells as needed; however, if this process goes wrong, gland cells become 
abnormal and form more cells in an uncontrolled manner.38   These extra cells form a tumor 
(mass of tissue) that can be benign (not cancerous) or malignant (cancerous).38   Therefore, 
prostate cancer is a disease in which malignant (cancer) cells divide without control or order in 
the tissues of the prostate gland.  Prostate cancer is considered an adenocarcinoma.39   Most 
common symptoms of prostate cancer are dysuria, incontinence, weight loss, and weakness.  
While the exact etiology of prostate cancer is unknown, specific genes (proto-oncogenes and 
oncogenes) have been implicated in the “transformation” of cells to a state of hyper-proliferation 
(cancer), which disrupts the cooperation among cells of an organ or tissue.40  In addition, 
according to the National Cancer Institute (NCI, n.d.), age (with nearly 63 percent of prostate 
cancer cases occurring in men over age of 65), race (more common in African American men 
than in any other group of men in the U.S.), and family history of prostate cancer can affect the 
risk of developing prostate cancer.  Further, high-fat diets also may increase risk (eating fats 
raises the amount of testosterone in the body, and testosterone speeds the growth of prostate 
cancer).39   Current diagnostic criteria for prostate cancer are based on findings from a physical 
examination, laboratory test and tissue examination.   
Source: 
http://photobucket.com/images/prostate%2
0cancer#/images/prostate%20cancer?page
=1&_suid=1390846511045063268358055
3763 
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Prostate Cancer prevalence and mortality 
 Prostate cancer is a curable disease but it is still one of the most prevalent malignancies 
worldwide.41   For example, in the United States (U.S.) prostate cancer is the most frequent 
cancer (after skin cancer) among men; it is estimated that about 238,590 new cases will be 
diagnosed in 2013.41   One out of six men will be diagnosed with prostate cancer in their lifetime 
and more than two million men are living with prostate cancer.  The five-year survival rate of 
non-metastatic prostate cancer approaches 100%; however, for metastatic diseases it is less than 
29%.41   In fact, prostate cancer is the second leading cause of cancer death in U.S. men.  
Approximately 29,720 deaths among U.S. men in 2013 were caused by prostate cancer and about 
1 in 36 men will die of prostate cancer in their lifetime.  Prostate cancer also is the most common 
male cancer in P.R. with 8,510 new cases diagnosed during the period of 2004-2006.2 
Treatment Options for Non-metastatic Prostate Cancer 
 
 Current treatment for non-metastatic prostate cancer is based on the National 
Comprehensive Cancer Network guidelines.42   Non-metastatic prostate cancer treatment consists 
of one or a combination of the following: active surveillance, surgery, hormonal therapy, and 
radiation therapy.  According to the National Comprehensive Cancer Network (2012),42 active 
surveillance involves actively monitoring the course of the disease to be able to intervene if 
cancer progresses, and is commonly appropriate for men with very low risk cancers (e.g., older 
men with low-grade tumors and low Prostate Specific Antigen (PSA) readings) or for patients 
with short life expectancy (< 10 years).  Advantages of active surveillance mentioned in the 
literature are: avoidance of common side effects of unnecessary cancer treatments, maintenance 
of good health related quality of life (HRQOL), and reducing risk of unnecessary cancer 
treatments of small or indolent cancers.  However, limitations include: (a) the need for periodic 
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biopsies, (b) chance of missed opportunity for cure, (c) risk of progression and/or metastases 
then requiring more aggressive treatments, (d) experiencing worse symptoms, and (e) feelings of 
anxiety and uncertainty about the natural history of prostate cancer.  If active surveillance is 
selected, Digital Rectal Examination and PSA's every three to six months are recommended, as 
are repeated prostate biopsy within six month of diagnoses if Digital Rectal Examination 
changes or PSA increases. 
 Surgery also is recommended to treat clinically non-metastatic prostate cancer.  An 
appropriate and most common surgical option for non-metastatic prostate cancer is the radical 
prostatectomy in which the cancerous prostate is removed from the body.  It is a recommended 
treatment for patients in which the prostate completely can be excised surgically, with life 
expectancy > 10 years, and with no serious co-morbid conditions that could contraindicate the 
surgery.  Overall, it is a highly favorable treatment for younger men with early stage disease, 
although it also may be performed in advanced stages of the disease for symptom relief.  It can 
be performed via open, laparoscopic or robotic technique.  Frequently reported side effects are: 
blood loss, urinary incontinence, loss of erection, and anastomotic stricture.   
 Additionally, androgen deprivation therapy (ADT), or hormonal therapy, is prescribed to 
reduce the amount of testosterone that prostate cancer needs to grow.  It is recommended for 
prostate cancer patients with intermediate or high risk of recurrence or local metastasis.42  ADT 
consists of once-a-month intramuscular injection of luteinizing hormone-releasing hormone 
agonist (e.g., leuprolide, goserelin), with bicalutamine that then has the effect of reducing 
testosterone.43  While hormone therapy cannot cure cancer, it has been shown to delay its growth 
and to provide relief.  The use of neoadjuvant ADT highly is recommended to be given before, 
during and/or after radiation therapy (RT) since studies have shown this improves survival.44-45  
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In addition, ADT given at a high dose of 150mg alone has been shown to delay recurrence of 
disease, but not to improve survival.  Commonly reported side effects of ADT are: osteoporosis, 
obesity, insulin resistance, alteration in lipids, and increased risk for diabetes, and cardiovascular 
diseases.42,46   
 Traditional RT for prostate cancer has caused concern among health care providers and 
patients with respect to targeting normal tissues as well as the prostate and about the 
development of more treatment-related symptoms.  Recent advances in image-based radiation 
treatment planning and localization led to the development of the external beam radiation 
therapy (EBRT).9  The purpose of EBRT is to deliver high-energy rays to tumors to inhibit cell 
proliferation or to induce apoptotic cell death in vitro and inhibit tumor growth in vivo by 
damaging the DNA--the molecule inside cells that carries genetic information.47  Ionizing 
radiation kills cells by inducing DNA damage such as base damage, single strand breaks, double-
strand breaks, and DNA-inter-strand cross-links.48  As a result of EBRT, cancer cells whose 
DNA is damaged beyond repair stop dividing or die and then are eliminated by the body’s 
natural processes.  The linear accelerator used for EBRT allows radiation beams to be delivered 
from any angle and shape to the contour of the tumor.  Linear accelerators use electricity to form 
a stream of fast-moving subatomic particles that create the high-energy radiation used to treat 
cancer.  Overall, it is considered a safe state-of-the-art radiation technology that enables targeting 
a tumor more accurately with higher doses of radiation, while minimizing damage to healthy 
tissue and nearby organs and diminishing the risk of side effects typically associated with 
radiation treatment.   
Gray (Gy) is the unit of measure used for radiation doses for cancer treatment; it is a 
measure of the amount of radiation energy absorbed by one kilogram of human tissue.  EBRT 
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requires patients to travel to the hospital or an outpatient facility up to five days a week for six to 
eight weeks to receive once-daily treatment or fractions.  Most non-metastatic prostate cancer 
patients are prescribed an approximate dose escalating to a total daily dose of 75.6 to 79 Gy of a 
3-dimensional conformal and intensity modulated radiation therapy in conventional 36-41 
fractions (6 to 8weeks), approximately at 2.0 Gy per day.42  With respect to outcomes, the 
American College of Radiology reported 83% of adjusted 5-year rates of no evidence of disease 
with a dose of 75 to 80 Gy.9  The occurrence of gastrointestinal or genitourinary toxicities or 
sexual dysfunction are the most common side effects of EBRT reported.9 
 Another type of RT is brachytherapy that consists of surgical implantation of radioactive 
pellets inside the prostate.  Over time, the pellets radiate the prostate and surrounding tissue, 
killing the cancer cells.  Permanent monotherapy of low-dose rate brachytherapy (145 Gy for 
125-Iodine and 125 Gy for 103-Palladium) also is indicated for men with low-risk cancers.  
Common side effects of brachytherapy reported by patients with a very large or very small 
prostate are symptoms of bladder outlet obstruction.  For patients that have a history of 
transurethral resection of the prostate, brachytherapy may not be appropriate as implantation may 
be more difficult and they are at increased risk for the side effect of bladder outlet obstruction.  
Overall, it has been reported that RT generally creates fewer side effects than surgery.9,46  For this 
reason, it is often the preferred treatment for older men. 
 Finally, even though active surveillance, radical prostatectomy, brachytherapy, and RT 
historically have been considered treatment options for early-stage prostate cancer patients, the 
most recent consensus from an expert panel on Radiation Oncology9 recognized EBRT as the 
standard of care.  Recent studies on outcomes after treatment for non-metastatic prostate cancer 
have shown no benefit of prostatectomy or brachytherapy over EBRT when assessing freedom 
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from biochemical failure, progression-free survival, and performance functional status.9,49  As a 
result, EBRT is one of the most popular treatment choices among non-metastatic prostate cancer  
patients, including Puerto Ricans (PR's),1who are not candidates or are not willing to undergo 
prostatectomy surgery often due to its well-known symptom occurrence of chronic urinary 
incontinence and sexual dysfunction.  
Background on Puerto Rico 
General Background  
The island of Puerto Rico is the smallest and the most eastern of the Caribbean Greater 
Antilles.  Puerto Rico is a geographically diverse archipelago of 78 municipalities with a total 
land area of 3,424.56 square miles.50  The 1940s were significant to Puerto Rico for shifting its 
economy from agricultural to industrial.  Since the establishment in 1952 of the Commonwealth 
of Puerto Rico as the primary basis of governance, Puerto Rico has been politically and 
economically linked to the U.S.  A Governor in Puerto Rico is the highest political figure elected 
in Puerto Rico.  Island Puerto Ricans do not vote for the president of the U.S.  Puerto Rico has its 
own government with Executive, Legislative, and Judicial branches.  A Resident Commissioner 
represents Puerto Rico in the U.S. House of Representatives having a voice but no vote.  As part 
of the Commonwealth benefits, Puerto Ricans have U.S. citizenship, allowing them to visit, 
work, and live in the U.S. freely.50   Puerto Ricans have their own sports teams to represent them 
during international and worldwide events.  In addition, the official language of Puerto Rico is 
Spanish but English is taught as a second language.  Puerto Rico remains essentially a Hispanic 
country with its own cultural heritage, yet, with certain characteristics due to U.S. influence.50 
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Similar to the education system, Puerto Rico has public, private, and privatized public 
health care institutions.  According to the American Hospital Directory,51 in 2012 Puerto Rico 
had 54 hospitals, 8 of them public (including privatized public hospitals) and 46 private 
hospitals.  Puerto Rico also has a Veterans Administration Hospital that provides services to 
members of the armed forces.  The government also covers part of the cost for employee’s 
private insurance.  It was estimated in 2008 that 1,500,000 patients had Reforma (Government 
Health Insurance), 1,500,000 had a commercial plan, 380,000 had Medicare advantage, 200,000 
had Medicare alone, and 400,000 were uninsured.52 
With respect to cancer care, when "Reforma" patients are diagnosed and receive cancer 
treatment, they qualify for a special coverage that gives them easy access to medications and 
services without the need for pre-authorizations.  Private insurance patients with limited cancer 
coverage can apply for “Reforma” coverage.  The Puerto Rico Medical Center as well as the 
American Cancer Society, Puerto Rico chapter, provides initial cancer care free of cost to those 
who are temporarily without insurance while waiting for permanent health insurance plans. 
There are two specialized cancer adult hospitals in Puerto Rico.  One is located in Centro 
Medico in the metropolitan area of San Juan and one is in Ponce in the southern part of the 
island.  Both are private hospitals that accept “Reforma” insurance.  Also, other general hospitals 
in Puerto Rico offer oncology services.  R.T. as well as chemotherapy services are available in 
several places all over the island, including at oncologist’s private offices.  There are three Bone 
marrow units (2 for pediatrics and 1 for adults) available in Puerto Rico, but these programs only 
offer autologous transplant.  Reasons for that may be: limited availability of donors, lack of trust 
in the system, delay in referrals, and limited qualified personnel.  Puerto Ricans also consider 
visiting U.S. hospitals for cancer evaluation and treatments.  The University of Puerto Rico 
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Cancer Center planned the construction of a hospital (started in 2014) with clinics and 
specialized services for all the adult and pediatric oncology population of Puerto Rico.   
Clinical oncology research has not been abundant, in part due to the limited number of 
doctoral programs available in the island to prepare researchers.  As an example, the University 
of Puerto Rico started the first Doctor in Nursing Science Program in Fall 2012.  Nonetheless, 
there is hope on the way for pediatric and adult patients to receive comprehensive oncology 
cancer care in the University of Puerto Rico Cancer Center as well as the option to participate in 
clinical trials once the new hospital is completed.   
Demography  
According to the U.S. Census, in 2010, the population of Puerto Rico was 3,979,000, and 
it is expected to increase to 4,024,000 in 2015.53   The median age was 38.2 years. Twenty-eight 
percent of the population was under 20 years and 14.1% was 65 years and older.  The population 
ranges from 434,373 in San Juan, the Capital City, to 1,868 in the island-municipality of 
Culebra.  In Puerto Rico, nearly two-thirds of the population lives in the northeastern half of the 
island.  Twenty-nine percent of Puerto Ricans live in rural areas. The less populated 
municipalities are located in the mountainous center of the island.53 
A significant emigration of P.R.'s to the U.S. took place between 1947 and 1957, mainly 
due to unemployment and economic reasons.  An estimated 4.7 million Hispanics of Puerto 
Rican origin reside in one of the 50 states and the District of Columbia.  New York has the 
largest population of Puerto Ricans, with approximately 1.1 million residing there.  Since the 
1990’s Puerto Ricans also have been immigrating to other states such as Illinois, Texas, Florida, 
Pennsylvania, New Jersey, and Massachusetts.  The U.S. 2010 census reported that Puerto 
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Ricans are the second largest population of Hispanic origin living in the U.S. accounting for 
9.2% of the U.S. Hispanic population.   Special attention to this population is warranted, 
especially since they are most likely to have larger tumors and/or metastatic disease at the time 
of diagnosis and to experience health disparities.54 
The Burden of Cancer in Puerto Rico 
 Cancer is the second leading cause of death in the island, despite cancer-control efforts 
that have been present in Puerto Rico for decades.  In 2004, 16.6% of all deaths were due to 
cancer.2   Cancer, which is more predominant in men than in women,2 touches almost every 
family.  It was estimated that 54,000 patients were living with cancer from 1987 to 2006.2  When 
addressing causes of cancer in Puerto Rican adults, Torres-Cintron, et al.54 encouraged 
considering causes such as: tobacco use, western diet, physical inactivity, hormonal and 
reproductive factors, and occupational exposures.  Improvements in prevention, detection, and 
treatment of cancers have led to a decline in the overall cancer death rate in Puerto Rico.2  
Despite these declines, patients with cancer continue to require significant resources.  
 Although monetary valuation of cancer does not take into account the psychological and 
emotional costs that cancer patients, their families, and society undergo due to the illness, 
accurate measuring of the economic impact of cancer is important for efficiently allocating 
limited resources with the aim to reduce the burden of cancer in society.  According to the Pan 
American Health Organization, 20.4% of the Gross National Product in Puerto Rico corresponds 
to health expenditures.2    This is twice as much as in Europe and 25% more than in the U.S. 
Therefore, cancer care is extremely costly and represents a great burden for Puerto Rico.  For 
example, in 2006, the total cost of cancer in Puerto Rico was estimated to be $1.2 billion, 
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including direct costs of about $396.8 million and indirect costs of about $805.5 million.  In 
addition, cancer was the leading cause of years of potential life lost for both sexes combined, 
accounting for more than 12% of all premature mortality in Puerto Rico in the year 2005.2 
 Prostate Cancer is the most common type of cancer for men in Puerto Rico accounting 
for 40.6% of male cancer cases in 2010.1  Alarming is the fact that according to the Cancer 
Control Plan,2 each year approximately 2,050 men are diagnosed with invasive prostate cancer.  
It is also the leading cause of cancer deaths.  The median age was 69 years at diagnosis for 
cancer of the prostate from 1999-2003, while the median age at death for men with cancer of the 
prostate was 82 years.  Although the incidence rate of prostate cancer (127.9 per 100,000 men 
per year ) is lower in Puerto Rico than among U.S. Caucasians (169.2 per 100,000 men per year), 
after African Americans, mortality in Puerto Rico is much higher among Puerto Rican men with 
prostate cancer than in all other racial groups in the U.S. (U.S. Blacks 65.1%, Puerto Rico 
36.4%, U.S. Caucasians 26.7%, U.S. Hispanics 22.1%, U.S. American Indian 18.3%, and U.S. 
Asian 11.8%; rates are per year and per 100,000 and age-adjusted to the 2000 U.S. standard 
population).2  Taken together, these data suggest Puerto Ricans may experience an ethnic health 
disparity. 
Cancer Disparities 
 Cancer disparities are adverse differences in cancer risks, incidence, prevalence, 
mortality, survivorship, and HRQOL among specific population groups.2,55-57  Heath disparities 
may be attributed to multiple factors such as: acculturation, language barriers, changes in 
lifestyle, genetic factors, limited information available on genetic predisposition, lower 
education, health literacy, elevated exposures to environmental risk, limited access to health care, 
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lack of health insurance, economical reasons, lack of knowledge about services, limited access 
to, and use of, cancer screening programs, and complex socio-cultural and geographic factors.56-7 
 The risk of developing cancer, and the risk of dying from cancer, increases with age. 
More than half (55%) of all cancers diagnosed in Puerto Rico occurs in people aged 65 years and 
older.2  Individuals in this age group make up 13% of the population.  This age group is estimated 
to increase to in 20257 2 and 68.6% of all cancer deaths in 2004 occurred in this age group.2 
 Disparities in health care persist for racial and ethnic minorities in the U.S.  Numerous 
explanations for the observed ethnic disparity of Hispanic Puerto Ricans cancer incidence, 
treatment, and outcomes have been offered.  Torres-Cintron et al.55 suggests that disparities in the 
incidence and mortality of selected cancer in Puerto Rico might be explained by socio-economic 
position.  Indeed, data on cancer incidence and mortality from the Puerto Rico Central Cancer 
Registry and data from the U.S. Census 2000 of the Puerto Rico socioeconomic position revealed 
that the incidence and mortality of cancer in Puerto Rico varied by socioeconomic position.55  
That is, municipalities with the lowest socioeconomic position (in the central region of Puerto 
Rico) had higher incidence and mortality from cancer of the esophagus and stomach.  However, 
incidence for breast, colorectal, and prostate cancer were higher for areas of higher 
socioeconomic position (municipalities around the San Juan metropolitan area).  An explanation 
provided by the authors of these differences in incidence was that this may be related to lack of 
access and use of medical care in the lowest socioeconomic position municipalities where fewer 
clinical facilities are available, which in turn may lead to under-diagnosis.  Thus, the higher 
incidence of the most common cancers types in Puerto Rico in areas of higher socioeconomic 
position may be because there is better access to health care facilities (e.g., where most 
mammography facilities, urologist, and gastroenterologist are located).55 
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 Other explanations include excess weight and physical inactivity among Puerto Ricans.  
Data from the Puerto Rico Heath Department show that in 2002, 58% of the population in Puerto 
Rico was overweight and 20% obese.2  An estimated 20 to 30% of the most common cancers in 
Puerto Rico may be related to excess weight and physical inactivity.2  Negron et al.58 
retrospectively reviewed the medical charts of 400 Puerto Ricans that underwent treatment for 
prostate cancer from 2003-2005, specifically to investigate if being overweight could affect both 
the sensitivity of the PSA as a diagnostic tool and the progression of prostate cancer among 
Puerto Ricans.  Indeed, the percentage of overweight and obese men that had positive prostate 
biopsies was 35.38% and 38.13%, respectively, as compared to 26.15% of normal weight men.  
In addition, patients with BMI > 25 kg/m2 had a 2.63 fold higher risk of metastases than those 
with normal BMI.  Thus, obesity may play a role in explaining the higher mortality from prostate 
cancer in Puerto Rico.  Similarly, Crespo et al.59 studied the association between physical 
activity and prostate cancer mortality in Puerto Ricans with a randomly selected sample of 9,824 
men age 35 to 79 years old who were followed for mortality for 40 years from 1965 until 2002.  
Physical activity did not predict prostate cancer mortality, the risk of prostate cancer mortality 
for the lowest level of physical activity was an OR of 0.99 (95% CI = 0.64-1.55).     
 One study examined how Hispanics (N = 54) treated with EBRT for non-metastatic PC 
differ from their Caucasian (N = 810) counterparts on biochemical disease-free survival.60  These 
investigators found that Hispanic men treated with EBRT for non-metastatic PC tend to present 
with unfavorable disease characteristics (higher PSA levels and Gleason scores) and larger 
tumors, and showed a poorer 5-year biochemical disease-free survival rate compared to their 
Caucasian counterparts.  Hispanic patients failed to reach a post-treatment PSA nadir of 
<1ng/mL seen in the other groups.  This difference in survival was not explained by differences 
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in follow-up.  Moreover, more advanced disease requires more radical treatments that may lead 
to increased treatment-induced symptoms among of Hispanics.  In contrast, Ho et al.61 while 
examining cancer rates among island Puerto Ricans, mainland Puerto Ricans, and U.S. non-
Hispanic whites from 1998-2002, found several statistical differences.  They found that in men, 
from 9 of 14 cancer sites incidence rates were lowest among island Puerto Ricans, followed by 
mainland Puerto Ricans and non-Hispanic whites.  The disparity between the two Puerto Rican 
populations was greater than that between mainland Puerto Ricans and non-Hispanic whites.  
Overall, cancer incidence rates for all sites combined were 34% lower in island Puerto Ricans 
compared to mainland Puerto Ricans and 16% lower in mainland Puerto Ricans compared to 
non-Hispanic whites (both p values < 0.05). 
 In sum, culture may influence many aspects of health and healthcare.  However, while 
examining health disparities, several authors addressed the importance of taking into 
consideration that Hispanics are diverse in nationality, exposed to different environmental 
factors, genetic composition, socio-economic status, culture, health outcomes, and, in the case of 
migration, patterns among subgroups are different.61  With some exceptions, it appears that 
evidence exists that supports the notion that Hispanic oncology patients in general may be at a 
disadvantage as they have more socio-economic difficulties, and present with unfavorable 
disease characteristics and poorer 5-year biochemical disease-free survival rates when compared 
with non-Hispanic Caucasian counterparts in the U.S.  What is not known is whether a second 
gap or source of disparities relates to issues of etiology, such as if there is a genetic 
predisposition and whether Hispanics also may perceive more treatment-related symptoms (pain, 
depression, and fatigue), self-image concerns, and worse HRQOL.62   This study will contribute 
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to knowledge about the interplay between genetics and symptom experience of prostate cancer 
patients in Puerto Rico. 
The symptom experience of cancer-related fatigue 
A symptom is a phenomenon subjectively experienced by individuals in situations of 
health and illness.63  Although the patient's symptom experience has been the subject of study in 
chronic diseases, cancer is of special interest to nursing as research studies have demonstrated 
that symptom distress predicts survival, quality of life, and treatment intolerance in oncology 
patients.63  Therefore, patients’ decision to select treatment for non-metastatic prostate cancer is 
influenced by both understanding which treatment provides better survival and which treatment 
results in fewer negative symptoms.49  The Hispanic culture sees male sexual dysfunction as a 
loss of sexuality and a public embarrassment.62  Approximately one third of newly-diagnosed 
prostate cancer patients in Puerto Rico prefer EBRT.49  We can speculate that this is due to the 
likelihood of impotence and erectile dysfunction accompanying  prostatectomy.  However, 
EBRT is not without side effects.11 
   Fatigue is one of many common side effects of radiation therapy (RT) that significantly 
affects HRQOL.10,13   It often has been reported as one of the most distressing symptoms prostate 
cancer patients face during treatment.64  The National Comprehensive Cancer Network defines 
CRF as a “distressing, persistent, subjective sense of tiredness or exhaustion related to cancer or 
cancer treatment that is not proportional to recent activity and that interferes with usual 
functioning.”65  While the literature on CRF during treatment reports that approximately 80% of 
cancer patients will experience CRF during treatment, and 30% will continue to experience 
fatigue after a treatment regimen is completed, there is evidence of variability in the symptom 
experience of CRF.64   For example, research has shown that some cancer patients report some 
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degree of fatigue prior to the initiation of RT, and that the peak of fatigue during RT was at week 
five.66  In contrast, two recent studies of patient assessments of CRF after RT showed 
significantly more fatigue only at the end of treatment that remained high at 6.5 weeks of follow 
up.67-68   In addition, some patients persist with fatigue years after termination of RT.11,36  
However, others have reported that RT precipitated minimal to no fatigue in cancer survivors.69 
 There is no singular explanation as to why this variability in the symptom experience of 
CRF during RT exists.  Some factors that have been proposed to contribute to or explain this 
variability include cancer diagnoses and patient's characteristics, such as age and gender, and or 
treatment characteristics.  Hickok et al.70 found that prostate cancer patients were least likely to 
report fatigue at the beginning of treatment when compared to breast, head and neck, lung, 
alimentary tract, or brain carcinomas.  However, the Hickok et al.70 study found that neither 
gender, age, nor total dose of RT predicted significant variance in fatigue severity.  Other 
significant proposed explanations are: genetic vulnerability, hormonal and other biological 
factors; cognitive coping styles; and the occurrence of clusters of symptoms related to the disease 
itself or treatments that may interact and potentiate (synergistic) CRF.6,13  Hence, researchers 
recommend a systematic and comprehensive evaluation of CRF during RT and as part of routine 
follow-ups.13 
 Research on the symptom of CRF has helped better understand the morbidity patients 
experience with RT for prostate cancer.  Fatigue also could persist or recur after completed RT. 
Vordermark et al.71investigated the occurrence of chronic fatigue after RT using103 prostate 
cancer patients who were 2.1 years (median) after treatment.  They found that 18.7% of patients 
reported that they were still suffering from severe fatigue, and that the symptom of fatigue 
significantly correlated with the occurrence of other symptoms such as fecal incontinence and 
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urinary symptoms, but not with age.  Lastly, not only is CRF a problem for patients, it also 
places a significant burden on the health care system.   
 Another important gap in the CRF literature is that no studies have examined the 
trajectory of fatigue, specifically among Hispanic or Puerto Rican men during EBRT, despite the 
availability of a valid and reliable Spanish version of the FACT-F.72  Not only is there a need for 
more culturally competent research in this area, but because the Puerto Rican oncology 
population does not always report symptoms, risking under-assessment and under-
management,2,69 the need for this study is particularly necessary.   
 Lastly, despite the high prevalence of CRF and the associated negative outcomes, the 
etiology and mechanism underlying the symptom remain elusive.  Both the Puerto Rico 
Comprehensive Cancer Control Plan (2008-2012) 2 and the 2013 Oncology Nursing Society 
Research Agenda 26 have called for more investigations on the incidence and etiology of CRF.  
While there is currently no optimal pharmacologic therapy and scant molecular evidence to 
guide the development of effective therapies for the management of CRF,15 several 
pathophysiological mechanisms have been proposed to explain the development of CRF.  
Among these is the pro-inflammatory hypothesis. 
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Pathophysiological mechanism of Cancer -Related Fatigue 
Figure 3. The Association of Inflammatory Markers and Cancer-Related Fatigue.   
   
Source: Saligan, L. N., & Kim, H. S. 15  (Used with permission.) 
 The pathophysiological model underlying Figure 3 is based on the pro-inflammatory 
hypothesis that suggests that bio-behavioral symptoms such as CRF may be caused by 
dysregulated inflammation brought on by cancer or cancer treatments.15  Briefly, it is well 
documented that the insult of cancer therapy (e.g., RT)25 and certain types of malignancies (e.g., 
breast)73 activate an initiation of molecular and cellular responses, including the expression of 
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pro-inflammatory cytokines (e.g., IL-1β, and IL-6)75-76 by white blood cells (especially 
monocytes).15  Specifically, it has been found that RT in prostate cancer patients causes elevation 
in circulating levels of pro-inflammatory cytokines (IFN-γ, interleukin-6 (IL-6).68  In addition, 
cytokines such as IL-6 and tumor necrosis factor alpha (TNF-α) have been found to be associated 
with fatigue severity in breast cancer survivors, and interleukin-1 receptor antagonist (IL-1ra)76-77 
and c-reactive protein in testicular cancer survivors.77  Based on this body of evidence, Saligan 
and Kim15 proposed that "the systemic experience of CRF may be related to the interaction of 
pro-inflammatory cytokines and immune cells with brain structures that migrate through a 
disrupted blood-brain barrier altered by pro-inflammatory cytokines-related activities” (p. 16).  
However, EBRT affects many biological networks, including those related to immune response 
and mitochondrial function.  Although the exact etiology of CRF has not been established, some 
evidence proposes that genetics plays an important role in the impairment of oxygen supply that 
is associated with EBRT-associated Fatigue.     
Biological Basis of EBRT-associated Fatigue 
 A biological basis for EBRT-associated fatigue proposes that ionizing radiation induces 
multiple cellular and biological effects by direct interaction with DNA or through the formation 
of hydroxyl radicals, leading to genetic instability.  DNA damage induces a cellular response that 
includes activation of a number of signal transduction cascades.78  There is increasing evidence 
that CRF is the result of ionizing radiation-induced gene expression in which respiratory function 
declines and the production of the ROS in the mitochondria increases, causing accumulation of 
mitochondrial DNA (mtDNA) mutation and oxidative damage and culminating in the metabolic 
shift from mitochondrial respiration to the glycolysis pathway for supply of adenosine 
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triphosphate (ATP).27 Since ATP is the energy source for cells, a reduction in ATP production 
can lead to an individual feeling fatigued.16 
 Further, mammalian genes are known to be activated in response to genotoxic stress such 
as ionizing radiation, including genes involved in cell cycle control or DNA repair, as well as 
transcription factors, growth factors and proteases.27  As previously addressed, EBRT affects 
many biological networks, including those related to immune response and mitochondrial 
function.16-19   Both of these mechanisms can contribute to the development of fatigue that 
compromises the HRQOL of cancer survivors.  Therefore, a plausible etiology of EBRT-related 
fatigue is based on the fact that, in addition to reducing cell survival, ionizing radiation has been 
shown to simultaneously induce accelerated biological aging leading to cellular senescence 
containing dysfunctional mitochondria.  In mammalian cells, mitochondria are the organelles 
that generate the majority of energy in the form of ATP via the respiratory chain and the 
oxidative phosphorylation system.27-28   An estimated 90% of tissue oxygen and 1-5% of the 
mitochondria are metabolized to form the reactive ROS under normal physiological conditions 
and mitochondria are the immediate targets of the ROS generated in the organelles of tissue 
cells.  Dysfunctional mitochondria are associated with the decline in mitochondrial respiratory 
function, excess production of the ROS and reactive nitrogen species, increase in the oxidative 
damage to mtDNA, lipids, and proteins in mitochondria, and altered expression of genes 
involved in intermediary metabolism.  ROS may cause oxidative damage and mutations of 
mtDNA and alteration of the expression of several genes in tissues and senescent cells.27,79-80 
Thus, dysfunctional mitochondria induces detrimental cellular damage, not only to irradiated 
cells but also to cells of surrounding normal tissues that receive signals from irradiated cells, 
causing short and long term bystander effects through cytokine stimulation to respond to tissue 
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damage.  Genomic changes could mediate some of the effects of ionizing radiation.  Therefore, 
to identify the molecular events associated with CRF, a number of investigators have used 
microarray technologies to examine how variations in gene expression patterns can play a part, 
or have a role, in the establishment of aberrant gene expression patterns among patients that 
culminate in experiencing severe fatigue.15-17 
Microarrays 
 The Human Genome Project, first described in 1995,81 provided the sequence of the 
entire human genome.  Briefly, genes are contained in the DNA of the organism.82  The 
mechanism by which proteins are produced from their corresponding genes is a two-step 
process: first, the transcription of a gene from DNA into a temporary molecule known as RNA; 
and second, translation, the step in which a protein is built using the RNA messenger as a 
blueprint. While there are other more recently developed high-throughput technologies, such as 
RNA sequencing, that use the capabilities of next-generation sequencing to reveal a snapshot of 
RNA presence and quantity from a genome at a given moment in time, the present study focused 
on microarray technology.81   Gene expression microarray is a high-throughput technique that 
allows one to monitor the transcription step (DNA-to-RNA).82  Molla, Waddell, Page, and 
Shavlik (n.d.)82 summarized the process of conducting and interpreting gene-expression 
microarray.  They explained that gene expression microarray provides extensive capabilities for 
the simultaneous assessment of the RNA expression levels of a large number of genes 
(thousands) or the whole genome.  These authors further explained that the benefit of measuring 
RNA expression levels versus measuring the protein-production rate directly is that the latter is 
currently very difficult and impractical on a large scale.  In contrast, researchers can measure the 
expression level of various genes by estimating the amount of RNA for that gene that is currently 
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present in the cell.  In addition, since the cell degrades RNA very quickly, this level will 
accurately reflect the rate at which the cell is producing the corresponding protein. Figure 4 
illustrates a summary of the process of gene expression microarrays. 
Figure 4. Process Involved in Gene Expression Microarrays 
 
Source: http://www.fastol.com/~renkwitz/microarray_chips.htm 
 
 
 The process involved in gene expression microarrays, illustrated in Figure 4, shows that 
in order to find the expression level of a group of genes, one labels the RNA from a cell or a 
group of cells and spreads the RNA across a chip that contains probes for the genes of interest.  
For a human,82  a single chip can only contain a subset of the genes present in the genome.  To 
determine which genes are turned on and which are turned off in a given cell, when researchers 
runs a microarray experiment, an optical scanner records the fluorescence-intensity values (the 
level of fluorescence at each spot on the gene chip).  Active genes generate a very bright 
fluorescent area; conversely, no fluorescence indicates that the gene is inactive.81  
 For the purpose of this study, the Affymetrix microarray technology was employed.83  
Affymetrix is a widely used RNA microarray that consists of pre-synthesized or in-situ 
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synthesized oligonucleotide microarrays manufactured by Affymetrix (Cupertino, CA).  The 
manufacturers developed a computer chip of oligonucleotides of approximately 25 base pairs in 
length that are synthesized in such a way that unique nucleotides representing a single human 
gene are present at every location on the array.83  Microarray experiments can provide 
information on gene expression levels ranging from a few hundred to 50,000 independent genes 
for each sample, requiring biological, mathematical, and statistical skills to address and interpret 
the large volume of the obtained data.  Even though several software algorithms have been 
developed to assist with the analysis of large datasets, they all rely on identifying genes that vary 
most over the samples being studied, with the purpose of discarding genes that do not change 
over experiments.83  Microarrays have allowed an unbiased assessment of gene expression in the 
tissue of prostate cancer patients which has led to the identification of a large number of genes 
differentially expressed in response to treatments. 
Some limitations of the use of microarray technology also have been identified, namely: 
heterogeneity (quantitative analysis of genes, while very informative, may not always be able to 
unravel the entire complexity of tissue damage processes in vivo); inability to detect isoforms 
and exon levels unless a specific kit is used to measure relative expression; and, cross platform 
comparison (there are inconsistencies between commercially-available platforms, making it 
difficult to compare independently obtained data sets addressing the same biological 
mechanism).  Lastly, microarrays have been used to investigate the complex molecular response 
of cells and tissues to radiation, including identifying possible targets to ameliorate EBRT side 
effects such as fatigue.79-80   The proposed study focused on a possible biological basis of EBRT-
associated fatigue. 
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Gene Expression and Cancer-Related-Fatigue 
 In vivo studies have shown that differential expression of genes activating several 
physiological pathways may explain the mechanisms behind CRF.15-19  Only a few studies have 
explored the use of genomic technologies to identify possible biomarkers of CRF,15 and most of 
these studies have been conducted on White breast cancer survivors.15, 84  In their review of 
literature on the association between immunogenomic markers and CRF, Saligan and Kim15 
identified seven cross-sectional studies exploring associations between levels of fatigue and 
genomic markers; all showed significant associations.  However, important limitations in the 
interpretation of these findings were identified.  These included use of small samples with further 
stratification of the samples during analysis, cancer patients and their family members for the 
analysis, and uncorrected p-values on the reported associations.  Recently, Saligan et al. 16-19 
found that changes in fatigue scores from Caucasian men with prostate cancer were significantly 
associated with changes in expression of mitochondrial-related and inflammation-related genes 
during EBRT.   
 Saligan and colleagues also described the relationships between mitochondria-related 
gene expression changes and self-reported fatigue in prostate cancer patients receiving EBRT16.  
These investigators used a prospective, exploratory, and repeated-measures design.  Self-report 
answers to the Piper Fatigue Scale and peripheral whole-blood samples were collected with the 
PAX gene blood RA tubes from 15 patients at seven time points.   Baseline data were compared 
against 15 healthy controls.  The "Human Mitochondria RT2 Profiler PCR Array" was used to 
identify differential regulation of genes involved in mitochondrial biogenesis and function.  With 
respect to fatigue scores, these investigator found that: (a) there was no significant difference in 
fatigue scores at baseline between patients and controls; (b) the mean fatigue score increased at 
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midpoint of EBRT, slightly decreased at completion of EBRT, and remained slightly elevated at 
30 days after EBRT; and (c) there was a significant change in fatigue score over time during 
EBRT compared with baseline data.  Moreover, Saligan et al, selected human mitochondria 
genes to study based on the hypothesis that the inability of mitochondria to produce a sufficient 
supply of energy in the form of ATP plays a major role in fatigue.  Their findings supported this 
hypothesis by demonstrating that 11 genes associated with mitochondrial integrity and functions 
critical to ATP production were differentially expressed during EBRT.  Eight of the 11 
differentially expressed genes were significantly associated with fatigue scores (AIFM2, BCL-2, 
FIS1, IMMP2L, MSTO1, SLC25A23, SLC25A37, and SLC25A4).  Furthermore, three of the 
eleven genes (BCL2L1, FIS1, SLC25A37) were greater than 2.5-fold up-regulated.  These 
investigators also found that genes (n = 25) with more than a 1.5-fold change in expression at p< 
.05 at days 14, 21, 42, or 72,were associated with cellular pathways that were related to 
morphology, assembly, or cell organization, and cell death.  Thus, this study provides beginning 
empirical evidence that genes related to mitochondria and their function are differently expressed 
during EBRT and are potentially associated with changes in fatigue symptoms among non-
metastatic prostate cancer patients.  The authors recommend a prospective study to validate and 
confirm the relationship of the expressed mitochondria-related genes with other co-variates to be 
included, such as race, disease severity, depression, and symptom clusters; and that studies with 
a larger sample size are needed.16 
 Saligan and colleagues17 also investigated the association of CRF with the activation of 
inflammatory and neuroprotective pathways among 16 patients (Caucasians n=10, African 
American n=2, and others n=4) receiving EBRT for non-metastatic prostate cancer.  Fatigue 
scores from the Piper Fatigue Scale and blood samples were obtained at baseline (prior to EBRT, 
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D0), at one hour following initiation of EBRT (D1), on day 7 (D7), on day 14 (D14), at midpoint 
(days 19-21, D21), at completion (days 38-42, D42), and four weeks post-EBRT (days 68-72, 
D72).  Gene expression profiling was determined using microarray analysis from peripheral 
blood.  Compared to baseline mean scores, the mean fatigue scores significantly increased at 
midpoint of EBRT, continued to be significantly higher than baseline at end of treatment, but 
showed no significant difference from baseline to one month post-EBRT.   Notably, the most 
differentially-expressed genes were related to inflammation, namely: interferon alpha-inducible 
protein 27 [IFI27], B-lymphocyte antigen CD20 [MS4A1], Ig mu chain C region [IGHM], C-C 
chemokine receptor type 7 [CCR7]), and iron synthesis (carbonic anhydrase 1 [CA1], 
hemoglobin subunit delta [HBD], hemoglobin subunit gamma-2 [HBG2], alpha hemoglobin 
stabilizing protein [AHSP], iron-sulfur cluster assembly 1 homolog [ISCA1]), and Alpha 
synuclein[ SNCA].  The investigators selected SNCA for further investigation in this study 
because of its known association with neuro-inflammation.  The SNCA gene had a 2.95-fold 
change in expression at D21 compared to baseline.  Also, fatigue scores were significantly 
correlated with SNCA gene expression on D14 and plasma α-synuclein concentrations on D42 of 
EBRT.  The canonical pathways related to SNCA over-expression during EBRT using Ingenuity 
Pathway Analysis (Ingenuity® Systems, www.ingenuity.com, Redwood City, CA) revealed 
pathways related to 14-3-3-mediated signaling, which is involved in phosphorylation-dependent 
protein-protein interactions.  One possible explanation provided by the researchers on over-
expression of the SNCA in this study was that it may be a part of a physiologic response to 
intrinsic or external stressors (i.e., EBRT), a-synuclein is expressed to serve as a neuro-protective 
mechanism against subsequent insults.  If so, neuro-inflammatory mechanisms may play a role in 
the development of fatigue.  Another important contribution of this study was the need to explore 
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the role of other networks involved in fatigue development, such as inflammation and iron-
synthesis, because genes related to these networks were observed to be differentially expressed 
in this study.17 
 Saligan’s group19 further studied the association between interferon alpha-inducible 
protein 27 (IFI27) expressions and fatigue intensification during EBRT for non-metastatic PC.  
IFI27 was the most up-regulated gene (expression value = 0.774, p<0.0001) among fatigued men 
with non-metastatic prostate cancer receiving EBRT in their earlier study.17  Peripheral blood 
samples and fatigue scores were collected at three time points (prior to EBRT, at midpoint, and 
at completion of EBRT) from 40 Caucasian men (20 on EBRT and 20 matched control 
participants on active surveillance).  Participants answered the Piper Fatigue Scale and the 
PROMIS fatigue scale.  Compared to baseline, the mean fatigue scores increased significantly at 
midpoint and at completion of EBRT; however, there was no significance difference from 
midpoint to completion of EBRT.  Significant up-regulation of IFI27 was confirmed, both via 
qPCR and (ELISA) techniques.  Also, IFI27 gene expression increased significantly from 
baseline to midpoint and from baseline to completion of EBRT.  Lastly, a significant association 
between changes in fatigue scores and IFI27 gene expression using qRT-PCR was observed 
from baseline to midpoint of EBRT, but no significant association was obtained between changes 
in fatigue scores and changes in the expression of IFI27 gene from baseline to completion of 
EBRT.  One possible explanation for up-regulation of IFI27 gene provided by the authors was 
that IFI27 is a gene known to induce apoptosis, and is highly induced by interferon-alpha (IFN-
α) and interferon beta (IFN-β), both cytokines that alter immune-response through activities of T 
lymphocytes and dendritic cells.   
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Thus, in order to capture the initial inflammatory response of EBRT, which peaks at 
midpoint (day 21),15-19 in this study only levels of the differentially expressed genes at baseline 
and at midpoint of EBRT will be determined.   Saligan and colleagues’ findings raise important 
information that fatigue intensification during EBRT may be a bystander response to radiation, 
and that this bystander response could be explained by up-regulation of IFI27, which influences 
mitochondrial function and immune response, both of which are mechanisms proposed to be 
related to CRF.  A genome-wide profiling using Microarray technology also has been useful in 
identifying genes associated with Interferon-alpha (IFN-alpha)-induced depression and fatigue 
treatment for chronic hepatitis C (e.g., OAS2 (ILMN_2248970)85 and chemo-radiation for head 
and neck cancer- induced oral mucositis (e.g., Dkk-1 gene).86 
 Unlike prior investigations that used microarray technology, Saligan and colleagues18 
used proteomics technology (measures protein directly) to investigate changes in expression of 
novel proteins with changes in fatigue symptoms of 12 non-metastatic prostate cancer patients 
receiving EBRT.  Proteomic-based techniques have been used to identify several biomarkers to 
diagnose many types of cancer and identify proteins that are involved in the underlying 
mechanisms of symptoms.  Fatigue scores were measured using the FACT-F sub-scale.  
Measures were collected at baseline (before EBRT) and at midpoint (Day 21) of EBRT. 
Depleted sera from both time points were analyzed using two-dimensional difference gel 
electrophoresis, and up-/down-regulated proteins were identified using liquid chromatography-
tandem mass spectrometry.  Western blot analyses confirmed the protein changes observed. In 
this study participants were grouped according to the change in fatigue scores during EBRT: the 
high fatigue (HF) group were those with increasing fatigue symptoms (declining FACT-F scores) 
from baseline to midpoint of EBRT, and the no fatigue (NF) group were those with no change or 
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with increasing FACT-F scores between the two time points.  Results showed that three subjects 
were categorized in the NF group (mean FACT-F score: baseline = 44.0 + 8.0, midpoint= 46.3 + 
9.0) and nine subjects were categorized in the HF group (mean FACT-F score: baseline = 47.0 + 
2.9, midpoint = 36.8 + 5.5).  No differences in hematocrit levels and depression scores were 
noted between the fatigue groups at baseline and at midpoint of EBRT.  The most notable 
finding was that ApoA1 levels were observed to be higher in HF subjects than in NF subjects at 
baseline, more significantly at midpoint of EBRT than at end of treatment.  Two important 
explanations were provided.18  First, apolipoproteins play a role in cholesterol transport and have 
been associated with several important physiological processes necessary to maintain immune 
regulation and cognition.  Second, the apolipoproteins also have been found to be involved in 
proteolytic breakdown of beta-amyloid in Alzheimer’s disease.  The authors explained that 
increasing ApoA1 protein levels during EBRT in this clinical population is a protective 
mechanism to counter an acute stressor to prevent neuro-inflammation and decrease 
proinflammatory cytokine production, in which both mechanisms were suggested to potentially 
explain the etiology behind RF.  An additional finding was that TTR or pre-albumin (a negative 
acute phase protein; its concentration is reduced during acute phase response) was the third 
differentially expressed protein, whose level was observed to be lower in HF subjects than in NF 
subjects.  In other words, the differential expression of these three proteins (ApoE, ApoA1, TTR) 
is linked with two mechanisms that are known to be associated with CRF: neuro-inflammation 
and proinflammatory cytokine production.18 
 Lastly, genome-wide profiling using microarray technology also has been useful for 
identifying genes associated with Interferon-alpha (IFN-alpha)-induced depression and fatigue 
treatment for chronic hepatitis C (e.g,.OAS2 (ILMN_2248970)85and chemo-radiation for head 
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and neck cancer-induced oral mucositis (e.g,.Dkk-1 gene).86  Genome researchers also have 
evaluated the associations of single nucleotide polymorphism (single positions of variation in 
DNA) of inflammation-related genes including (IL1B, IL6, and TNFα) with changes in fatigue in 
PC patients receiving other type of treatment such as ADT 43 and apoptosis-related genes (BDNF 
Val66Met) in breast cancer survivors (6 months or more post-treatment).87  The former 
demonstrated that prostate cancer patients treated with ADT who carry alleles of the IL6 and 
TNFA genes are susceptible to developing severe fatigue.43  The latter study showed that, among 
breast cancer survivors (6 months or more post-treatment), the presence of the BDNF Val66Met 
SNP biomarker was related to lower symptom scores, but the effect size was small and the 
relationship did not persist when controlling for confounders.87  Heinz87cites Kim, Barsevick, & 
Tulman88 who found that low levels of BDNF have been associated with ROS that result in 
oxidative stress leading to cell death [apoptosis] processes that have been linked to a variety of 
cancer-related symptoms.   
 In sum, it appears that genetic variation plays a role in the development of CRF during 
treatment.  Findings from the above studies also provide support for the value of microarray in 
understanding regime-related toxicities other than CRF, and the future of the use of genetic 
testing as a tool to predict toxicity risk.  In addition, researchers have found that CRF is a 
symptom with multiple factors contributing to its presentation and outcomes.13,15, 64  Relevant 
studies that identify physiological, psychological, and situational factors that interact and 
influence the symptom experience of CRF are presented next.  
Other Factors Influencing Cancer-Related Fatigue 
Situational factors 
Situational factors are aspects of the social and physical environment that need to be 
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considered when examining CRF since they may affect the individual's experience and reporting 
of symptoms.30  Servaes, Verhagen, and Bleijenberg’s36 review of literature on prevalence, 
correlates, and interventions for CRF during and after cancer treatments revealed that in 9 out of 
10 studies marital and working status were not found to be significantly related with CRF.  The 
exception study showed that in mixed-diagnoses cancer patients, increased general fatigue during 
RT was found to be significantly associated with being in a de-facto relationship (not legally 
married) when compared with being legally married or single (p < .05, 2.21, (0.74-3.67)).  
Fatigue also was significantly associated with unemployment (p < .05, 2.04 (0.44, 3.63)), but not 
significantly associated with education.  Other researchers have documented that non-metastatic 
prostate cancer patients experienced worsening of CRF from 4 to 10 years after EBRT as well as 
financial difficulties.89   The participants' situational factors of employment status, marital status, 
and education were used to describe the sample in the present study.   
Psychological factors 
 CRF is a multidimensional symptom that also is influenced by psychological factors.  
Several studies have documented that depression and anxiety were significantly correlated with 
fatigue.  Purcell et al.'s90 study of 210 patients receiving RT for mixed-cancer diagnoses found 
that increased general fatigue and increased physical fatigue were found to be significantly 
associated with depression (p = .05, 0.41, CI = 0.00-0.27; p < .01, 0.27, CI = 0.14-0.36, 
respectively.)  However, the relationship between anxiety and general fatigue and physical 
fatigue was not statistically significant.  Irvine et al.91 study on prevalence and correlates of 
fatigue among 101 patients receiving treatment with either radiotherapy or chemotherapy found 
that mood disturbance was one of the strongest correlates of fatigue (r = 0.47, p < .0001).  
Redeker et al.92 study among 263 cancer patients receiving chemotherapy found that fatigue, 
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depression, and anxiety were positively correlated with one another  (r = 0.26 to  r = 0.69, p < 
0.001).  Similar findings in a mixed group of cancer patients during cancer treatment were 
reported by others.33,91  These findings provided support to measure depression in the current 
study.  Overall, these results are consistent with the contention that CRF among patients during 
RT is related to the psychological factors of anxiety and depression.91 
Physiological factors 
 Physiological factors include normally functioning body systems and the occurrence of 
any pathology, including cancer.30   A variety of physiological factors have been postulated to be 
associated with RT-associated fatigue.  For example, studies have described a negative 
correlation between general fatigue during RT and age (p = .05, -0.07 [-0.11, -0.03]),90 but other 
researchers have found that neither gender nor age was predictive of fatigue severity at any time 
point.36,66  In a prospective study of 55 non-metastatic prostate cancer patients treated with RT, 
researchers found that treatment-related symptoms, including fatigue, were more likely to 
worsen if baseline PSA values, Gleason score, and CTV2 (tumor stage) were above the desirable 
limits.36  However, as in other studies,36,66  Troung et al.'s 66 study of 28 prostate cancer patients 
having EBRT for non-metastatic prostate cancer found that fatigue was not significantly 
associated with the participant's T-stage, Gleason score, baseline PSA, number of RT fractions 
and number of RT fields, or total RT dose.  Hickok et al.70  also identified the need to assess the 
presence of co-morbid physical illnesses, such as hypothyroidism or congestive heart failure, as 
contributing factors to CRF.   
While anemia is believed to be related to CRF, during RT it may be less significant as the 
erythropoietin system effectively compensates by proliferating upon demand.93  A study of 2,111 
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complete blood counts (CBC) from 299 cancer patients showed no statistically significant 
decrease in total red blood cells (RBC) during and at the end of RT, or any clinically significant 
anemia.93  However, Wratten et al.74 found that higher baseline fatigue level and higher baseline 
neutrophil and RBC counts were the most predictive factors for fatigue during radiotherapy for 
breast cancer.  
Additional covariates of fatigue  
Meta-analysis and a Cochrane report have provided evidence that randomized controlled 
trials on exercise, which improves aerobic capacity, muscle strength, body composition, and 
physical functioning, have been shown to reduce fatigue.94-95   Windsor et al.96 tested whether an 
aerobic exercise intervention during EBRT for prostate cancer would reduce the incidence of 
fatigue.  The investigators found that moderate-intensity walking produced a significant 
improvement in physical functioning with no significant increase in fatigue and that men in the 
control group had significant increases in fatigue from baseline to the end of radiotherapy.  
Similar findings in a mixed group of cancer patients during RT were reported by Mustian et al.97   
After a 4-week home-based aerobic and resistance exercise training, participants in the 
intervention group reported significant lower fatigue at the end of radiotherapy and at three 
months.   These findings suggest that it is possible that increasing physical activity during EBRT 
may decrease worsening of fatigue.   
 Ample evidence exists on the relationship between sleep disturbance and CRF during 
cancer treatments.  Sleep disturbance has been found to be positively correlated with 
fatigue,12,36,90  to exacerbate CRF,98 and, to be a significant predictor of fatigue.12,99   For 
example, Miaskowski et al.100 found that higher sleep disturbance was one of the predictors of 
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baseline levels of morning fatigue in prostate cancer patients who underwent EBRT.  Dhruva et 
al.101 reported similar findings among breast cancer women who underwent RT.   
Disparities in Symptoms Experience 
While CRF during EBRT appears unrelated to age, cancer stage, radiation dose/fraction, 
it is frequently associated with ethnic differences.  Symptom management inequities also are 
evident.20, 4-5  Specifically, Hispanics are more likely to experience delays in diagnosis and to 
receive less than optimal treatment plans than Caucasians.14  Multiethnic cohort research studies 
suggest that Hispanics are more likely than their Caucasian counterparts to experience treatment-
related symptoms, including fatigue.7  For example, in their study of 116 breast cancer survivors, 
Eversley et al.14 reported that Hispanic women showed significantly higher rates of fatigue and 
depression than Caucasians.  Similarly, in a research study of 139 breast cancer survivors, 
fatigue was the most common (76%) symptom.20  When comparing ethnic groups, Hispanics 
were significantly more likely than Caucasians to report more than 10 symptoms even after 
adjusting for several covariates.  Being Hispanic, or older than 65 years old, or unemployed, was 
related to reports of chemotherapy-related symptoms.  Pain-related symptoms also were 
significantly reported by Hispanics and those older than 65 years.  A longitudinal study7on early 
referral to a supportive care specialist for symptom burden in a study of 752 lung cancer patients 
showed that Hispanics reported higher rates of fatigue, pain, depression, and swelling and that 
fatigue was significantly associated with referral for symptom management.  In addition, no 
significant improvement in pain or fatigue was observed among Hispanics in general when 
compared to Caucasians.7 
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 Regardless of the documentation of disparity in the symptom experience of CRF reported 
by Hispanic groups, few CRF studies have included prostate cancer patients during EBRT, 
particularly Puerto Rican participants, as a separate group in their analysis.  This investigator 
conducted a descriptive study with 50 Puerto Rican cancer participants reporting their symptoms 
and self-care methods used to alleviate their symptoms during treatments from August to 
October, 2010.25   Participants were 64% female, had a mean age of 56.6 years; 37 had 
chemotherapy alone and 13 had RT.  The diagnoses mostly were breast, cervical, colorectal, and 
prostate cancer.  All the symptoms in the fatigue subscale were reported: feeling sluggish (56%), 
difficulty sleeping (54%) and depression (46%).  The Therapy Related Symptom Checklist 
(TRSC) scores correlated with Symptom Alleviation: Self-Care Methods (r = 0.82; p < .001) and 
with HRQOL (r = -0.37; p < .01), indicating that the higher the total TRSC scores (indicating 
more frequent and more severe symptoms), the lower the reported HRQOL scores, and the lower 
the functional status rating.  The Puerto Rican prostate cancer participants' (N=13) characteristics 
included: mean age of 55 (range 42-69); Karnofsky Performance score mean of 87.6 (range 60-
100); HRQOL mean 8.3 (range 7-10); 23% with less than a high school education; 38% who 
were currently working; and 80% who reported feeling sluggish.   
 The literature on pain is consistent with the CRF literature; the occurrence and severity of 
pain among non-Hispanic African-Americans (OR= 1.78; 99% CI, 1.33-2.37) and Hispanics 
(OR= 1.80; 99% CI, 1.26-2.56) is higher compared with that among Caucasians.69,102-3  This 
suggests there may be a  greater need for symptom surveillance, treatment and control for these 
subgroups.   In another study, one notable finding was that health care providers under-
recognized and under-treated cancer-related-symptoms, especially among Hispanic women.104  
Thus, Hispanic cancer patients in general have a higher risk of adverse effects from treatment 
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and a need for  more targeted interventions.14  These findings have important ramifications for 
current theory regarding the etiology of disparity in the symptom experience of CRF. 
Numerous explanations for the observed ethnic disparity have been offered.  These 
include level of acculturation, quality of information regarding therapeutic interventions, ability 
to afford rehabilitative therapies, language barriers, effectiveness of communication with 
providers, culture, and socio-economic factors.14, 20   Much remains to be investigated, including 
whether physiological evidence can explain the variability of fatigue responses to EBRT between 
ethnic groups.  Indeed, others have proposed focusing on biological causal pathways to explain 
the variability in the symptom experience of fatigue.21-24 
Biological vulnerability to disparity in symptoms experience 
 While the etiology and mechanism underlying disparity in the experience of CRF remains 
elusive, findings from recent studies on the symptoms of pain and depression that propose 
intrinsic biological vulnerabilities as plausible explanations, may apply to CRF.24   
Contemporary researchers24 have proposed that inflammation, particularly from IL-6, IL-8 and 
TNF-α, may be a common biological mechanism causing variability in self-report of cancer-
related pain and that IL-6, IL-8 and TNF-α may be potential targets for treating pain.  For 
example, Reyes-Gibby et al.24examined the extent to which functional polymorphisms in TNF-a 
-308 G/A,IL-6 -174G/C, and IL-8 -251T/A are associated with the severity of pain among a 
sample of 446 Caucasians, 125 African-Americans, and 35 Hispanics with newly diagnosed  
lung cancer (untreated patients).  These researchers observed that African-Americans (31.5%) 
had the highest proportion reporting severe pain, followed by Hispanics (20%) and Caucasians 
(17%; p< 0.001), but no significant association was obtained between genotypes in TNF-a, IL-6, 
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and IL-8 and severe pain for either African-Americans or Hispanics.  In a review of literature on 
gender disparities in depression, Accortt, Freeman and Allen105 found evidence that supports the 
premise that biological factors may contribute to explaining this disparity.  A study with 
adolescents106 also found gender differences in the effects of 5HT (2A) (human serotonin-2A 
receptor gene), TPH (tryptophan hydroxylase), and 5HTTLPR (serotonin transporter gene 
promoter polymorphism) in genetic vulnerability to depression.  In contrast, a similar study with 
adults found no differences in the genotype frequency between genders.105,107  Importantly, 
researchers reported that the empirical evidence for gender-specific vulnerabilities to depression 
does not suggest that this disparity in depression rates is due to differential symptom reporting.8  
Further research is needed to clarify the contributions of biological factors to disparities in the 
symptom experience of fatigue because that may lead to genetic discoveries with more target 
therapeutic implications. 
Saligan et al. found changes in fatigue scores among Caucasian men with prostate cancer 
were significantly associated with changes in expression of mitochondrial-related and 
inflammation-related genes during EBRT.16-19  No similar studies have looked at the associations 
of changes in gene expression and fatigue symptoms in Hispanic PR men during EBRT.  
Showing no difference in physiologic profiles associated with fatigue intensification during 
EBRT among ethnic groups will bridge this gap. 
Summary 
 In summary, Gonzalez preliminary study in 2011 showed that Puerto Rican men with 
prostate cancer (N=13) have a higher prevalence (80%) of fatigue at midpoint of EBRT.25  
Despite variation in symptom reporting among ethnic groups, it is well documented that 
45 
 
Hispanic P.R.'s are an understudied population who are underrepresented in clinical trials, 
especially in symptom research.2  While the etiology and mechanism underlying this disparity in 
symptoms experience remains elusive, recent studies propose intrinsic biological vulnerabilities 
as a plausible explanation.21,14  The current study bridges that gap by comparing gene expression 
patterns of Hispanic Puerto Rican men treated with EBRT with Saligan's findings among 
Caucasian men receiving the same treatment.  Gene expression measured from RNA is tissue 
specific.83   Microarray technology can provide an unbiased approach to investigating potential 
biological pathways associated with specific conditions, including symptoms such as fatigue.  
Saligan and colleagues recently found significant associations between differential expression of 
eight mitochondria-related genes and changes in fatigue among Caucasians receiving EBRT for 
non-metastatic prostate cancer.16  They also found a significant correlation between changes in 
fatigue and the up-regulation of  α synuclein during EBRT, providing preliminary evidence of 
the role of neuro-inflammation in the development of CRF.17  This investigator employed a 
similar microarray technique to explore the differential expression of genes from peripheral 
whole blood RNA collected from Hispanic Puerto Rican men at baseline and at midpoint of 
EBRT.  Functional networks of the differentially expressed genes were examined using 
Ingenuity Pathway Analysis to determine pathways that may explain the possible physiological 
mechanisms that influence fatigue intensification during EBRT in this population.    
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CHAPTER III 
 
METHODOLOGY 
Research Design 
 The present study is a prospective exploratory and comparative study designed to 
describe and better understand the fatigue experienced by Hispanic Puerto Rican men over the 
course of EBRT.  Microarray technology was employed to explore the differential expression of 
genes from peripheral whole blood RNA collected at baseline and at midpoint of EBRT.  
Functional networks of the differentially expressed genes were examined to identify pathways 
that may explain the physiologic underpinnings of fatigue and fatigue changes during EBRT 
treatment for prostate cancer.  To accomplish the proposed objectives of the research study, three 
aims were proposed: (a) assessment of fatigue and changes of fatigue overtime (Aim 1); (b) 
assessment of gene expression overtime (Aim 2); and (c) relationship between gene expression 
changes and fatigue changes (Aim 3).     
Sample 
 The sample for the proposed study included 26 Hispanic Puerto Rican men with non-
metastatic prostate cancer who received EBRT.  Study participants were recruited from the 
ambulatory Radio Oncology Center at the “Clinica Las Americas.” After obtaining Human 
Subjects Committee approval from both the University of P.R. Human Subjects Committees and 
the KUMC Institutional Review Board (IRB), the principal investigator (PI) recruited 
participants for the proposed study from patients being evaluated to receive EBRT for non-
metastatic prostate cancer.   
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Participants’ Inclusion Criteria 
The inclusion criteria were: Hispanic PR males over 40 years of age with clinical 
diagnosis of non-metastatic prostate cancer, who were scheduled for EBRT.  Eligible participants 
also needed to be able to read and write at the 6th grade level and to provide written informed 
consent. 
Participants’ Exclusion Criteria 
Exclusion criteria included: progressive or unstable disease of any body system causing 
clinically significant fatigue; systemic infections (e.g., human immunodeficiency virus, active 
hepatitis); documented history of major depression, bi-polar disorder, psychosis, or alcohol 
dependence/abuse within the past five years; uncorrected hypothyroidism or anemia; second 
malignancies; concurrent chemotherapy with EBRT; and those with chronic inflammatory 
disease that may alter pro-inflammatory cytokines profiles (e.g., rheumatoid arthritis).  
Additionally, patients taking sedatives, steroids, or non-steroidal anti-inflammatory agents were 
excluded because these medications are known to affect immunogenetic changes.16 Inclusion and 
exclusion criteria were verified by patient interview. 
Sampling procedure 
 A radiation oncologist at the Clinica Las Americas Tomé & Ubiñas Radio Oncology 
Center facility assisted with recruitment of participants for the study.  To address concerns about 
educating staff about the protocol, the investigator scheduled a short presentation for faculty and 
staff of the RT unit to explain the study and the flyers (Appendix B) with study details placed at 
the RT facility.  The radiation oncologist informed potential participants about the study and 
introduced interested patients to the investigator, who was available at the facility.  The 
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investigator’s responsibilities with the participants' included: (a) providing information about the 
study, (b) verifying inclusion criteria, (c) obtaining informed consent, and (d) coordinating study 
data collection dates and times (at participants’ convenience).   
Setting 
 Recruitment and data collection of study participants took place at the ambulatory Radio 
Oncology Center at the “Clinica Las Americas.” The Tomé & Ubiñas Radio Oncology Center is 
a free standing facility located in San Juan, Puerto Rico, approximately 3 miles from the 
University of P.R. Medical Sciences Campus.  The facility is housed in two separate buildings 
providing office space and treatment space inside the main medical office compound called 
"Clinica Las Americas."  The radiation oncologist provided a designated private 
interview/examination room and, after obtaining patient consent, access to participants’ medical 
chart, to verify the inclusion and exclusion criteria and to obtain selected heath information. 
Procedures 
The procedures section begins with a figure that shows a summary of the study data 
collection procedures.  Next, a detailed discussion of participant recruitment and what happened 
at baseline, midpoint, and end of treatment visits is presented.  This is followed by a discussion 
of the study variables and measurements, statistical analyses, and pitfalls and resolution for each 
aim.  At the end of the chapter, the ethical considerations are discussed. 
The data collection process included four visits: recruitment, baseline, midpoint and end 
of treatment (see Figure 5).   
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Figure 5. Study Data Collection Procedures
 
Subject Recruitment 
Prior to beginning data collection, approval by the Human Subjects Committee of both 
the Midwestern academic medical center and University of Puerto Rico was granted (see 
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evaluation and one for simulation.  Evaluation days occurred approximately 14 days prior to 
simulation (Monday and Wednesdays afternoons), and during simulation, which is 14 days prior 
to initiation of treatment (Tuesdays and Thursday mornings). 
Subject recruitment occurred on evaluation days after the physician evaluation.  The 
enrollment process occurred using the following steps: (a) patients who were likely to meet the 
inclusion and exclusion criteria were approached by the radiation oncologist who had knowledge 
of those criteria; (b) patients were informed about the research study investigating fatigue in 
prostate cancer patients under EBRT; (c) patients were asked them if they were interested in 
getting more information; then, (d) the staff introduced those patients interested in receiving 
more information to the PI who was available at the facility and interviewed them in a private 
room at the RT unit.  Patients interested in participating in this study were screened by the PI for 
eligibility with a brief health history interview that included summary questions about cancer 
disease characteristics, previous and planned cancer treatments, concomitant medications, co-
morbid conditions, systemic infections, and documented history of major depression, bi-polar 
disorder, psychosis, or alcohol dependence/abuse within the past 5 years (see Appendix D).  The 
radiation oncologist referred a total of 31 participants interested in receiving more information.  
Of these 31 patients, three were not interested in participating.  It is unknown how many were 
not interested in receiving any further information. 
Eligible participants were formally asked if they wanted to participate in the study, which 
involved self-report questionnaires and blood draws, and if they permitted, selected chart review.  
They were given a written informed consent form (see Appendices E & F) to sign after they 
indicated their understanding of the study procedures and willingness to participate.  All patients 
interviewed by the PI were assured that their decision to participate would not affect their care in 
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any way.  The recruitment took approximately three months.  After signed informed consent, the 
PI scheduled the three study data collection dates and times.  All study procedures at baseline 
(prior to EBRT), midpoint (days 19-21) and completion (days 38-42) of EBRT were scheduled 
to take place at the participants’ convenience.  Thirty-one individuals were approached for 
possible participation in the study; three refused participation, 28 agreed, and 26 of these were 
eligible and gave their informed consent.  The reasons for those that refused to participate were: 
"agreed to answer questionnaires but not to give blood" (2 patients) and "not interested" (1 
patient).  Two were ineligible due to diagnosis of chronic renal failure. 
Baseline Visit 
On baseline evaluation days, the demographic information on the demographic form (see 
Appendices G & H) was obtained from study participants.  The PI reviewed with the study 
participants the instructions on how to fill out each questionnaire.  The following self-report 
instruments (discussed below under Measures) were completed by study participants: the 
validated Spanish-versions of the Fatigue sub-scale from the Functional Assessment of Cancer 
Therapy-Fatigue (FACT-F) (see Appendices I & J), the International Physical Activity 
Questionnaire Short Form (IPAQ, SF) (see Appendices K & L), and the PROMIS-sleep 
disturbance questionnaires (see Appendices M & N).  The PI then administered the Hamilton 
depression scale (HDRS) (see Appendix O), validated in Spanish speaking populations, to obtain 
depression scores.   
 No participants experienced psychological distress from answering the fatigue, IPAQ, 
PROMIS-sleep disturbance questionnaires or from the HDRS, or were observed to have 
increasing depressive symptoms.  A clinical psychologist, and director of the Behavioral 
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Sciences Research Institute, University of P.R., advised and trained the PI in the process of: (a) 
using and scoring the HDRS; (b) recognizing signs and symptoms of depression and sleep 
disturbance; and (c) referral to further resources.  Since no participants scored 15 or more on the 
HDRS at any time point during the study, there was no need to refer to the clinical psychologist 
for further evaluation for depression.  An increase in HDRS score during the study was not a 
criterion for withdrawal of subjects from participation.  Combined participants’ self-report of 
demographics and administration of questionnaires and the PI’s rating on the HDRS required 
less than 30 minutes of the participants’ time. 
 After completing these forms, participants were measured for height and weight (required 
for BMI calculation) using standardized techniques in a private location.  This was followed by 
the PI taking a whole blood sample for RNA analysis.  Blood samples were managed and 
transported in accordance with OSHA regulations and University of Puerto Rico policies.  The 
blood drawing, height and weight measuring required approximately 15 minutes of the 
participants’ time.  Participants were informed about the molecular analysis that was conducted 
on their blood and they were given the option of learning about laboratory results of the blood 
tests as approved by both Human Subjects Committees.  As per University of Puerto Rico policy, 
if medical care was necessary as a result of the blood drawing, it would have been provided free 
of cost by the University of Puerto Rico Medical Center.  This was not necessary for this study’s 
participants. 
 Following baseline study procedures, the PI reviewed each subject’s medical chart for 
recording selected clinical information on the health form (see Appendix P) and entering into the 
data base.  Unique identifiers were assigned to each participant.  The unique identifier was used 
to match demographics and questionnaire data with the blood samples and medical chart data.   
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Midpoint Visit 
 Midpoint visit procedures were similar to baseline.  Participants once again completed 
the FACT-F, IPAQ, and PROMIS-sleep questionnaires.  In addition, participants’ BMI and 
blood sample were obtained.  Lastly, the PI rated the HDRS and gathered other clinical 
characteristics of participants (e.g., infections, CBC) by chart review. 
End of Treatment Visit 
The procedures at the end-of-treatment visit were the same as at midpoint with one 
exception.  No blood samples were drawn at this visit. 
MEASURES 
 Variables, method, and frequency of measurement for each variable are summarized in 
Table 1.  A detailed description of each variable is provided below. 
Table 1 
Summary of Measurements 
 
Variables Method of Measurement Frequency 
Cancer-Related Fatigue FACT-F Baseline, mid-point, and 
end of treatment 
Gene Expression levels of 
peripheral blood cells 
PAXGene blood RNA tube Baseline, Mid-point 
Age, marital status, 
religious preference, 
occupational status, and 
education level 
 
Stage of cancer, comorbid 
conditions, T-stage,  
Gleason score, type and 
duration of hormone 
therapy, the planed 
number of RT fractions, 
number of RT fields 
Demographic Form 
 
 
 
 
Information on co-morbid 
conditions and medications 
was obtained from the partici-
pant’s interview, and 
corroborated using the health 
record.  The remaining Health 
Form information was 
Baseline 
 
 
 
 
Baseline 
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Variables Method of Measurement Frequency 
obtained from their health 
record. 
 
Infections, PSA, CBC, 
albumin, thyroxine,  
 
 
BMI 
 
 
Energy Expenditure 
 
 
 
Sleep Disturbance 
 
 
Depression 
Health Form information 
gathered from their health 
record. 
 
Obtained by the PI 
 
 
International Physical Activity 
Questionnaire Short Form 
(IPAQ-SF) 
 
PROMIS-Sleep disturbance 
(PROMIS-SD) 
 
Hamilton Depression Rating 
Scale (HDRS)  
Baseline 
 
 
 
Baseline, Mid-point, and 
End of Treatment 
 
Baseline, Mid-point, and 
End of Treatment 
 
Baseline, Mid-point, and 
End of Treatment 
 
Baseline, Mid-point, and 
End of Treatment 
 
Cancer Related Fatigue (CRF; see Appendices I & J).  The subjective perception of 
CRF is defined operationally for this study as the score from the Spanish-validated version of the 
Fatigue sub-scale from the Functional Assessment of Cancer Therapy- Fatigue QOL 
questionnaire, the FACT-F.  The instrument was developed by Cella and colleagues (1997)108 
specifically for cancer survivors.108-109   The FACT-F 13 statements about fatigue (e.g. “I feel 
weak all over”, “I am too tired to eat”) were rated by the patients who were asked to indicate the 
degree to which they felt that each statement was true during the preceding week.  Each item is 
anchored by a five-point Likert-type scale response (0 = not at all, 1 = a little bit, 2 = somewhat, 
3 = quite a bit, or 4 = very much).  Scores on the FACT-F can range between zero and 52.  After 
appropriately reverse coding items 7 and 8, scoring for this scale was computed by adding the 
individual item scores, and dividing by the number of items answered.  Higher scores represent 
less severe fatigue.109-110 
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 The FACT-F has been rigorously tested for reliability and validity.  Recently, reliability 
and validity testing of the scale was conducted on 131 mixed-diagnosis cancer patients 
participating in a longitudinal observational study of fatigue and quality of life during 
chemotherapy.111  The FACT-F showed strong internal consistency (Cronbach’s alpha = .93 to 
.95).  Further, fatigue was assessed twice: at baseline and three to seven days later to evaluate 
test stability (test–retest reliability) that reflected good test stability over time (intraclass rFS = 
0.89).   The FACT-F was found to successfully discriminate patients based on hemoglobin (Hb) 
level (r = 0.75 p < 0.001).  In the original reliability and validity testing of  the scale, using 49 
cancer patients during treatment, validity testing revealed: a significantly positive relationship 
with other known measures of fatigue (Piper Fatigue Scale; r = 0.77; POMS Fatigue, r = 0.83); a 
significant negative relationship with vigor (Vigor subscales of the Profile of Mood States; r = -
0.61); and an anticipated lack of relationship with social desirability (short form of the Marlowe-
Crowne Social Desirability Scale; r = 0.07).108-110 
 The FACT-F has been validated with Spanish-speaking cancer patients, with good 
psychometric properties including: a significantly positive relationship with other known Spanish 
measures of fatigue (Perform Questionnaire; r = 0.80, n = 437; POMS Fatigue, r = 0.64, n = 92); 
overall Cronbach's alpha of 0.89.72,112  Researchers concluded that: "Spanish language translation 
as reported here provides sufficient assurance of equivalence to the English-language version to 
proceed with its use in clinical trials and clinical practice (p. 1,417)."72 
 The FACT-F has been widely used in clinical studies for fatigue interventions113 
including breast cancer survivors’ responses to treatments.  For example, in a randomized 
controlled trial of an individual-based intervention that combined social support and physical 
activity, Naumann et al.113found a significant reduction in fatigue among Australian women 
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when compared with a counseling only group using the FACT-F instrument.  In addition, Saligan 
and Kim15 found that "the FACT-F is the most preferred instrument to measure CRF because it 
has been used extensively in large studies, has been shown to be sensitive to clinically significant 
changes in fatigue, and has robust psychometric properties" (p. 2).15 
Gene expression of peripheral blood cells.  Peripheral blood samples (2.5 mL) were 
collected from each subject at baseline and at mid-point using PAXGene blood RNA tubes 
(Qiagen, Frederick, Maryland).  The collection tubes with peripheral blood cells were inverted 
10 times to ensure red blood cell lysis immediately after collection.  Although the PAXGene 
blood RNA tubes can be kept up to three days at room temperature (15–25° C) prior to storage in 
a  –80° C freezer, the samples were kept at room temperature in a safe transportation box until 
stored within four hours in a -80o C freezer at the Puerto Rico Clinical Research Center until 
RNA extraction.  According to the manufacturer, the advantage of this tube is that the tube 
contains an additive that stabilizes the in vivo gene transcription profile by reducing in vitro 
RNA degradation and minimizes gene induction. One study showed that this tube reduced RNA 
degradation compared with whole blood collected in tubes containing anticoagulants like EDTA 
extracted by an organic method.40 
Prior to RNA extraction, the PAXgene Blood RNA tubes were placed out of the freezer 
overnight at room temperature (15-250C) in order to achieve complete lysis of blood cells.  The 
bench areas were clean with RNase-free water to prevent contamination of the blood samples.  
The process of RNA extraction and purification were as follows: (a) centrifugation to pellet 
nucleic acids in the Paxgene Blood RNA tubes: the PAXgene Blood RNA tubes were centrifuge 
for 10 minutes at 3500xg and at 220C using a swing-out rotor to prevent tubes from breaking 
during centrifugation; (b) the supernatant was removed by decanting and the pellet of 
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lymphocytes was retained; (c) wash pellet: 4 ml RNase-free water was added to the pellet; (d) re-
suspend the pellet: the tube was vortexed until the pellet was visibly dissolved (assuring to keep 
the pellet), followed by centrifuging the tube for 10 minutes at 3500xg and at 22oC; (e) using a 
pipette (by decanting), the supernatant was once again removed and discarded; (f) 350ul buffer 1 
was added and vortexed until the pellet was visibly disolved; (g) the pellet was transferred to a 
microcentrifuge tube: the sample was pipetted into a 1.5 ml microcentrifuge tube; Manual RNA 
purification followed; (h) the re-suspended pellet was incubated in optimized buffers together 
with proteinase K to bring about protein digestion; adding proteinase K and binding buffer: 300 
μl Buffer BR2 and of 40 μl proteinase K was added to the 1.5 ml  microcentrifuge tube 
containing dissolved pellet then mixed by vortexing for 5 seconds and incubating for 10 minutes 
at 55° C using a shaker–incubator at 1100 rpm; (i) an additional centrifugation through the 
PAXgene Shredder spin column was carried out to homogenize the cell lysate and remove 
residual cell debris; the lysate was pipetted directly into a PAXgene Shredder spin column (lilac) 
placed in a 2 ml processing tube, and then centrifuged for 3 minutes (19900 xg); (j) the 
supernatant of the flow-through fraction was transferred to a microcentrifuge tube and ethanol 
was added to adjust binding condition:  the entire supernatant was transferred to a new 1.5 ml 
microcentrifuge tube without disturbing the pellet in the processing tube and 350 μl ethanol (96–
100%) was added, next it was mixed by vortexing and centrifuging briefly (1–2 seconds at 500–
1000 x g) to remove drops from the inside of the tube lid; (k) during a brief centrifugation, RNA 
is selectively bound to the PAXgene silica membrane as contaminants pass through: 700 μl 
sample was pipetted into the PAXgene RNA spin column (pink) placed in a 2 ml processing 
tube, and centrifuged for 1 minute at 8000–20,000 x g (15,500 xg); then placing spin column in a 
new 2ml processing tube, discarding old processing tube containing the flow-through and repeat 
58 
 
steps with remaining sample (l) remaining contaminants are removed in several wash steps: 350 
μl Buffer BR3 was pipetted into the PAXgene RNA spin column, centrifuged for 1 minute at 
8000–20,000 x g (15,500 xg) and the spin column was placed in a new 2 ml processing tube, the 
old processing tube containing flow-through was discarded; (m) the membrane is treated with 
DNase to remove traces amounts of bound DNA ( DNA digestion to ensure elimination of 
genomic DNA): 10 μl DNase I stock solution was added to a 70 μl Buffer RDD in a 1.5 ml 
microcentrifuge tube and mixed; the DNase I incubation mix (80 μl) was pipetted onto the 
PAXgene RNA spin column membrane, and placed on the benchtop (20–30°C) for 15 minutes; 
(n) washing: 350 μl Buffer BR3 was pipetted into the PAXgene RNA spin column, and 
centrifuged for 1 minute at 8000–20,000 x g (15,500 xg) followed by placing the spin column in 
a new 2 ml processing tube and discarding the old processing tube containing flow-through;  500 
μl Buffer BR4 was pipetted to the PAXgene RNA spin column, and centrifuging for 1 minute at 
8000–20,000 x g (15,500 xg)  followed by placing the spin column in a new 2 ml processing tube 
and discarding the old processing tube containing flow-through; another 500 μl Buffer BR4 was 
added to the PAXgene RNA spin column and centrifuged for 3 minutes at 8000–20,000 xg 
(15,500 xg); (o) the tube containing the flow-through was discarded  and the PAXgene RNA spin 
column was placed in a new 2 ml processing tube followed by Centrifuge for 1 minute at 8000–
20,000 xg (15,500 xg); (p) after the wash steps, RNA is eluted in elution buffer (Buffer 5) and 
heat-denatured; elution in the tube containing the flow-through was discarded , then the 
PAXgene RNA spin column was placed in a 1.5 ml microcentrifuge tube, and 40 μl Buffer BR5 
was pipetted directly onto the PAXgene RNA spin column membrane followed by centrifugation 
for 1 minute at 8000–20,000 x g (15,500 xg)  to elute the RNA and this step was repeated; the 
eluate was incubated for 5 minutes at 65°C in the shaker–incubator without shaking followed by 
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chilling immediately on ice (This incubation at 65°C denatures the RNA for downstream 
applications).  The quantity of total RNA was measured by a spectrophotometer at optical 
density of 260 nanometers.  RNA quality was assessed using the RNA 6000 NanoLabChip® on 
a Bioanalyzer Agilent 2100 (Agilent Technologies, Palo Alto, CA); (q) lastly, the RNA samples 
were stored at a -80o C freezer.  The above described method (RNA extraction) was conducted at 
the laboratory of Dr. Leorey N. Saligan, PhD, CRNP, RN, Symptom Biology Unit, National 
Institute of Nursing Research (NINR), Intramural Research Program, National Institutes of 
Health, Bethesda, MD.  All biologic samples were coded and stored in a locked -80o C freezer at 
the UPR Clinical Research Center facilities until a monthly shipment via FEDEX to the NINR 
for analysis. The monthly shipment of blood samples followed the manufacturer’s procedure and 
the standard operating procedures of the Puerto Rico Clinical Research Center  approved by the 
UPR Institutional Review Board and Biosafety Committees.  
Demographic form (see Appendices G & H).  Demographics included the respondent’s 
age, marital status, religious preference, occupational status, and education level.  The PI 
obtained that information from the participants’ self-report on the demographic form.   
Health form (see Appendix P). The PI obtained the health information for this form 
from the participants and from their RT medical chart.  The PI asked the participants about co-
morbid conditions (e.g. HTN, Diabetes) and current medications.  In general, the participants’ 
knowledge about their current medications was limited, therefore, the PI used the health record 
to clarify the information.  The clinical information obtained from the medical chart included: 
stage of cancer, Gleason score, type and duration of hormone therapy, number of RT fractions 
and number of RT fields.  Laboratory results including PSA level, CBC, albumin, thyroxine were 
only available at baseline visit, however laboratory results other than PSA level were not 
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available for some participants.  Histories of infections, visits to ER, hospital admissions or need 
for interruption of treatments were recorded at each visit.  Weight and height measurements 
obtained by the PI were recorded on this form.   
Body Mass Index (BMI). Weight was measured once at each time point using a manual 
scale.  Participants were instructed to stand straight with no shoes and to wear light clothes.  
Weight was recorded in kilograms (kg) and height in centimeters (cm) and later converted to 
meters.  For this study, BMI was the person’s weight (in kilograms) divided by the square of 
their height (in meters).114  While BMI is the most commonly used measure for estimating 
whether an individual person is overweight or obese, it is also an indicator of excess body fat.  
Overweight or BMI > 25 kg/m2 has been found to be highly correlated with clinically significant 
fatigue nine months after breast cancer treatment.115  Therefore, BMI has commonly been 
included as a potential confounder in longitudinal studies of fatigue.   
Energy expenditure (see Appendices K & L).  Energy Expenditure was defined 
operationally as the score on the International Physical Activity Questionnaire Short Form 
(IPAQ-SF).  The IPAQ was developed in 1998 by the International Consensus Group for 
Physical Activity Measurement (1996), with short and long versions of the questionnaire.116  The 
purpose of the Consensus group was to develop a self-reported measure of physical activity 
suitable for assessing population levels of physical activity across countries.  The IPAQ-SF self-
administered format consisted of nine items that ask about a seven-day recall of the amount of 
minutes spent in activity at four intensity levels: (a) vigorous-intensity activity such as aerobics; 
(b) moderate-intensity activity such as leisure cycling; (c) walking; and (d) sitting.  It includes 
items such as "During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, digging, aerobics, or fast bicycling?"  For all categories respondents had to 
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specify how many days and how many minutes each day they spent on a specific activity 
category. 
 Meus et al.117summarize the guidelines for data processing and analysis of the IPAQ-SF.   
First, for all categories, the amount of Metabolic Equivalents (METs)-minutes was calculated by 
multiplying the number of minutes by 8.0 (vigorous), 4.0 (moderate), 3.3 (walking), or 1.3 
(sitting).  Second, a total score was calculated by adding the METs-minutes of the first three 
categories together.   Lastly, in order to obtain the energy expenditure (expressed in kilocalories 
or kcal), METs-minutes were multiplied by the respondent’s weight in kilograms and then 
divided by 60 (METs-minutes x kg weight/60). 
 Craig et al.118 reported a reliability and validity study of the IPAQ-SF that were 
completed in 14 centers in 12 countries using healthy adults.  Results showed a good test-retest-
reliability (Spearman’s ρ = 0.80) and a moderate criterion validity (Spearman’s ρ = 0.30) with an 
accelerometer.  Recently, similar results were reported by Ramırez-Marrero et al.119during the 
validity and reliability testing of the Spanish version of the IPAQ-SF using 58 Hispanic Puerto 
Ricans living with HIV.  The IPAQ-SF Spanish version was administered by personal interview 
before and after the 7-day evaluation period with the ActiGraph and DigiWalker.  Test-retest 
reliability was acceptable: IPAQ measure one was significantly (p < 0.05) related to the IPAQ 
measure two with r values ranging from 0.32–0.75; and, Spearman correlation coefficients 
between the sleep /sit (min/d) IPAQ 2 nd measure and ActiGraph were only modestly correlated 
(rs = .28, p =.05).  However, the IPAQ min/day of moderate Physical Activity correlated well 
with the Digi Walker average number of steps/day (rs = .76, p = .04).The IPAQ-SF is a widely 
used measure of physical activity, inactivity, and energy expenditure in cancer patients during 
treatments.120-122   The IPAQ was used in this study instead of objective measures of physical 
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activity (e.g., accelerometer) even though the latter may be more reliable and valid, given the 
high costs of acquisition and data analysis with the use of accelerometers and pedometers during 
longitudinal studies, and that data on physical activity was not the central concern for this study, 
but rather was desired for possible use as a covariate given prior research on the role of physical 
activity in fatigue. 
Sleep disturbance (see Appendices M & N). The subjective experience of Sleep 
Disturbance was assessed by the adult PROMIS-Sleep disturbance Spanish form.123  The adult 
PROMIS-Sleep disturbance short form assessed sleep disturbance (i.e., perceptions of sleep 
quality, sleep depth aρρnd restoration associated with sleep; perceived difficulties and concerns 
with getting to sleep or staying asleep; and perceptions of the adequacy of and satisfaction with 
sleep) over the previous seven days.  For example, one of the items reads: "In the past seven days 
my sleep was refreshing".  Each item was anchored by a five-point Likert-type scale response (1 
= not at all, 2 = a little bit, 3 = somewhat, 4 = quite a bit, or 5 = very much).  Scores were totaled 
and divided by the number of items answered, to compute the mean score.  A conversion table 
available in the manual was then used to translate this score into a T-score for each participant.  
The T-score re-scales the raw score into a standardized score with a mean of 50 and a standard 
deviation (SD) of 10.  Therefore, a person with a T-score of 40 is one SD below the mean, 
representing less sleep disturbance that the average.  The standardized T-score was reported as 
the final score for each participant.  In testing the PROMIS with a general population sample, 
preliminary reliability and validity evidence showed that the short form correlated strongly with 
the full form, r = 0.96 (n = 2,252; 10% Latino).  Construct validity for the sleep-disturbance was 
supported by a high correlation with the Pittsburgh Sleep Quality Index, r = 0.80 (n =300) and a 
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lower correlation with the Epworth Sleepiness Scale, r = 0.45.  This was not surprising because 
sleepiness is a slightly different construct from sleep disturbance.124   
Depression (see Appendix O). The Hamilton Depression Rating Scale (HDRS) is a 
clinician-rated paper questionnaire developed by Hamilton in 1967 for psychiatry in-patient and 
out-patient settings.125-126  While initially intended to be used by a psychiatrist, studies have 
shown that it can be used by clinically inexperienced researchers after standardized training.127  
Bagby's128 review of literature in 2004 on 70 studies that examined the psychometric properties 
of the HDRS scale showed overall good psychometric properties such as: internal reliability 
ranging from Cronbach’s alpha (α) of 0.46 to 0.97; inter-rater reliabilities (Pearson’s r) ranged 
from 0.82 to 0.98;  and retest reliability (Pearson’s r) ranged from 0.81 to 0.98.  Validity of the 
HDRS has been reported to range from r = 0.48-0.85 with the global measure of depression, the 
"Beck Depression Inventory."  In addition, the HDRS has been employed successfully in 
psychopharmacological and clinical research with good internal reliability, Cronbach α's ranging 
from 0.81-0.98.129 
 The HDRS is composed of 17 items which are rated on a three-point (0-absent, 1-slight 
or trivial, 2-clearly present) or four-point (symptom is: 0-absent, 1-mild, 2-moderate, or 3-
severe) scale according to standardized descriptors.125-126   The total score can range from zero to 
54.  In general, the higher the total scores the more severe the depression.  According to Cusin, 
Yang, Yeung, and Fava,130 it is accepted by most clinicians that scores between zero and six do 
not indicate the presence of depression, scores between seven and 17 indicate mild depression, 
scores between 18 and 24 indicate moderate depression, and scores over 24 indicate severe 
depression.  The pre-defined cutoff score for depression is 15 in cancer patients, with higher 
scores indicating more symptoms of depression.129 
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 The HDRS has been validated in the Spanish-speaking population with good 
psychometric properties, including appropriate discriminative validity (HDRS-Clinical Global 
Impression: p < 0.0001), internal consistency (Cronbach’s α > 0.70), test-retest reliability (intra-
class correlation coefficient [ICC] > 0.9), and sensitivity to change (effect size > 1.5).131 
Data Analyses 
Specific Aim 1: To describe the trajectory of fatigue over the course of EBRT among 
Hispanic PR men receiving EBRT for non-metastatic PC and compare it with historical 
data of fatigue symptoms of Caucasian men with PC during EBRT. 
Overview of approach in Aim 1.  FACT-F was administered at three time points: 
baseline (prior to EBRT), midpoint (days 19-21), and completion (days 38-42) of EBRT.  FACT-
F scores obtained from this study were compared with the published FACT-F scores for the 
general US population and from scores for Caucasian cancer patients. 
Statistical analysis.  A code book was created prior to data entry.  All the data obtained 
from paper measures were double entered in a Microsoft Excel data base format developed by 
the data manager of the Cancer Center and coded and locked in a secured location.  Descriptive 
statistics were generated for the participants’ demographic and clinical characteristics as well as 
for the FACT-F, PROMIS-SD, and HDRS scales and for the IPAQ for each of the time points. 
To assess the change in fatigue at the three time-points (pre, midpoint, and end of EBRT), 
we compared all pair-wise fatigue scores measured at the three time points (i.e., pre vs midpoint; 
pre vs end, midpoint vs end) using both parametric (paired t-tests) and non-parametric (Wilcoxon 
Signed Rank Test) tests to assess the robustness of results.  In addition, we conducted subset 
analysis and case levels of the fatigue scores using descriptive statistics.  The change in energy 
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expenditure, sleep disturbance and depression at the three time-points (pre, midpoint, and end of 
EBRT) was assessed using paired t-tests.  We also assessed for significant differences between 
those on ADT and those not on ADT in the changes in fatigue (baseline minus midpoint), using 
independent sample t-test.  Finally, multiple linear regressions (baseline, mid-point and end-
point) were conducted to assess the impact of several independent variables on the dependent 
variable of fatigue.   
Power analysis. We planned a study of a continuous response variable, fatigue, collected 
at multiple time-points for each study subject.  Assuming the change in fatigue score between 
two measurements was normally distributed, we estimated that the standard deviation in the 
change of fatigue score was around 10.  This estimate was based on the following: the 
anticipated range = maximum change – minimum change, observed to be around 40, yielding an 
estimated SD ≈ 10 based on empirical rule for normal distribution.  The empirical rule states that 
approximately 95% of the differences will be within two SD of the mean.  Therefore, a power 
analysis for a desired power of .8 and α = .05, suggests the need for 26 subjects to detect a mean 
score change of five points.  The Type I error probability associated with this test of this null 
hypothesis is 0.05 for a one-sided test that fatigue gets worse over the course of EBRT.  Power 
calculations were performed using R 2.15.0 for Windows.  
Pitfalls and resolution. It is an acknowledged limitation that the current study is based 
on a self-report measure of fatigue.  However, symptoms by definition are subjective and self-
report measures of CRF are in fact, most appropriate and can provide the strongest evidence of 
support for behavioral interventions, particularly when instruments with good psychometric 
properties have been culturally validated and adapted for the population to be studied.  Although 
several important control variables were included in the study and controlled for in the 
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association testing, due to the relatively small sample size of this study we were unable to control 
for all potential variables that might affects CRF among PR prostate cancer patients during 
EBRT (e.g., anxiety).   
Specific Aim 2: To assess gene expression changes from baseline to midpoint of EBRT 
among Hispanic PR men receiving EBRT for non-metastatic PC. 
Overview of approach in Aim 2.  In order to capture the initial inflammatory response 
of EBRT which peaks at midpoint (day 21), only levels of the differentially expressed genes at 
baseline and at midpoint of EBRT were assessed.  Hence, for this aim involving genome-wide 
assessment of gene expression levels we focused on determining the changes in expression of 
genes from whole blood samples that were collected at baseline and midpoint of EBRT.  A total 
of 2.5 mL of peripheral blood was collected using RNA PAXGene tubes (Qiagen Frederick, 
MD) for each of the two study time points.  All biologic samples were stored in a securely-  
locked -80oC freezer until shipment to Dr. Saligan’s laboratory at the NINR for RNA extraction.  
De-identified blood samples were transferred via FEDEX to NINR for analysis.  De-identified 
blood samples microarray data results were returned via secure file from NINR for analysis. 
Gene expression microarray. RNA extraction, purification, cDNA and cRNA synthesis, 
amplification, hybridization, scanning and data analyses were conducted at the NINR lab by the 
same technician following standard protocols.  After total RNA isolation and extraction 
(described on p. 56) from frozen whole-blood samples following the PAXgene blood RNA kit 
procedure (PreAnalytiX).  RNA yields were 300 ng or greater from each 2.5 mL of whole blood 
collected.  The quantity of total RNA was measured by a spectrophotometer at optical density of 
260 nanometers.  RNA quality was assessed using the RNA 6000 NanoLabChip® on a 
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Bioanalyzer Agilent 2100 (Agilent Technologies, Palo Alto, CA). All extracted RNA was 
purified using RNeasymini kit (Qiagen, Valencia, CA).  The total RNA concentration was tested 
using the NanoDrop (ND-1000; Wilmington, DE), and the purity and integrity with the Experion 
systems (Biorad, Hercules, CA).  Following RNA preparation, the samples were treated with 
DNase to ensure elimination of genomic DNA.  A total of 100 to 150 ng of extracted RNA per 
sample was then converted to cDNA using the RT2 First Strand Kit (SABiosciences, Frederick, 
MD).  After cDNA synthesis reaction, the cDNA was diluted using nuclease-free H2O and 
immediately stored at -20o C until used for human gene expression profiling.  Affymetrix 
microarray chips (HG U133 Plus 2.0, Santa Clara, CA) were used to assess gene expression 
levels for genes across the genome.  The Affymetrix HG-U133 Plus 2.0 microarray chip is 
composed of more than 54,000 probe sets and 1,300,000 distinct oligonucleotide features, which 
can analyze the expression level of over 47,000 transcripts, including 38,500 well characterized 
human genes. Affymetrix Gene Chip Command Console (AGCC, 3.0 V) was used to scan the 
images for data acquisition (i.e., gene expression level). 
Figure 6. Summary of the Major Steps for the Microarray Experiments 
 
  
Provided by Dr. Leroy N. Saligan  
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Figure 6 summarizes the process involved in the microarray experiments.  The first 
square shows the process of peripheral blood collection using RNA PAXGene tubes.  After RNA 
extraction and purification, 50ng of total RNA were required for global expression profiling.  
Prior to hybridization on arrays, RNA samples were amplified, fragmented and labeled with 
biotin.  Square 2 shows that after amplification, RNA was combined with hybridization cocktails 
and transferred to Affymetrix arrays and incubated for 18 hrs at 37° C in a hybridization oven.  
After hybridizing samples onto the probe array, the chips were washed and stained.  Square 3 
shows that after staining, the chips were scanned; then, the scanning software converted raw 
image data (.DAT files) to numeric intensity files (.CEL).  
Statistical analysis.  Affrymetrix CEL files (the file format that stores the results of the 
intensity calculations of the pixel values of the scanned image from a microarray chip) were 
imported into LIMMA132 package in R.  Background correction, quantile normalization, and 
summarization were conducted with the Robust Multichip Average (RMA) algorithm developed 
by Irrizarry.133  RMA consists of three steps: (a) background correction: a preprocessing step 
employed to correct for background noise and processing effects in the microarray data in which 
probe-level data for each microarray are background corrected independently using a 
probabilistic model; (b) quantile normalization: whereby the background corrected probe-level 
data on each microarray were normalized to a common set of quantiles, derived from 
background corrected data from all microarrays; and (c) summarization: which computes an 
expression value for each gene from all the probes for the gene.  Then, assessment of 
differentially expressed genes between time-points was assessed using the LIMMA package.  
This step consists of the LIMMA program fitting for each gene a linear regression model to 
determine if genes were differentially expressed using a modified -test (to find differences 
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between midpoint and baseline expression) that shrinks non-differentially expressed gene effect 
sizes towards zero (or fold-change towards 1).  The fold-change is initially calculated as an 
antilog of a mean log fold-change over all possible between-chip comparisons contributing to the 
midpoint vs. baseline comparison.  Both a p-value and a Benjamini-Hochberg false discovery 
rate (FDR) were computed to adjust for multiple testing.132,133    The FDR is the proportion of 
discoveries that are false among all discoveries, i.e., the proportion of incorrect rejections among 
all rejections of the null hypothesis.  Subsequently, a p-value adjustment was conducted using 
the LIMMA global method with the Benjamini-Hochberg approach for control of false discovery 
rate (FDR).  The FDR is the proportion of discoveries that are false among all discoveries, i.e., 
the proportion of incorrect rejections among all rejections of the null hypothesis.  In order to 
restrict the false discovery rate to 0.01, all the genes with a FDR less than 0.01 were considered 
candidate differentially-expressed genes.  Lastly, the genes from the list of the FDR <0.01 were 
then sorted and filtered by the log fold change column to obtain a list of the top 10 significant 
up-regulated genes, and the top 10 significant down-regulated genes.  
In order to obtain a better understanding of the physiologic pathways that are associated 
with the genes that are differentially expressed from baseline to midpoint of EBRT, a functional 
network analysis was conducted.  Ingenuity Pathway analysis (Ingenuity® 
Systems,www.ingenuity.com, Redwood City, CA) identified functional networks of the 
differentially expressed genes from the Ingenuity’s Knowledge Base.  Functional networks and 
the top differentially expressed genes that were identified from baseline to midpoint of EBRT in 
this study were compared for similarities with the functional networks and top differentially 
expressed genes identified from Caucasian men during EBRT reported by Saligan et al.15-16,19  
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These functional networks suggested biological underpinnings of the possible physiological 
mechanisms that influence fatigue intensification during EBRT in this population.   
Power Analysis. With 26 subjects included in the study (the minimum sample size 
needed to meet aim 1), we had 80% power to detect a minimum of 2.0 fold change in gene 
expression from baseline to midpoint of EBRT.  Power was computed using the web application 
at http://bioinformatics.mdanderson.org/MicroarraySampleSize/.  For 80% power, the required 
sample sizes (number of subjects with paired baseline-midpoint measurements) for various fold 
changes, number of expressed genes analyzed and number of false positives that are acceptable 
are presented in Table 2.  
Table 2 
Sample size needed to detect differentially expressed genes between baseline and midpoint of 
EBRT. 
Sample Size  #Expressed 
Genes  
# of Acceptable False 
Positives 
Fold Change 
19 10,000 5 2 
21 10,000 2 2 
21   5,000 1 2 
22 10,000 1 2 
23 15,000 1 2 
24 20,000 1 2 
 
Pitfalls and resolution. One could argue that using blood to assess gene expression 
patterns may not be optimal when compared to gene expression measured in the tissue of interest 
(i.e., tumor tissue).  However, since the etiology of fatigue remains unknown and no specific 
system has been directly linked to its development, a tissue-specific approach is not an ideal path 
to pursue at this time.  Early studies using lymphocytes and RNA extracted from these cells for 
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gene expression analysis have demonstrated that this approach is sensitive for the detection of 
patterns of gene expression in association with a variety of medical conditions.17,47, 80  We did not 
have any technical difficulties in the blood sample collection and conservation of RNA until 
extraction since the process of collection, transportation, storage, and shipment of blood samples 
followed the manufacturer’s procedure and the standard operating procedures of the UPR Cancer 
Center approved by the UPR Institutional Review Board and Biosafety Committees.  
Specific Aim 3: To determine the association between changes in genes expression with 
changes in fatigue score from baseline to midpoint of EBRT in Hispanic PR men with non-
metastatic PC. 
Overview of approach in Aim 3. Three hundred seventy-three genes (130 up-regulated 
and 243 down-regulated) were differentially expressed from baseline to midpoint of EBRT after 
the genes passed filtering criteria of 1% FDR (see Appendix R).  The changes in expression level 
of these genes were going to be associated with changes in fatigue scores from baseline to 
midpoint of EBRT.  The purpose was to determine not only which genes are differentially 
expressed pre and at midpoint EBRT, but also those genes where the change is associated with a 
change in fatigue (i.e., EBRT associated genes that are also associated with changes in level of 
fatigue).  Due to the surprising finding that fatigue did not significantly change over the course of 
EBRT (see Chapter 4), the planned analyses for Aim 3 were not possible.  
 
Ethical considerations 
Human Research Protection Office’s approval was obtained from the University of 
Puerto Rico and the U.S. Midwestern academic medical center Human Subjects Committees.  No 
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participants experienced psychological distress from answering the fatigue, IPAQ, PROMIS-
sleep disturbance questionnaires and, HDRS nor experienced any bruise or sign of infection from 
the venipuncture site at any time-point.  To safeguard confidentiality, unique identifiers were 
assigned to all participants for all portions of the study and all data collection instruments and 
blood samples.  Logs linking participants’ identifying information to study numbers are kept 
locked in a file cabinet at the UPR School of Nursing, available only to the PI and her mentoring 
team.  Names of study participants will not be reported at any time; only the data obtained as a 
result of their participation will be made public; study findings will be presented only in the 
aggregate.   
 All responses from paper questionnaires collected at all study time points are kept in a 
secure cabinet at the PI’s office in the UPR School of Nursing.  All biologic samples were coded 
and stored in a locked -80o C freezer at the UPR Clinical research Center facilities until shipped 
to the laboratory of Dr. Leorey N. Saligan, PhD, CRNP, RN, Symptom Biology Unit, National 
Institute of Nursing Research, Intramural Research Program, National Institutes of Health, 
Bethesda, MD.  Every effort was made to ensure participant confidentiality as prescribed by U.S. 
Midwestern academic medical center Human Subjects Committees and UPR Medical sciences 
Campus Institutional Review boards and HIPAA standards. 
Potential risks. We acknowledge that there were a small number of relatively minor 
risks associated with participation in the study.  Even though the participants were given the 
option to withdraw from the study at any time during its course, no one withdrew.  In the rare 
event a participant experienced severe distress, or if the score on the HDRS scale was above the 
cut-off score for depression, or if participants reported signs of infection around the venipuncture 
site, they would have been referred for evaluation, counseling, and follow-up medical care 
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services. However, during the study there were no side effects, hence no patient evaluation was 
needed. We did not offer any participation incentives.   
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CHAPTER IV 
RESULTS 
The purpose of this study was to examine the clinical fatigue experienced by 26 Hispanic 
Puerto Rican men over the course of external beam radiation therapy (EBRT). Also, an unbiased 
a microarray platform was used to explore the differential expression of genes from peripheral 
whole blood RNA collected from Hispanic Puerto Rican men at baseline and at midpoint of 
EBRT.  Functional networks of the differentially expressed genes were examined using 
Ingenuity Pathway Analysis to determine pathways that may explain the possible physiological 
mechanisms that influence fatigue intensification during EBRT in this population.  A 
comprehensive database that included demographics and study measures responses at three time 
points (baseline [prior to EBRT], midpoint [days 19-21], and end of treatment [days 38-42]) 
from the 26 participants was developed.  An independent reviewer examined the data entry and 
confirmed that each data point was accurately entered.  The medical record and the participant-
reported data were analyzed using SPSS 18.0 statistical software, and differential expression of 
genes data were analyzed using the LIMMA132 package in R.  This chapter presents the results of 
the study, including the participants' characteristics and the findings for each study aim. 
Sample 
 Thirty-one individuals were approached for possible participation in the study; three 
refused participation, 28 agreed, and 26 of these were eligible and gave consent.  The reasons for 
those that refused to participate were: "agreed to answer questionnaires but not to give blood" (2 
patients) and "not interested" (1 patient).  Of the 28 who agreed to participate, two participants 
were found to be ineligible due to a diagnosis of chronic renal failure, and that they were 
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currently on dialysis.  As no one dropped out of the study, data were obtained from the required 
number of subjects identified in the power analysis.  To avoid missing data points from the 
instruments administered, prior to the participants leaving the site, the principal investigator 
reviewed that the participants answered all the instruments’ items and kindly requested 
participants to complete any missing items.  Data were missing on some laboratory results from 
the radiotherapy medical chart: 19 had thyroid-stimulating hormone (TSH) levels missing; 10 
had albumin levels missing, and four had hemoglobin levels missing.  However, the medical 
history and the inclusion/exclusion criteria interview confirmed no disease exclusion and since 
these participants had no values missing on each instrument, they were all included in the data 
analyses.  Blood samples were taken from all the participants at baseline and midpoint of EBRT 
for the gene expression analyses.  This resulted in a sample of 26 participants who completed all 
the study procedures. 
Sample Demographics 
 The convenience sample consisted of 26 Hispanic Puerto Rican men, ages 52-81 years, 
all being treated with EBRT for non-metastatic PC at one site ("Tome" ambulatory Radio 
Oncology Center).  The average age was 67.01, with a SD of 7.56.  The majority of participants 
reported falling in the racial category of White (85%).  Most of the participants were Catholic 
(73.1%), and retired (69.2%).  While 96.2% of the participants were married or partnered, three 
(11.5%) participants reported that they cared for themselves on their own or were caring for their 
dementia-affected spouse.  Participants' number of children ranged from zero to six, with a mean 
of three (SD = 2).  The participants were for the most part well educated with only four (15.4%) 
participants not having a high school diploma.  Fifty percent of the participants had a 
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baccalaureate degree or higher education.  A summary of the sample demographics is provided 
in Table 3. 
Table 3 
 
Demographic Characteristics of Study Participants 
 
Characteristics N     (%) 
Racial categories  
  White 22  (85.0) 
  African American   4  (15.0) 
Marital status  
  Married 24  (92.3) 
  Single   1    (3.8) 
  Living together   1    (3.8) 
Highest education completed  
  Elementary/middle school   2    (7.7) 
  Some High School   2    (7.7) 
  High School Diploma   8  (30.8) 
  Some university no degree   1    (3.8) 
  Bachelor   7  (26.9) 
  Doctoral degree   3  (11.5) 
  Post-doctoral   3  (11.5) 
Religious preferences  
  Catholic 19   (73.1) 
  Protestant   3   (11.5) 
  None   4   (15.4) 
Occupation  
  Retired 18   (69.3) 
  Working   7   (26.9) 
  Handicap   1     (3.8) 
Primary caregiver  
  Wife 23   (88.5) 
  None   3   (11.5) 
 
Sample Clinical Characteristics 
  Approximately one third of the sample (34.6%) had low risk disease with a prostate 
cancer clinical stage of T1 and a Gleason score between six and nine, 46.2% had stage T2, 
15.4% had stage T3, and one participant had stage T4 prostate cancer.   Baseline prostate-
specific-antigen levels ranged from 0.02 to 17.70ng/mL.  Most participants (57.7%) received 
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neo-adjuvant hormonal therapy (androgen deprivation therapy) eight weeks prior to the initiation 
of EBRT, and only 23.1% received radical prostatectomy more than a year before receiving 
EBRT.  Of the 26 participants, 14 (53%) received a total of 43 fractions with 77.4 Gy, six (23%) 
received a total of 42 fractions with 75.6 Gy, five (19%) received a total of 38 fractions with 68.4 
Gy, and one (5%) received a total of 38 fractions with 61.2 Gy using the IMRT technique.  
Baseline hemoglobin (M = 13.96 [SD = 1.17]), albumin (M = 4.06 [SD = .28] g/dL), and TSH (M 
= 2.68 [SD = 1.33] ųIU/mL) were within reference range (see Table 4).  None of the participants 
had uncorrected hypothyroidism, anemia, or chronic inflammatory disease.  More than half of 
the participants had co-morbid conditions such as hypertension (69.2%) and diabetes (53.8%).  
The average body mass index (BMI) across the three time points was 29.39 (SD 4.16), consistent 
with being overweight.134.   None of the clinical features in table four were significantly 
correlated with fatigue at baseline.  
Table 4 
 
Participants’ Clinical Characteristics during Prostate Cancer Treatment 
 
Variable Mean    SD Range N  Reference Range 
Gleason score 
(median) 
  7.00   .99 6-9 26  
PSA levels, ng/mL   5.42 4.34 .02-17.70 26 0-2.5 ng/mL 
Hemoglobin 13.96 1.17 12.20-17.70 22 11-18g/dL 
Albumin levels, g/dL   4.06   .28 3.4-4.5 16 3.4-5.0 g/dL 
TSH, μIU/mL   2.68 1.33 1.18-5.27 7 0.465-4.68 μIU/mL 
Number of RT 
Fractions (median) 
42.00 2.10 38-43   
Number of RT Fields 
(median) 
  7.00   .39 6-8   
 
Instrument Evaluation 
 Due to the relatively small sample size, visual inspections as well as frequency 
distributions of the data were conducted on all items to identify outliers and responses 
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inconsistent with instrument options.  Histograms were evaluated for normalcy of distribution.  
Descriptive characteristics of mean, mode, median, variance, standard deviation, kurtosis and 
skew were generated and reviewed.  Internal consistency reliability and the interrelationship 
among items were investigated based on the data from all self-report instruments across the three 
time points.  Mean scores of all scales were calculated.  As previously stated, there were no 
missing values on each instrument. 
Internal Consistency Reliability 
 Coefficient alphas were calculated for all instruments at the three time points and item 
analysis for each scale was conducted using the reliability analysis procedure.  The Cronbach 
alphas for all the numeric rating scales at the three time points are presented in Table 5.  The 
Functional Assessment of Cancer Therapy-Fatigue (FACT-F) and the PROMIS-Sleep 
disturbance (PROMIS-SD) scale showed acceptable internal reliability. The range of the 
Cronbach alphas for the FACT-F scale across the three time points was .91-.93, for the 
PROMIS-SD was .89-.95, and for the Hamilton Depression Rating Scale (HDRS) was .55-.84.   
Table 5 
 
Cronbach Alpha Reliability of the Functional Assessment of Cancer Therapy-Fatigue (FACT-F), 
PROMIS-Sleep disturbance (PROMIS-SD), and the Hamilton Depression Rating Scale (HDRS) 
across the 3 Time Points 
 
 Reliabilities of Scales Across Time Points 
Scales Baseline Midpoint End of 
treatment 
                                      Cronbach Alpha 
Fatigue (FACT-F) .91 .92 .93 
PROMIS-total score .92 .89 .95 
HDRS .86 .55 .84 
 
 The HDRS is not a self-report measure; it is a clinician-rated paper questionnaire that 
allowed the principal investigator to assess participants for symptoms of depression.  At each 
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time point, all participants were rated zero on a number of items (at baseline, all participants 
were rated 0 on 6 of the 17 items, at midpoint  on 7 items, and at end of treatment on 6 items).  
This resulted in these items having no variability.  Therefore, in assessing the internal 
consistency reliability for the HDRS, the SPSS program excluded these items from the analysis.  
Table 6 show which items all participants were rated zero across the three time points.  Lastly, 
because the International Physical Activity Questionnaire Short Form (IPAQ-SF) is not a scale, 
but rather provides the amount of Metabolic Equivalents (METs)-minutes of activity, no 
Cronbach alpha was determined for this measure. 
Table 6 
 
Items from the Hamilton Depression Rating Scale that the Participants’ Assessment was 0 across 
the 3 Time Points 
 
Baseline Midpoint End of Treatment 
Item # 3 
Item # 8 
Item # 10 
Item # 12 
Item # 15 
Item # 17 
Item # 1 
Item # 3 
Item # 8 
Item # 9 
Item # 10 
Item # 15 
Item # 16 
Item # 2  
Item # 3  
Item # 8  
Item # 13  
Item # 14 
Item # 17 
Note: Specifically each item assesses: #1depressed mood, #2 feelings of guilt, # 3 suicide, 
# 8  psychomotor retardation, # 9 agitation, # 10 Psychic anxiety, # 12 gastrointestinal 
symptoms, #13 general somatic symptoms, # 14 genital symptoms, #15 hypochondriasis, 
# 16 loss of weight, and # 17 patient's insight for depression 
 
Dimensionality 
 Inter-item correlations were assessed using Pearson correlation coefficients for the 
FACT-F, PROMIS-SD, and HDRS scales across the three time points during EBRT.  With 
respect to the FACT-F, findings showed that: (a) at baseline, the range of inter-item correlations 
was from -.02 to .98; (b) at midpoint, a range from .01 to .95; and (c) at end of treatment, a range 
from .22 to .96.  The HDRS showed: (a) at baseline, a range of inter-item correlations from -.11 
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to 1.0; (b) at midpoint, a range from -.20 to 1.00; and (c) at end of treatment, a range from -.09 to 
1.00.  Lastly, the inter-item correlation matrix for the PROMIS-SD showed that: (a) at baseline, 
correlations ranged from .29-.94; (b) at midpoint, from .15-.89; and (c) at end of treatment, from 
.5-.93. Specifically, with respect to the FACT-F: at baseline and at midpoint, seven items had 
inter-item-correlations above, and six items below .5, and at endpoint, 10 items had inter-item-
correlations above and three items below .5.  With respect to the PROMIS-SD: at baseline, seven 
items had inter-item-correlations above and one item below .5, at midpoint, five items had inter-
item-correlations above and three items below .5, and at endpoint, all items had inter-item-
correlations  above .5; and with respect to the HDRS: at baseline, four items had inter-item-
correlations above and seven items below .5, at midpoint, nine items had inter-item-correlations 
above and one item below .5, and at endpoint, eight items had inter-item-correlations above and 
three items below .5.  In sum, the instruments in this study demonstrated overall higher, rather 
than lower, inter-item-correlations, and Cronbach alphas > 0.70 across the three time points, 
except for midpoint HDRS.   
Distributions and Mean Scores for the FACT-F, PROMIS-SD, and HDRS Scales, and the 
IPAQ, across the 3 Time Points  
 Descriptive statistics were generated for the FACT-F, PROMIS-SD, and HDRS scales 
and for the IPAQ for each of the time points.  For each of the three assessments (baseline, 
midpoint, and end of treatment of EBRT), a mean score for each scale was calculated for use in 
the subsequent statistical analyses.  Distributions and mean scores for the FACT-F, PROMIS-
SD, HDRS scales, and the IPAQ across the three time points appear in Table 7.  To assess the 
change in sleep disturbance, energy expenditure, and depression at the three time-points (pre, 
midpoint, and end of EBRT), we compared all pair-wise scores measured at the three time points 
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using paired t-tests.  The paired t-test for the FACT-F will be described later under the aim 1 
results. 
Table 7 
 
Distributions and Mean Scores for the Functional Assessment of Cancer Therapy-Fatigue 
(FACT-F), PROMIS-Sleep disturbance (PROMIS-SD), the Hamilton Depression Rating Scale 
(HDRS), and the International Physical Activity Questionnaire Short Form (IPAQ-SF) across 
the 3 time points 
 
Scales Mean SD Actual range 
FACT-F 
(possible range: 0-52) 
Baseline  42.38 9.34 21-52 
Midpoint 42.11 8.93 20-52 
End 43.03 8.62 2152 
PROMIS-SD 
(possible range: 0-40) 
Baseline  20.35 9.82 8-44 
Midpoint 19.00 7.73 8-34 
End 17.04 8.67 8-39 
HDRS 
(possible range: 0-54) 
Baseline  1.23 2.27 0-9 
Midpoint 1.08 1.41 0-5 
End .96 1.93 0-8 
IPAQ-SF 
(possible range: 0 - cannot be determined*) 
Baseline  2375.02 3815.64 0-15420.00 
Midpoint 2905.65 4281.05 0-17394.00 
End 3882.29 7056.55 0-29040.00 
*Cannot be determined because there is no limit to the frequency or intensity of the exercise 
done. 
 
The FACT-F is a 13-item questionnaire.  After appropriately reverse coding (items 7 and 
8), scoring for this scale was computed by adding the individual item scores, and dividing by the 
number of items answered.  Higher scores represent less severe fatigue.108-109   The mean fatigue 
score at baseline (pre-EBRT) was 42.38, at mid-point 42.12, and 43.04 at end of EBRT.    
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  The PROMIS-Sleep disturbance short form assesses sleep disturbance over the past 
seven days.  To compute the raw mean score, scores were totaled and divided by the number of 
items answered.  In addition, the authors of the scale also present a T-score version.  The T-score 
re-scales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) 
of 10.  A higher PROMIS raw and T-score represents more sleep disturbance.  The mean sleep 
disturbance raw total score was 20.35 at baseline, 19.00 at midpoint of EBRT, and 17.04 at end 
of EBRT.  The mean T-score showed a similar pattern, namely, 48.65 at baseline 47.75 at 
midpoint of EBRT, and 44.80 at end of EBRT.  The results of the paired t-test for the PROMIS-
SD, HDRS scales, and the IPAQ across the three time points appear in Table 8.  As shown in 
Table 8 there were no significant differences in any of these variables across time.   
Table 8 
 
Paired Samples t-test for the PROMIS-Sleep disturbance (PROMIS-SD), the Hamilton 
Depression Rating Scale (HDRS), and the International Physical Activity Questionnaire Short 
Form (IPAQ-SF) across the 3 Time Points   
 
Scales Pairs t (df) Two-sided p-values 
   
PROMIS-SD Baseline vs.  .83 (25)   .42 
 Midpoint   
 Baseline vs.  1.80 (25)   .09 
 End   
 Midpoint vs. 1.90 (25)   .07 
 End   
   
HDRS Baseline vs.  .32 (25)  .75 
 Midpoint   
 Baseline vs.   .60 (25)  .55 
 End   
 Midpoint vs.  .43(25)  .67 
 End   
   
IPAQ-SF Baseline vs. -1.23 (25) .23 
 Midpoint   
 Baseline vs.  -1.63 (25) .12 
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Scales Pairs t(df) Two-sided p-
value 
 End   
 Midpoint vs. -1.06 (25)  .30 
 End   
 
 The HDRS comprises 17 items which are rated on a three-point (0-absent, 1-slight or 
trivial, 2-clearly present) or four-point (symptom is: 0-absent, 1-mild, 2-moderate, or 3-severe) 
scale.125-126   A total score was obtained by adding the 17 items; the higher the total scores, the 
more severe the depression. The mean depression score of the HDRS was 1.23 at baseline, 1.08 
at midpoint, and .96 at end of EBRT.  A paired t-test showed that there were no significant 
changes between the baseline and midpoint HDRS total mean scores, between the midpoint and 
the endpoint HDRS total mean scores, or between the baseline and the endpoint HDRS total 
mean scores.  None of the participants reached the cutoff score (15) for depression at any time 
point.   
 The IPAQ-SF self-administered format consist of nine items that ask about a seven-day 
recall of the amount of minutes spent in activity of four intensity level vigorous-intensity activity 
(1); moderate-intensity activity (2); and walking (3).  For all categories respondents have to 
specify how many days and how many minutes they spent at a specific activity category.  The 
amount of Metabolic Equivalents (METs)-minutes was calculated by multiplying the number of 
minutes by 8.0 (vigorous), 4.0 (moderate), and 3.3 (walking).  A total score was calculated by 
counting the METs-minutes of these three categories together.  The mean of a combined total 
physical activity score (Metabolic Equivalent of Task (MET)-minutes/week) was 2,375.02 at 
baseline, 2,905.65 at midpoint of EBRT, and 3,882.29 at the end of EBRT.  Similar to that with 
the PROMIS-SD and the HDRS, paired t-tests showed that there were no significant changes 
between the baseline and the midpoint MET total mean score, between the midpoint and the 
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endpoint MET total mean scores, or between the baseline and the endpoint MET total mean 
scores.  In summary, compared with baseline, there were no significant changes in any of the 
scales (PROMIS-SD and HDRS) or the IPAQ-SF between baseline and midpoint, midpoint and 
completion, and baseline and completion of EBRT. 
Findings for Aim 1 
Aim 1: To describe the trajectory of fatigue among Hispanic Puerto Rican men over the course 
of receiving EBRT for non-metastatic prostate cancer and compare these findings with historical 
data of fatigue symptoms of Caucasian men with prostate cancer during EBRT. 
Fatigue was measured at each time point using the Functional Assessment of Cancer 
Therapy Fatigue subscale (FACT-F).  To assess the change in fatigue at the three time-points 
(pre, midpoint, and end of EBRT ), we compared all pair-wise fatigue scores measured at the 
three time points (i.e., pre vs midpoint; pre vs end, midpoint vs end) using both parametric 
(paired t-tests) and non-parametric (Wilcoxon Signed Rank Test) statistical tests to assess the 
robustness of results.  Table 9 presents the results of the paired-t-tests and the Wilcoxon Signed 
Rank Tests. 
Table 9 
 
Summary of Paired Samples t-test and Wilcoxon for the Functional Assessment of Cancer 
Therapy Fatigue subscale (FACT-F) 
 
Paired Samples T-test Wilcoxon 
Pairs Mean (SD) T p-value   Z p-value 
Baseline vs.  42.38 (9.34)  .179 .859 -.66 .51 
Midpoint 42.11 (8.93)     
Baseline vs.  42.38 (9.34) -.389 .701 -.53 .60 
End 43.03 (8.62)     
Midpoint vs. 42.11 (8.93) -.791 .437 -1.14 .26 
End 43.03 (8.62)     
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 Mean fatigue score at baseline (pre-EBRT) was 42.38 for the sample.  It remained about 
the same at mid-point 42.12, and slightly increased to 43.04 at completion of EBRT, but was not 
significantly statistically different.  We also conducted the Friedman's test that is the 
nonparametric test equivalent to the repeated measures ANOVA.  Those results also confirmed 
no significant difference (Friedman's test: χ21.20 [df, 2], p =.55).  As a group the present sample 
did not change in fatigue over time.   
We further compared the result of the changes in fatigue (baseline minus midpoint) 
among those receiving the concomitant use of neo-adjuvant hormonal therapy (ADT) (n = 11) 
with those who did not (n = 15).  The t-test showed that there were no significant differences 
between those on ADT and those not on ADT in changes in fatigue  (t = -.45 (24), p = 0.66); and, 
there was no significant correlation between changes in fatigue (baseline minus midpoint) and 
participant’s age (Spearman’s rho .23, p = .25).  
 While as a group there were no statistically significant changes in fatigue over the course 
of EBRT, subset analysis of the fatigue scores showed that, of the 26 subjects, most of the 
participants also had no clinically significant change (i.e. > 3 point decrease) in fatigue (baseline 
to midpoint: 17 (65%); baseline to endpoint: 16 (62%); and, midpoint to endpoint: 18 (68.5%).  
As shown in Table 11, only a small number of participants had a clinically significant increase in 
fatigue (more than a 3-point decrease in fatigue score) across time points.  Similarly, and also 
contributing to the lack of statistically significant difference, a small number of participants had 
a clinically significant decrease in fatigue (more than a 3-point increase in fatigue score) across 
time points.  Table 10 presents the distribution of the participants with respect to clinically 
significant changes in fatigue across time points. 
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Table 10 
 
Distribution of the Number of Participants Reflecting Clinically Significant Changes in Fatigue 
across the 3 Time Points 
 
Changes in FACT-F Scores Baseline to 
mid-point 
N (%) 
Baseline to 
end-point 
N (%) 
Mid-point 
to end-
point 
N (%) 
more than a 3-point decrease in fatigue score 
(clinically significant increase in fatigue) 
5 (20.0)  4 (15.0) 3 (11.5) 
more than a 3-point increase in fatigue score 
(clinically significant decrease in fatigue) 
4 (15.0)  6 (23.0)  5 (20.0) 
3 or less point change in any direction  
(no clinically significant change in fatigue) 
17 (65.0) 16 (62.0) 18 (68.5) 
 
   Figure 7 shows the individual fatigue scores of those participants who had clinically 
significant increases in fatigue at any time point.  For example, there was one participant 
(PR013) who not only had a clinically significant increase in fatigue from baseline to mid-point, 
but also from baseline to completion, and from mid-point to completion. There were three cases 
(PR02, PR10, PR17) who reflected a clinically significant increase in fatigue from baseline to 
mid-point, from baseline to completion, but remained about the same from mid-point to 
completion.  And there was one participant (PR03) who remained about the same from baseline 
to midpoint, but had a clinically significant increase in fatigue from baseline to completion and 
from mid-point to completion.  
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Figure 7. Individual Fatigue Scores of Participants Who Reflected Clinically Significant 
Changes in Fatigue (more than a 3-point decrease in fatigue score) across the 3 Time Points 
 
 
 
Linear Regression Models 
Multiple Linear Regression Analysis 
Multiple linear regressions (baseline, mid-point and end-point) were conducted to assess 
the impact of several possible independent variables on the dependent variable of fatigue.  While 
sample size was determined for the primary aims of this study, the Green135 formula for 
determining sample size needed was applied post hoc to determine the number of predictors we 
could use in the multiple linear regressions with sufficient power.  Calculation showed that, for a 
small sample size of 26, only two independent variables should be used (N needed for a 
regression with 2 IVs: 8 + 1.5 = 9.5 = L; for a large effect of R2 = .26; then f = .26/(1-.26) = 
.26/.74 = .35; N= L/f = 9.5/.35 = 27).  Among the potential variables, we did not include 
laboratory values as independent or as control variables since all laboratory results were in the 
normal range, and were only available from prior to the baseline visit (approximately 3 months 
before baseline visit).  We excluded: (a) the concomitant use of neo-adjuvant hormonal therapy 
(ADT) because the results of the t-test showed that there were no significant differences between 
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those on ADT and those not on ADT in fatigue across time (baseline vs. midpoint: t = -.72 (24), 
p = 0.48; baseline vs. end: t = -.41(24), p = 0.69; and, midpoint vs. end: t = -1.64, p = 0.11); and, 
(b) age, because even though the descriptive data showed some variability (range = 52-81, SD = 
7.56), the correlation between age and the dependent variable baseline FACT-F was very weak (r 
= 0.06; age and FACT-F).  In addition, if we consider as possible independent variables those 
obtained at the time the fatigue measures were taken, then the latter variables will be important 
for factoring in or for controlling their effect on measures of fatigue.136  Weight was taken at 
each time point, but we excluded body mass index (BMI) because as with  age, regardless of 
some variability (M = 29.35, SD = 4.16), it had no independent relationship with fatigue (r = 
0.09; BMI and FACT-F).  MET was taken at each time point, but we excluded MET as we did 
age and BMI, regardless of some variability (M = 2,415.78, SD = 3,888.54), because although 
the correlation between MET and the dependent variable at baseline FACT-F was moderate, it 
was not significant (r = 0 .31 p >.05, MET and FACT-F see Table 11).  Among the variables that 
we selected to investigate for their contribution to fatigue were the depression measure (HDRS) 
and Sleep disturbance (PROMIS-SD).  Results of the descriptive statistics and regression 
analysis will be presented next.  All statistical testing used an alpha of 0.05.  
Table 11 
Correlations among the Baseline Functional Assessment of Cancer Therapy Fatigue subscale 
(FACT-F) and Age, Body Mass Index (BMI), Metabolic Equivalent of Task (MET), PROMIS-
Sleep disturbance (PROMIS-SD), and the Hamilton Depression Rating Scale (HDRS) scores 
Variable  1  2  3  4  5  6  
1- Age  1.00       
2- BMI -.48*   1.00      
3- MET -.29 -.03 1.00     
4- PROMIS-sleep disturbance -.15 -.30 -.13 1.00    
5- HDRS -.10 -.24 -.09 .68**  1.00   
6- Total FACT-F scores  .06 .09 .31 -.70**  .69**  1.00 
* p < .01; ** p < .001    
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Examination of Assumptions for Regression Analysis  
The analysis was conducted with data for 26 participants.  Examination of the main 
assumptions for regression demonstrated that: (a) data were normally distributed as the Z-
Residual Histogram showed an approximate normal curve, and the P-P Plot showed dots 
approaching to be on a line; (b) linearity was not an issue since the examination of residual plots 
showed a linear relationship; (c) constancy of variance represented no concern since the scatter 
plot of standardized residuals against standardized predicted values showed no clear pattern; (d) 
the obtained value of Durbin-Watson of 2.10 (between 1.5 to 2.5) suggested that the data points 
were independent; (e) outliers did not seem to be an issue because the standardized residual 
ranged between -1.79 to 1.90 (between -3.5 to + 3.5); (f) co-linearity, however, was an issue.  As 
shown in Table 11, the bivariate correlation between baseline HDRS and baseline total 
PROMIS-SD score was moderately high (r =.68; p <.001).  The skewness and kurtosis for each 
variable also was examined.  The skewness (S) ranged from -0.84 to 2.48.  Kurtosis (K) ranged 
from -2.05 to 7.99.   The results of PROMIS-SD at baseline were (S = .645; K = -.337), at 
midpoint (S = .395; K =  -1.067), and at end (S = 1.139; K = .424).  At baseline, MET (S = 2.342; 
K=5.445) and HDRS (S = 2.075, K= 4.432), at midpoint, MET (S = 2.244; K =5.128), and at end, 
MET (S = 2.562; K = 6.578) and HDRS (S = 2.524, K = 6.803), with a skewness above one and 
kurtosis above three that suggests that these variables do not follow a standard normal 
distribution. 
Baseline Bi-variate Correlations 
The two variables considered for inclusion in the regression analysis was the PROMIS-
Sleep disturbance and the HDRS.  FACT-F scores were significantly associated with sleep 
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disturbance scores (r = -.70, p = .001), indicating that persons who perceive feeling less fatigue 
tend to have less sleep disturbance.  Similarly, the FACT-F was negatively correlated with 
HDRS scores (r = -.68, p = .001), indicating that persons who have less depression symptoms 
tend to perceive feeling less fatigue.  However, because the PROMIS-SD scale was strongly 
correlated with HDRS (r = .68, p =.001), there was co-linearity between these two variables.  
Despite this co-linearity, we decided to include both in the regression analysis because each was 
so strongly related to fatigue.   
When depression and sleep disturbance are enter separately, they both explain significant 
variability and when they are entered in a step-wise fashion each provides additional explanation.  
Therefore, multiple regression was conducted on the baseline data using the simultaneous 
method to enter the independent variables for the analysis.  The linear combination of these 
variables was significantly related to FACT-F scores: R2= .56, adjusted R2=.53, F (2, 23) = 14.84, 
p <.001.  Thus, in the model the adjusted R-squared value revealed that 53% of the variance in 
total FACT-F scores was explained by the independent variables (PROMIS-SD and HDRS).  
The model summary of the multiple regression is presented in Table 12.     
Table 12 
Summary of Multiple Regression Analysis for Independent Variables to Explain Baseline 
Functional Assessment of Cancer Therapy Fatigue subscale (FACT-F) 
       
Variable b SE     Βeta   t Sig.  
Constant  52.74 
 
3.33 
 
 
 
2.75 
 
.012 
 
 
PROMIS-
sleep  
-.41 .18 -.43 -2.03 .03  
HADS  -1.58 .78 -.38 -2.04 .05  
R2 = .56; Adjusted R2 = .53; SE of Estimate = 6.44 F (2,23) = 14.84 
p <.001 
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Examination of these results showed that baseline sleep disturbance variability emerged 
as a strong explanatory variable of fatigue (b = -.41, SE = .18, β = -.43, t = -2.03, p = .03).  
Similarly, the HDRS, reflecting the symptom of depression, also emerged as a significant 
explanatory variable of fatigue (b = -1.58, SE = .78, β =-.38, t = -2.04, p = .05). These results 
show that both variables are having a strong effect, despite their co-linearity, and both are 
statistically significant.  Thus, higher total FACT-F scores (meaning less fatigue) was associated 
with lower depression (HDRS) and lower sleep disturbance (PROMIS-sleep disturbance).  
Midpoint Multiple Linear Regression Analysis 
The same analysis was conducted using Midpoint Fatigue as the dependent variable and 
midpoint measures of the independent variables, using the simultaneous enter method.    Similar 
to the baseline bi-variate correlations, midpoint sleep disturbance (PROMIS-SD) and midpoint 
depression (HDRS) were strongly correlated with fatigue (FACT-F) and were correlated with 
each other (see Table 13).   
Table 13 
Correlations among the Mid-point Functional Assessment of Cancer Therapy Fatigue subscale 
(FACT-F) and PROMIS-Sleep disturbance (PROMIS-SD), and the Hamilton Depression Rating 
Scale (HDRS) scores 
 
Variable  
1  2  3  
1- PROMIS-sleep disturbance 1.00    
2- HADS .71**  1.00   
3- Total FACT-F scores  -.71**  -.63**  1.00 
Note:  * p < .01; ** p < .001     
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This midpoint linear model also was statistical significant: R2 = .54, adjusted R2 at .50, (F 
(2, 23) = 13.34, p < .001).   However, only midpoint sleep disturbance emerged as a significant 
predictor in this analysis (b = -.62, SE = .23, β =-.53, t =-2.66, p = .01).  It is likely that 
depression did not become a significant predictor because sleep got credit for most of the shared 
variability between these co-linear variables Table 14 presents the results of this linear 
regression. 
Table 14 
Summary of Multiple Regression Analysis for Independent Variables to Explain Mid-point 
Functional Assessment of Cancer Therapy Fatigue subscale (FACT-F) 
       
Variable b SE  Βeta   T Sig.  
Constant 55.54 3.78  14.68 .001  
PROMIS-SD  -.62 .23 -.53 -2.66 .010  
HDRS  -1.59 1.27 -.25 -1.25 .22  
R2 = .54; Adjusted R2 = .50; SE of Estimate = 6.34; F (2,23) = 
13.34, p < .001 
 
End of Treatment Multiple Linear Regression Analysis 
In another multiple regression, the dependent variable end-point FACT-F was regressed 
on end-point values of PROMIS-SD and HDRS as independent variables.  Similar to the baseline 
and midpoint regressions, sleep disturbance (PROMIS-SD) (r = - 0.75, p =.001) and depression 
(HDRS) (r = -.75, p =.001) were strongly correlated with fatigue (FACT-F), and were correlated 
with each other (r = 0.77, p = .001) (see Table 15). 
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Table 15 
Correlations among the End-point Functional Assessment of Cancer Therapy Fatigue subscale 
(FACT-F) and PROMIS-Sleep disturbance (PROMIS-SD), and the Hamilton Depression Rating 
Scale (HDRS) scores   
Variable  1  2  3  
1- PROMIS-sleep disturbance 1.00    
2- HADS .77**  1.00   
3- Total FACT-F scores  -.75**  .75**  1.00 
Note:  * p < .01; ** p < .001     
 
The linear model also was a significant for end-point fatigue (FACT-F): the R2 value was 
similar to the baseline model at .64, as was the adjusted R2 at .61, (F (2, 23) = 20.45, p < .001).  
Similar to the baseline model both end-sleep disturbance (b = -.43, SE = .19, β = -.43, t =-2.23, p 
= .04) and end depression (b = -1.86, SE = .87, β = -.42, t = -2.13, p = .04) remained significant 
explanatory variables in this analysis.   Table 16 presents the results of this linear regression. 
Table 16 
Summary of Multiple Regression Analysis for Independent Variables to Explain End-point 
Functional Assessment of Cancer Therapy Fatigue subscale (FACT-F) 
       
Variable b SE Βeta t Sig.  
Constant 62.19 2.92  17.90 .001  
PROMIS-
SD  
-.43 .19 -.43 -2.23 .04  
HDRS  -1.86 .87 -.42 -2.13 .04  
R2 = .64; Adjusted R2 = .61; SE of Estimate = 5.39; F (2,23) = 20.45,  p < 
.001 
 
 In summary, fatigue (at baseline, midpoint and end-point) was regressed on sleep 
disturbance and depression at each time-point.  At each time point the linear combination of 
these variables was significantly related to fatigue. In all three regressions, sleep disturbance 
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emerged as the stronger explanatory variable of fatigue.  While baseline and end-point 
depression reached statistical significance as an explanatory variable of fatigue, depression was 
not significant at midpoint likely due to the co-linearity between sleep disturbance and 
depression.  Given the similarity of the correlations between these variables and fatigue, the role 
of sampling variability in these findings cannot be ruled out. 
 
Findings for Aim 2 
Aim 2: To assess gene expression changes from baseline to midpoint of EBRT among Hispanic 
PR men receiving EBRT for non-metastatic prostate cancer. 
Peripheral blood (2.5 mL) was collected from each subject at baseline and midpoint of 
EBRT to explore changes in gene expression using PAXgene blood ribonucleic acid (RNA) 
tubes (PreAnalytiX, Hombrechtikon, OH).  Total RNA was extracted using the PAXgene™ 
Blood RNA system (Qiagen, Frederick, Maryland) according to the manufacturer’s instructions 
described under the methods section.  The quantity of total RNA was measured by a 
spectrophotometer at optical density of 260 nanometers.  RNA quality was assessed using the 
RNA 6000 Nano LabChip® on a Bioanalyzer Agilent 2100 (Agilent Technologies, Palo Alto, 
CA).  Total amount of good quality RNA was adequate to proceed with the experiment (see 
Table 17).  A minimum of 50 ng of total RNA as starting material is suggested in order to 
proceed with the microarray experiment.    
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Table 17 
 
RNA quality data shows adequate amount of starting good quality total RNA material to proceed 
with the microarray experiment. 
   
ID ng/ul 
143 86.93 
127 52.63 
142 77.04 
138 97.74 
151 102.13 
125 105.38 
118 164.43 
141 197.05 
116 87.43 
101 61.47 
117 96.7 
115 120.62 
112 94.68 
144 126.06 
152 69.36 
 
RNA purification, cDNA and cRNA synthesis, amplification, hybridization, scanning and 
data analyses were conducted by one laboratory technician following standard protocols as 
described under the methods section.   Affymetrix microarray chips (HG-U133 Plus 2.0, Santa 
Clara, California) were used for gene expression analysis.  The Affymetrix HG-U133 Plus 2.0 
microarray chip is comprised of more than 54,000 probe sets and 1,300,000 distinct 
oligonucleotide features, which analyzed the expression level of over 47,000 transcripts, 
including 38,500 well characterized human genes.  Affymetrix GeneChip Command Console 
(AGCC, 3.0 V) was used to scan the images for data acquisition (see Figure 6, p. 67).  
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Global Gene expression analysis  
Affymetrix CEL files (the file format that stores the results of the intensity calculations of 
the pixel values of the scanned image from a microarray chip) were imported into LIMMA132  
package in R.  Background correction, quantile normalization, and summarization expression 
calculation were conducted with the Robust Multichip Average (RMA) algorithm and the linear 
model with LIMMA package.   In addition to the laboratory quality control steps, after RMA, 
data quality was assessed via per-subject box plots and MA plots.  The subjects box plots shows 
that all arrays are within the expected range and that the distributions are similar to each other 
(see Figure 8). 
Figure 8.  Boxplots of all Genes in each Array on the x-axis (n = 52 arrays), and the log 
base 2 of the Expression Values on the y axis  
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In addition, the MA plot figure shows that no further normalization after RMA is needed 
because the distribution of the data of most of the genes (points on the y-axis are located at 0, 
since Log (1) is 0 (see Figure 9).    
Figure 9.  MA Plot of Log-intensities Ratio where M (y-axis) Represents the Mean-
difference between the Specified Array and the Artificial Average Array, and A (x-axis) is 
the Average Expression Value of that Gene in all Arrays.  
 
After the normalization step and the data quality check, gene expression differences 
between midpoint and baseline of EBRT were assessed using the linear modeling features 
available in the LIMMA package.  This analysis consists of fitting a linear regression model for 
each gene to determine if genes were differentially expressed using a modified -test that shrinks 
non-differentially expressed gene effect sizes towards zero (or fold-change towards 1).  To adjust 
for the testing of thousands of genes, we used the approach of Benjamini-Hochberg to estimate 
the false discovery rate (FDR).  To account for statistical significance, genes with a FDR < 0.01 
were considered candidate differentially-expressed genes.   
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Three hundred seventy genes (130 up-regulated and 243 down-regulated) were 
differentially expressed from baseline to midpoint of EBRT FDR <0.01 (see Appendix R).  
Figure 10 illustrates a volcano plot of results for all genes for determining differentially 
expressed genes from baseline to midpoint of EBRT.  This plot shows that a significant amount 
genes are differentially expressed, where a significant upward trend of ferredoxin reductase 
FDXR expression (Log Fold-Change = 0.496086; FDR = 4.0 x 10-6) was noted.   
Figure 10.  Volcano Plot Showing -log10 (p-value) versus Fold Changes in the y- and x-axis 
respectively of Differentially Expressed from Baseline to Midpoint of EBRT  
    
Table 18 presents the list of genes with FDR < 0.005.  Five genes (FDXR, YIPF6, AEN, 
SLC28A1, CSRP2) were significantly up-regulated and 25 genes (PRRC2B, NFATC1, CHMP7, 
RSBN, PPP1R3E, BPTF, LDLRAP1, MYCBP2, FOXP1, TCF7, ZBTB20, HSP90AB1, JADE2, 
NAPEPLD, MYC, ADARB1, ITPR1, CD79A, FAIM3, RAB30, ABLIM1, P2RX5, PAX5, BACH2, 
and FCRLA) were significantly down-regulated at midpoint of EBRT compared to the baseline 
expression levels.  It is plausible that more down-regulation occurred because the cells were 
FDXR 
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over-stimulated by radiotherapy or by prostate cancer for this period of treatment, and the 
expressions of the receptor protein were decreased in order to protect the cell.86 
Table 18 
 
The probes, gene symbols, names, Log(Fold-Change), regulation direction (Up/Down), p-values 
and FDR that were differentially expressed in the microarray experiment at a FDR <0.005. 
 
 
Probes Symbol Name Log(Fold-
Change) 
Up/Down 
Regulation 
p-
value 
FDR 
207813_s_at FDXR ferredoxin reductase 0.496086 ↑ 7.42E-
11 
4.06E-06 
221234_s_at BACH2 BTB and CNC homology 
1, basic leucine zipper 
transcription factor 2 
-0.98963 ↓ 4.86E-
07 
0.003632 
221602_s_at FAIM3 Fas apoptotic inhibitory 
molecule 3 
-0.64948 ↓ 5.25E-
07 
0.003632 
221601_s_at FAIM3 Fas apoptotic inhibitory 
molecule 3 
-0.76284 ↓ 2.2E-
06 
0.005014 
223287_s_at FOXP1 forkhead box P1 -0.49372 ↓ 4.04E-
07 
0.003632 
224838_at FOXP1 forkhead box P1 -0.5481 ↓ 1.7E-
06 
0.004576 
224837_at FOXP1 forkhead box P1 -0.52587 ↓ 2.7E-
06 
0.005447 
240052_at ITPR1 inositol 1,4,5-
trisphosphate receptor, 
type 1 
-0.618 ↓ 5.44E-
07 
0.003632 
202431_s_at MYC v-myc avian 
myelocytomatosis viral 
oncogene homolog 
-0.59249 ↓ 4.92E-
07 
0.003632 
207560_at SLC28A1 solute carrier family 28 
(concentrative nucleoside 
transporter), member 1 
0.316246 ↑ 5.98E-
07 
0.003632 
235308_at ZBTB20 zinc finger and BTB 
domain containing 20 
-0.51191 ↓ 4.54E-
07 
0.003632 
219361_s_at AEN apoptosis enhancing 
nuclease 
0.330497 ↑ 7.99E-
07 
0.003642 
1555779_a_at CD79A CD79a molecule, 
immunoglobulin-
associated alpha 
-0.648 ↓ 7.94E-
07 
0.003642 
212660_at JADE2 jade family PHD finger 2 -0.56362 ↓ 7.73E-
07 
0.003642 
232279_at JADE2 jade family PHD finger 2 -0.48261 ↓ 4.15E-
06 
0.005447 
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Probes Symbol Name Log(Fold-
Change) 
Up/Down 
Regulation 
p-
value 
FDR 
 
212313_at 
 
CHMP7 
 
charged multivesicular 
body protein 7 
 
-0.40711 
 
↓ 
 
1.18E-
06 
 
0.004277 
235401_s_at FCRLA Fc receptor-like A -1.07415 ↓ 1.58E-
06 
0.004572 
210448_s_at P2RX5 purinergic receptor P2X, 
ligand-gated ion channel,5  
-0.72014 ↓ 1.57E-
06 
0.004572 
212340_at YIPF6 Yip1 domain family, 
member 6 
0.378059 ↑ 1.59E-
06 
0.004572 
207030_s_at CSRP2 cysteine and glycine-rich 
protein 2 
0.227633 ↑ 1.76E-
06 
0.004576 
205254_x_at TCF7 transcription factor 7 (T-
cell specific, HMG-box) 
-0.49858 ↓ 2.02E-
06 
0.004805 
200965_s_at ABLIM1 actin binding LIM protein 
1 
-0.6754 ↓ 3.74E-
06 
0.005447 
203865_s_at ADARB1 adenosine deaminase, 
RNA-specific, B1 
-0.59477 ↓ 3.2E-
06 
0.005447 
207186_s_at BPTF bromodomain PHD finger 
transcription factor 
-0.45831 ↓ 3.5E-
06 
0.005447 
200064_at HSP90AB1 heat shock protein 90kDa 
alpha (cytosolic), class B 
member 1 
-0.52668 ↓ 3.82E-
06 
0.005447 
232279_at JADE2 jade family PHD finger 2 -0.48261 ↓ 4.15E-
06 
0.005447 
57082_at LDLRAP1 low density lipoprotein 
receptor adaptor protein 1 
-0.48592 ↓ 3.39E-
06 
0.005447 
201959_s_at MYCBP2 MYC binding protein 2, 
E3 ubiquitin protein ligase 
-0.4865 ↓ 3.8E-
06 
0.005447 
238722_x_at NAPEPLD N-acyl 
phosphatidylethanolamine 
phospholipase D 
-0.57602 ↓ 3.42E-
06 
0.005447 
211105_s_at NFATC1 nuclear factor of activated 
T-cells, cytoplasmic, 
calcineurin-dependent 1 
-0.34769 ↓ 4.24E-
06 
0.005447 
221969_at PAX5 paired box 5 -0.95211 ↓ 3.84E-
06 
0.005447 
229001_at PPP1R3E protein phosphatase 1, 
regulatory subunit 3E 
-0.43205 ↓ 3.55E-
06 
0.005447 
212068_s_at PRRC2B proline-rich coiled-coil 2B -0.27695 ↓ 4.16E-
06 
0.005447 
229072_at RAB30 RAB30, member RAS 
oncogene family 
-0.66549 ↓ 4.23E-
06 
0.005447 
222789_at RSBN1 round spermatid basic 
protein 1 
-0.43139 ↓ 2.93E-
06 
0.005447 
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One of the 5 up-regulated genes ferredoxin reductase (FDXR) has a p-value = 7.42E-11 
and a FDR of 4.0 x 10-6, two were greater than 3.6 x 10-3 (SLC28A1, AEN) and the last two 
(CSRP2, YIPF6) were greater than 4.5 x 10-3.  FDXR was the most significantly up-regulated 
(logFC 0.50, p=0.00000406) gene.  Eight of the 25 down-regulated genes (FOXP1, ZBTB20, 
MYC, ITPR1, FAIM3, BACH2, JADE2, CD79A) had an FDR = 3.6 x 10-3, four (CHMP7, 
P2RX5, FCRLA, TCF7) had an adjusted p-value that was less than 4.8 x 10-3,  and, thirteen 
(PRRC2B, NFATC1, RSBN1, PPP1R3E, BPTF, LDLRAP1, MYCBP2, HSP90AB1, NAPEPLD, 
ADARB1, RAB30, ABLIM1, PAX5) had an adjusted p-value that was less than 5.4 x 10-3 log fold 
change.  A list was generated of the top 20 significant up- or down-regulated genes accounting 
for both statistical and biological significance (see Table 19).  Genes with a FDR < 0.01 and a 
fold change >0.4 in either direction were considered top candidate differentially-expressed 
genes.  Table 19 also shows the genes from this top 20 up or down-regulated differentially 
expressed genes that were also observed to be the top 20 up or down-regulated genes in 
Caucasian men treated with localized radiation therapy for non-metastatic prostate cancer when 
microarray was conducted on RNA collected from these men at baseline and midpoint of 
EBRT.17 
Table 19 
 
Top 20 Up-regulated and Down-regulated Differentially Expressed Genes between Mid-point 
and Baseline based on Adjusted p value and Log Fold Change 
  
Up-regulated Genes Down-regulated Genes 
*S Genes 
Symbol 
Gene name Expression 
value 
*S Genes 
Symbol 
Gene name Expression 
value 
√ XK X-linked Kx 
blood group 
(McLeod 
syndrome) 
0.982 
FC=1.97 
√ MS4A1 membrane-
spanning 4-do-
mains, sub. fam A 
-1.112 
FC=0.46 
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Up-regulated Genes 
 
 Down-regulated Genes 
 FGFR1OP
2 
FGFR1 oncogene 
partner 2 
0.851 
FC=1.80 
√ FCRLA Fc receptor-like A -1.074 
FC=0.74 
 KLF1 Kruppel-like 
factor 1 
(erythroid) 
0.692 
FC=1.61 
√ POU2AF1 POU class 2 
associating factor 
1 
-1.042 
FC=0.48 
 SESN3 sestrin 3 0.649 
FC=1.56 
 BANK1 B-cell scaffold 
protein with 
ankyrin repeats 1 
-1.039 
FC=0.61 
 ITLN1 intelectin 1 
(galactofuranose 
binding) 
0.533 
FC=1.44 
√ IGHM immunoglobulin 
heavy constant 
mu 
-0.999 
FC=0.39 
 FDXR ferredoxin 
reductase 
0.496 
FC=1.41 
 BACH2 BTB and CNC 
homology 1, basic 
leucine zipper 
transcription 
factor 2 
-0.989 
FC=0.5 
 DPM2 dolichyl-
phosphate 
mannosyltransfer
ase polypeptide 2, 
regulatory subunit 
0.457 
FC=1.37 
 TCL1A T-cell 
leukemia/lympho
ma 1A 
-0.977 
FC=0.53 
 DPCD deleted in primary 
ciliary dyskinesia 
homolog (mouse) 
0.441 
FC=1.35 
 LINC0092
6 
long intergenic 
non-protein 
coding RNA 926 
-0.957 
FC=0.51 
√ RHD Rh blood group, 
D antigen 
0.408 
FC=1.32 
√ PAX5 paired box 5 -0.952 
FC=0.51 
 ZER1 zyg-11 related, 
cell cycle 
regulator 
0.406 
FC=1.32 
√ CCR7 chemokine (C-C 
motif) receptor 7 
-0.856 
FC=0.55 
*S √ = is a gene found in a previous study/publication (Caucasian study, Saligan et al., 2013) N=20 
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Network and Pathway Analyses 
After the identification of differentially expressed genes from the microarray analysis, we 
employed network and pathway analyses to identify the key molecular and functional pathways 
associated with these differentially expressed genes.  These functional networks suggested 
biological underpinnings of the possible physiological mechanisms that influence fatigue 
modulation during EBRT in this population.   
A significance level of p < 0.0001 was used for determining significant up- or down-
regulated genes and for selection of genes for inclusion in the Ingenuity Pathway (IPA) 
(Ingenuity® Systems,www.ingenuity.com, Redwood City, CA) because of the exploratory 
nature of this study.  The 646 probeset with a p < 0.0001 from midpoint to baseline of EBRT 
were subjected to pathway analysis using IPA.  The cutoff log ratio was set at 0.4 providing the 
opportunity to analyze only those highly up-regulated and down-regulated differentially 
expressed genes (N = 220 genes).  The IPA revealed several common biological networks that 
are associated with these 220 differentially expressed genes: (a) molecular and cellular functions 
such as cellular development, function and maintenance, growth and proliferation,  protein 
synthesis, and, cell death and survival (see Figure11); (b) diseases and disorders such as cancer, 
hematological, immunological diseases, developmental disorders, and, organismal injury and 
abnormalities; and, (c) physiological system development and function such as hematological 
system development and function, hematopoiesis, lymphoid tissue structure and development, 
tissue morphology, and, cell-mediate immune response.     
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Figure 11. Top 10 Molecular and Cellular and, Physiological System Development 
Functions of Radiotherapy-induced Gene Expression 
 
 
Further, Figure 12 shows the distinct canonical pathways of the differentially expressed 
probesets from the Ingenuity’s Knowledge Base.  Specifically, the significance of the association 
between the dataset and the identified pathway is represented: (a) as the percentage of regulated 
genes in our dataset divided by the total number of genes assigned to this pathway (this number 
is given above the pathway) and (b) by the p value calculated by Right-tailed Fisher’s exact test 
(represented by their negative log-transformed value) determining the probability that each 
biological function and/or disease assigned to these networks was not due to chance alone.  The 
top five canonical pathways that were associated with the 220 differentially expressed genes 
include: Phospholipase C Signaling, Role of NFAT in Regulation of the Immune Response, Gαq 
Signaling, Tec Kinase Signaling, and PI3K Signaling in B Lymphocytes (see Figure 12).   
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Figure 12. Top 10 Canonical Pathways of Radiotherapy-induced Gene Expression 
 
 
A network of the top three canonical pathways (Phospholipase C Signaling, Role of 
NFAT in Regulation of the Immune Response, Gαq Signaling) and its associated differentially 
expressed genes was generated (see Figure 13).  Coloring is based on the expression values of 
the genes, down-regulation in green and, up-regulation in red.  The direct and indirect 
relationships from the Ingenuity knowledge database are shown by solid and dashed lines, 
respectively.  The arrow indicates specific directionality of interactions.    
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Figure 13: Top 3 Canonical Pathways of Radiotherapy-induced Gene Expression 
 
 
Findings for Aim 3 
Aim 3: To determine the association between changes in genes expression with changes in 
fatigue score from baseline to midpoint of EBRT in Hispanic PR men with non-metastatic PC. 
The list of the three hundred seventy-three genes (130 up-regulated and 243 down-
regulated) that were differentially expressed from baseline to midpoint of EBRT (FDR <0.01; 
see Appendix R) was generated (Aim 2).  However, the planned analysis of association between 
the changes in expression level of these genes with changes in fatigue scores from baseline to 
midpoint of EBRT was not conducted due to the unexpected finding that fatigue did not 
significantly change over the course of EBRT.   
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CHAPTER V 
DISCUSSION 
Trajectory of Fatigue 
The purpose of this exploratory study was to describe the trajectory of fatigue among 
Hispanic Puerto Rican men over the course of receiving EBRT for non-metastatic prostate 
cancer and to explore gene expression changes over the course of EBRT.  We also were 
interested in comparing these findings with historical data of fatigue symptoms of Caucasian 
men with prostate cancer during EBRT.  To our knowledge, this study is the first to examine the 
trajectory of fatigue before, at mid-point, and at the end of EBRT in Puerto Rican men with 
prostate cancer, an understudied population.  We employed well-validated and reliable Spanish 
versions of instruments commonly used in other studies and that have been found sensitive to 
changes over time to assess fatigue and other symptoms.  This sample was carefully assessed for 
potential confounding factors such as renal failure, uncorrected hypothyroidism, anemia, or 
chronic inflammatory disease resulting in participants with relatively homogeneous 
characteristics.  In the gene expression analyses, measures were taken to correct for false positive 
results that may arise from high-through output techniques.   
Fatigue can be a side effect in individuals undergoing radiotherapy that can negatively 
impact their health-related quality of life and physical functioning.66,91   The FACT-F used in the 
present study is a widespread instrument used to assess fatigue among cancer patients.  There are 
a number of publications that used the FACT-F with which we compared the scores obtained in 
this study, such as: normative scores for the U.S. general population (N = 1010; 3.8% 
Hispanics)137; scores from prostate cancer patients receiving androgen deprivation therapy (N = 
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23);138 a national survey from cancer patients receiving chemotherapy and/or radiotherapy in the 
U.S. (N = 814; ethnicity not reported)139; and non- anemic cancer patients from the US (N = 113; 
1.8% Hispanics)137 with mixed cancer diagnoses under treatments.  
At baseline and at end of treatment respectively, the Puerto Rican men of this sample had 
similar FACT-F mean scores (42.38, SD = 9.34 and 43.03, SD = 8.62, respectively) compared to 
those published using the same measure of fatigue for the U.S. general population (43.6, SD = 
9.4).137 At each of the three time point the Puerto Rican participants reported higher FACT-F 
mean scores, indicating less level of fatigue as compared to: Canadian prostate cancer men 
receiving androgen deprivation therapy (M = 37; SD = 24);138 US non-anemic (M = 13.5; SD = 
1.2)137 cancer patients; and US cancer patients receiving chemotherapy and/or radiotherapy (M = 
30.1, SD = 13.1)139 using the same measure of fatigue.  Our smaller sample size may have 
contributed in part to the observed differences in fatigue, but it may also be due to the above 
studies dealing with more aggressive cancer types and/or more intense treatments.  
Longitudinal studies have consistently reported that fatigue in prostate cancer patients 
increases over the course of EBRT.16-17  The results of this study do not support these findings.  
Unexpectedly, there were no significant differences in fatigue scores over time during EBRT 
(i.e., pre vs midpoint; pre vs end, midpoint vs end) in our Puerto Rican sample.  In comparison, 
the work by Saligan et al.16-17 with a Caucasian sample found that, compared to baseline, fatigue  
increased significantly at midpoint and at completion of EBRT (p = .001-.04) using the Piper 
Fatigue Score and the PROMIS-F.  Other longitudinal studies of Caucasian men with PC 
(Truong et al. N = 28;66 Miaoskowski et al. N = 82100) found that compared to baseline, fatigue 
measured by the Brief Fatigue Inventory and the Lee Fatigue Scale increased significantly during 
EBRT.  While similar EBRT protocols and data collection time points were used, differences in 
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assessment scales also may affect the observed results.136  Although these instruments may have 
good psychometric properties, they may not lead to  the same conclusions since they may also 
assess different aspects or characteristics of fatigue.136  For example, the Piper Fatigue Scale 
assesses four dimensions of fatigue: behavioral/severity, sensory, cognitive/mood, and 
affective.140  The FACT-F is unidimensional, like the Brief Fatigue Inventory, but the Brief 
Fatigue Inventory141 assesses the interference of fatigue with activities of daily living and 
categorizes fatigue severity.  Several studies have demonstrated that CRF is sufficiently 
unidimensional to be measured as such.142   However, the work of Stein et al.143 highlights that 
fatigue in cancer patients is a multidimensional experience composed of five dimensions: general 
fatigue, physical fatigue, emotional fatigue, mental fatigue, and vigor.  With this concept in mind 
it is possible that some other dimension of fatigue not assessed in the present study might have 
changed over there course of EBRT.   In addition to using different instruments to measure 
fatigue, these other studies had different sample sizes and were not limited to Hispanic 
participants.  Due to these variations, direct comparisons between these studies and our study are 
limited. 
Specific reasons why fatigue may have not worsened over the course of EBRT in our 
sample of patients are unclear.  Recent evidence suggests that physical activity decreases during 
treatment for cancer.  Interestingly, the participants of the present study showed an overall 
increase of physical activity (see Table 8) over the course of EBRT.  Specifically, at baseline the 
level of total physical activity exceeded the 600 MET-minutes/week (required to fit in the 
“Moderate” category); at midpoint it was almost 3000 MET-minutes/week (required for the 
“High” category), and at completion it was even higher.  
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Although it appears that physical activity might have been related to fatigue scores in the 
present study, the Paired Samples t-test results were not statistically significant.  The physiology 
of the effects of exercise on radiotherapy-related fatigue remains to be elucidated; the 
predominant physiological explanation appears to be related to inflammatory factors.  It has been 
proposed that physiologically, radiation activates cellular signaling pathways that lead to the 
expression of pro-inflammatory cytokines that helps regulate the inflammatory process in 
response to tissue injury.15  Regular aerobic exercise reduces inflammation also by  triggering the 
release of pro-inflammatory cytokines from the skeletal muscle and inhibiting the production of 
inflammatory cytokines.144 
There is increasing evidence focusing on fatigue and physical activity in prostate cancer 
patients undergoing radiotherapy which shows that exercise prevents fatigue through 
improvement in cardiovascular fitness, flexibility, and muscle strength.  Monga et al.145 
conducted an interventional study of a supervised program of aerobic exercise three times a week 
for eight weeks on prostate cancer patients (N = 11) during radiotherapy.  Participants of the 
exercise group showed improvements in post-radiotherapy METS and fatigue using the Piper 
Fatigue Scale, among other variables compared to pre-radiotherapy levels.  In contrast, the 
control group showed significant worsening of post-radiotherapy scores on the Piper Fatigue 
Scale and no statistical change in MET.  Windsor et al.96 conducted a home-based moderate 
intensity exercise intervention for four weeks (walking for at least 30 minutes  three times a 
week) using the Brief Fatigue Inventory in a larger sample size (N = 33) of prostate cancer 
patients during EBRT.  Men in the control group reported significant worsening of fatigue scores 
from baseline to end of radiotherapy (p = 0.013) with no significant increases reported by 
participants in the exercise group (p = 0.203).  Similar results have been obtained by other 
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investigators with home-based interventions on prostate cancer patients 97,146 as well as among 
breast cancer patients.147  This evidence suggests that physical activity appears to have potential 
benefits in reducing fatigue in prostate cancer patients during EBRT.96,145   Taken together these 
findings suggest it is plausible that a good physical condition and maintenance of physical 
activity prior and during EBRT among the men of this sample may have contributed to no 
significant changes in fatigue.  This finding also suggests the need for clinicians to be aware of 
the possibility of worsening of fatigue among those who present with lower physical activity, 
and consider promoting aerobic exercise in accordance with the guidelines of the American 
College of Sports Medicine on exercise for cancer survivors.148 
Culture influences everyday social life as well as how people and their family and 
significant others respond to cancer diagnoses and treatment.149  Family members have become 
aware that social support during cancer treatments might not only impact the course and success 
of treatment, but also may be beneficial in ameliorating the short and long-term side effects, such 
as fatigue.150-151  It has been proposed that psychosocial support during cancer treatments helps 
patients in coping with the disease and is an important part of any comprehensive oncological 
care.150  There have been few studies that have investigated if family/social support is a major 
positive factor to affect treatment-related symptoms.150-151   Indeed, Brix and colleagues150 found 
in patients with mixed cancer diagnoses undergoing RT treatment (N = 239), that those in need 
for psychosocial support reported significantly higher fatigue scores on the Multidimensional 
Fatigue Inventory  than patients who were not identified as needing psychosocial support. In 
contrast, So et al.151 found that fatigue measured by the Brief Fatigue Inventory was not 
significantly associated with social support measured by the Medical Outcomes Study Social 
Support Survey among Chinese woman undergoing treatment for breast cancer.  The explanation 
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provided by So et al.151 about this finding was that, since the subjects were on active treatment, 
the effect of social support on pain and fatigue may have being relatively minimal compared to 
the effect caused by the toxicity of treatments.   
In a qualitative study that explored cultural factors that influenced treatment decisions 
among Latino men, support received and role changes were among the emerging themes.152  
Under the theme of support, the investigator provided important information regarding Latino 
participants reporting receiving a lot of support from their immediate and extended family.152  
Specifically, a prostate cancer participant in the Carrion study152 discussed how his friends and 
family members helped him accomplish tasks for which he was responsible in his home.  Fatigue 
is a common side effect of RT frequently discussed during physician’s conversations on 
treatment decisions in which the spouses of the Puerto Rican prostate cancer patients are most 
likely present.  Fatigue is a multidimensional symptom comprising extreme tiredness and 
exhaustion that may result in poor physical, psychological, and social functioning.150   Spouses 
of the participants of this study were identified as their primary caregivers and likely were the 
primary source of social support during treatment.  Although not studies, as the PI witnessed 
family members accompanying patients to EBRT every day, it is possible that the participants 
received enough help from their family members to experience less ‘causes’ of fatigue.  Within 
the cultural context, family members of the participants may have been so responsive to and 
supportive of the patients, that fatigue may not have been a major issue for them.   
Spirituality also has been found as one of the most important coping mechanism that 
different cultures use to confront cancer diagnoses and treatment.  When facing stressors, 
spirituality can be a great source of strength and comfort for some cancer patients and their 
families.153  For example, it has been reported that prostate cancer patients with high levels of 
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concern about their disease and prostate-related symptoms such as sexual and urinary 
dysfunction, were more likely to report increase in religiosity and spirituality after the cancer 
diagnosis.153  There is evidence suggesting that spiritual-well-being is associated with the fatigue 
experienced by cancer patients during treatments.  Indeed, Lewis et al.154 study found that there 
was a significant inverse relationship between fatigue scores with spiritual well‑being and that 
spiritual well‑being also emerged as a significant negative predictor for fatigue using the FACT-
F in 200 patients with mixed cancer diagnoses undergoing treatments.  Similar results were 
reported by Kandasamy et al.155 among 50 patients with advanced cancer in India.  Whether 
patients who remained less fatigued also remained more spiritual during the trajectory of 
treatments is not known; no longitudinal study was found that could provide support for such a 
relationship.   
Puerto Rican cancer patients have reported using spirituality for symptom management.  
For example, Gonzalez et al.156 found that praying together and reading the Bible were common 
methods practiced by mothers of 65 Puerto Rican children/adolescents during cancer treatments 
when their cancer child was “afraid”, had difficulty sleeping or had mood changes.  In addition, 
these PR mothers encouraged optimistic thoughts and communication among children and 
parents to alleviate the psycho-social and respiratory symptoms, and found it useful.  Family-
focused alleviation practices of seeking encouragement, advice, or help from relatives increased 
adherence to “Familismo” (familism)157 values on the importance of building upon existing 
family strengths and coping strategies when promoting positive family functioning.  
Anecdotally, while at the recruitment center, the PI had the experience of listening to patients in 
the waiting room giving themselves positive reinforcement and talking about spiritual comfort.  
Despite what fatigue may represent to the men in this study, it is possible that any changes in 
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fatigue the patients may have perceived was obscured by the feelings of comfort, strength, hope, 
and optimism that a spiritual state brings to individuals.      
Situational factors also have been shown to affect the perception of fatigue.  For example, 
Purcel et al.90 found that being in a de facto relationship (compared with being married or single) 
was a strong correlate of fatigue among 210 cancer patients undergoing RT.  Similarly, in a 
larger study Henry et al139 found in a sample of 1,569 mixed-diagnosis patients receiving 
treatment that employed patients reported significantly higher fatigue on the FACT-F than 
unemployed patients.  Henry et al.139 also reported that those with at least a college degree 
reported lower fatigue than those with less than a college degree, and those with higher incomes 
reported significantly lower fatigue levels than those with lesser incomes.  In comparison, in the 
present study the participants varied little on these situational characteristics since they were, for 
the most part married, well educated, and retired (probably receiving a fixed monthly income).  
The PI speculates that this finding suggests that issues related to being employed full-time that 
contribute to worsening of fatigue,139 such as inability to take time off from work or to reduce 
working hours, and loss of income and productivity, may have not been present in our sample 
and also may account for the lack of increase in fatigue over the course of EBRT.  
While fatigue did not worsen over the course of EBRT for this sample as a group, there 
was variability in fatigue across the sample.  Also, some participants did experience worsening 
of fatigue while others experienced improvement in fatigue.  When combined with the fact that 
most men in this sample did not change on their reported fatigue levels, it is not surprising that 
there were no group differences in fatigue over the course of EBRT.  Our sample was too small 
to do any sub-group analyses on those for whom fatigue worsened.  Further research with larger 
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samples is needed to better characterize patients who experience increased fatigue, as well as 
those who experience improvement of fatigue.   
Experimental studies documenting associations among genes related to oxidative 
phosphorylation, energy production, and mitochondrial membrane integrity with fatigue during 
RT have led to the proposition that alteration in ATP production may be a potential mechanism 
underlying RT-related fatigue.16,27  Extrinsic factors such as EBRT can lead to oxidative stress.27  
Oxidative stress is the reflection of the inability of the mitochondria to detoxify ROS.27,206  ROS 
damages the mitochondria, which in turn results in a reduced efficiency of oxidative 
phosphorylation, a reduction in production of adenosine-5'-triphosphate (ATP), and may lead to 
RT-related fatigue development.206  Genomic changes could mediate some of the effects of 
ionizing radiation dysfunctional mitochondria.27  The PI speculates that perhaps no changes in 
fatigue is a reflection of the combinations of antioxidant diet and supplements that can reduce 
ROS formation (less oxidative stress)207 thus maintaining the patient’s ATP production and/or 
naturally restoring mitochondrial function.   In particular, in the current study, mitochondrial-
function relevant genes previously found to be associated with fatigue were not differentially 
expressed.  Within this context, it is plausible that ATP production was maintained based on no 
mitochondrial gene expression resulting in no change in fatigue in the Puerto Rican sample. 
In vivo and ex vivo studies suggest that dietary supplementation based on antioxidants 
may serve as a potential factor for improving behavioral symptoms such as stress and fatigue.   
For example, according to Pandareesh and Anand,208 dietary L-carnitine (LC) plays a central role 
in fatty acid metabolism and in skeletal muscle bioenergetics through improving the energy 
charge by increasing the levels of ATP of skeletal muscle.  Pandareesh and Anand’s 208 study 
showed that dietary L-carnitine and fat supplementation ameliorated induced physical fatigue in 
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rats.  Gramignano et al.'s 207 study suggests that fatigue, as measured by the Multidimensional 
Fatigue Symptom Inventory-Short Form, decreased significantly with L-carnitine (LC) 
supplementation administered orally at 6 grams per day for 4 weeks in cancer patients receiving 
chemotherapy.  Carrillon et al.’s 209 trial of 12 weeks provided evidence that healthy individuals’ 
(n=32) physical and mental fatigue as well as stress, were reduced with superoxide dismutase 
(SOD)-melon concentrate supplementation daily capsules compared to placebo (n=29).  Stress 
was measured with the Cohen Perceived Stress scale and fatigue was measured with the Prevost 
Subjective Fatigue scale.  The PI speculates that the consumption of an antioxidant rich diet (i.e. 
rich in vegetables and fruits) and/or supplements may have contributed to the attenuation of RT-
related fatigue in the current study clinical population.   
A sufficient dose and volume of radiotherapy can control tumor recurrence and the 
spread to nearby lymph nodes in locally advanced prostate cancer.210  Overall, the total 
therapeutic radiation dose (ranging 61.2 Gy to 77.4 Gy) to tumor was relatively similar among 
patients in the current study.   Despite the evidence that fatigue in prostate cancer patients 
increases over the course of EBRT,16-19 longitudinal studies have also shown that patients 
symptoms peaked after treatment completion.211  For example, Goineau e al.211 found at 2 and 54 
months post IMRT that patients reported significant and clinically relevant differences in fatigue 
with respect to baseline levels.  Similarly, Wang et al.212 found that the symptom burden of pain, 
fatigue, lack of appetite, disturbed sleep, and sore throat on patients undergoing chemo-radiation 
therapy for locally advanced non-small cell lung cancer peaked in severity after completion of 
therapy at week 8, and remained high for several more weeks, not returning to baseline severity 
until week 13 (about 5-6 weeks post-therapy).  The current study collected fatigue data across 
time (at baseline, midpoint and at end of treatment) of EBRT and used their baseline fatigue 
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assessment for comparison for the study; however, it is possible that the effect of accumulating 
radiation dose on the dynamic changes in patients’ RT-related fatigue was not effective until 
after completion of RT.   Specifically, the PI speculates that it is possible that a significant 
worsening of fatigue during EBRT did not peak at mid-point or end of treatment (week 8) but 
may have peaked later in response to accumulated radiation.  Future research should examine the 
prevalence of post-radiotherapy-related fatigue and evaluate the need for more effective post-
treatment symptom assessment and management.  
Despite the recognition of conventional radiotherapy as a form of treatment for localized 
prostate cancer, over the last decade advances in radiation technology have led to the 
development of safer, high-dose radiotherapy techniques such as three-dimensional conformal  
radiation treatment (i.e. intensity modulated radiotherapy (IMRT).210,213-216  Conventional 
radiotherapy had the limitation of requiring large safety margins due to the inability to identify 
the tumor precisely and did not allow for shaped blocking to shield normal tissues, thus 
potentially resulting in other organs adjacent to the prostate, such as bladder and rectum, 
receiving the same dose as the prostate tumor.210,213-216    However, the development of the CT 
scan technologies not only allows a more precise definition of the geometry and location of the 
prostate and seminal vesicles, but also allows the CT-assisted EBRT planning.210,213-216    
Overall, three-dimensional conformal  radiation treatment allows a more precise and safer 
delivery of high dose of radiation to the tumor target while reducing the chance of irradiating the 
normal tissue, improving treatment efficacy, and leading to less radiation-related side effects. 
210,213-216  Specifically, the Puerto Rican men of this sample received IMRT.  IMRT is a type of 
conformal radiation treatment that enables dose escalation by obtaining the information needed 
to individually prescribe a required dose distribution of the desired high-dose to the tumor target 
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volume while treatment-related complications are potentially minimized.216  Lips et al.216 
reported that patients in the IMRT group who received dose escalation to the prostate corpus 
showed significant improvements in QOL, less pain and urinary symptoms between baseline and 
one month after treatment compared to the group with no dose escalation (conformal 
radiotherapy with a dose of 70 Gy).  Mangar et al.213 reported that IMRT has resulted in reduced 
rectal toxicity when using doses greater than 80 Gy, can potentially escalate the dose to prostate 
tumor resistant cells, and/or can be used to extend the high-dose region to pelvic lymph nodes.  
Similar results of IMRT associated with the reduction of acute rectal symptoms, late rectal 
bleeding, and decreased urinary toxicity among non-metastatic prostate cancer patients have 
been reported by other investigators as well.210,214  However, Lilleby et al.215 found that fatigue, 
anxiety and QOL changed significantly over time in men with high-risk or locally advanced 
prostate cancer receiving both IMRT and conformal radiotherapy.  Nonetheless, it is possible 
that the cells of surrounding normal tissues might have received less radiation due to the IMRT 
technique and improved position verification, resulting in less fatigue symptoms during RT in 
our sample.  Longer follow-up is required to explore the possibility of late fatigue that might 
occur within 1 year of completion of radiotherapy. 
Predictors of Fatigue 
Consistent with our model “Gene Expression and Cancer-Related Fatigue ” (see Figure 1, 
p. 5) our study found that sleep disturbance repeatedly emerged as a significant predictor of 
fatigue in the baseline, mid-point, and end of EBRT multiple regression analyses.  These results 
suggest that participants who report more sleep disturbance are more likely to have more fatigue.  
This finding is consistent with that of others reported in the literature.  Miaskowski et al.100 found 
that the patients’ baseline level of sleep disturbance measured by the General Sleep Disturbance 
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Scale predicted evening and morning fatigue in 82 men with prostate cancer during radiotherapy.  
Dhruva et al.101 provided evidence that breast cancer patients with sleep disturbance prior to 
radiotherapy predicted the trajectory of morning fatigue but not the trajectory of evening fatigue.  
Similar findings regarding the relationship between sleep disturbance and fatigue also were 
reported by Stepanski et al.158 in a large cohort of cancer patients undergoing treatment in which 
patients with sleep disturbance reported significantly more fatigue.   
Depression also emerged as a predictor for fatigue at baseline and end-point of treatment 
regression models.  This finding suggests that patients assessed with higher levels of depression 
are at greater risk for fatigue at the beginning of EBRT.  Of note, none of the participants in the 
present study reached the cutoff score of 15 for clinically-concerning depression at any time 
point.  One explanation for not showing as a predictor of midpoint fatigue may have been the co-
linearity issue.  Our measures of sleep and depression were strongly correlated in this study 
(baseline r = .68 p <.001, midpoint, r = .71 p <.001, end-point r = .77, p <.001).  These findings 
also are conceptually congruent as sleep disturbance may lead to depression, or viceversa.159 
Other investigators have found sleep disturbance associated with depression.158   
Another important limitation to be considered in interpreting these findings is that the 
selected measure of depression may not have been the best.  The Hamilton Depression Rating 
Scale (HDRS) was originally designed for use with patients suffering from affective disorder of 
the depressive type (more severe) and not for use on normal subjects.126  Consequently, the 
participants of this study were rated zero or one in the majority of the items of the scale that 
resulted in restricted variance.  Further research may consider using other instruments for 
depression that are calibrated with normal populations such as the Patient-Reported Outcomes 
Measurement Information System (PROMIS).160  
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Nonetheless, these findings support the proposition of our model that an interrelationship 
exists between psychological, physiological, and situational factors and fatigue during EBRT.  
Redeker et al.92 found that insomnia, fatigue, depression and anxiety were positively correlated 
with one another among 263 patients undergoing chemotherapy.  Miaskowski et al.100 also found 
that depression scores at baseline measured by the Center for Epidemiological Studies-
Depression (CESD) Scale predicted variability in the trajectory of morning fatigue measured by 
the Lee Fatigue Scale in 82 men with prostate cancer during radiotherapy 
It is difficult to visualize the occurrence of the single symptom of fatigue.  An important 
consideration is to address the symptom cluster phenomena, in which sleep disturbance, 
depression and fatigue are common co-occurring symptoms experienced by cancer patients 
during treatment.158  Indeed, Ho et al.161 provided evidence for the manifestation of the symptom 
cluster of fatigue, sleep disturbance and depression among breast cancer patients, before, during, 
and after chemotherapy treatment.  However, researchers are having difficulties understanding 
the causal direction among these symptoms.158   For example, similar to other studies, in the 
present study increased sleep disturbance predicted increased fatigue.  Other studies have shown 
that fatigued patients are at an increased risk to experience sleep disturbance.162  A similar 
pattern has been identified in the relation between fatigue and depression, such that chronic 
fatigue is noted to cause depression,162 and depressive patients are at increased risk to develop 
fatigue.163  Sleep disturbance and depression have both been shown to commonly co-occur with 
fatigue.161  This body of evidence provides support for the possibility of a bi-directional relation 
between these symptoms as integrated in our model.  However, it is also true that both sleep 
disturbance and fatigue are more generally viewed as symptoms of depression.163  
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In the oncology arena, it is particularly important to understand this relationship among 
symptoms in order to develop and deliver targeted interventions in comprehensive oncology 
care.  For example, given that our findings suggested that persons who sleep better and feel less 
depressed are less likely to experience fatigue, an intervention targeting depression and sleep 
disturbance would be expected to improve fatigue symptoms.  In practice, it remains unclear 
which one of these symptoms comes first or why many cancer patients during EBRT experience 
these symptoms simultaneously.  Additional exploration of these variables of interest is required 
to confirm if these are indeed the main predictors of fatigue, and by doing so, it will enable 
health care providers to better characterize fatigue in prostate cancer patients receiving EBRT.  
Further research using qualitative methodologies may be helpful to better understand why the 
Puerto Rican men in this study did not experienced changes in fatigue. 
It also should be noted that none of the disease or treatment characteristics (i.e., 
pretreatment laboratory results; Gleason score, T-stage), were evaluated as predictors of fatigue 
at any time point because there was little variability in these variables: the laboratory results 
were all within normal range, and previous studies consistently reported that none of these 
measures were predictors of  fatigue.66,70  The exception was ADT hormonal therapy, but it was 
excluded because the results of the t-test showed that there were no significant differences 
between those on ADT and those not on ADT in fatigue across time, a finding supported in other 
studies.66  
Changes in Gene Expression 
EBRT remains a mainstay of prostate cancer therapy for Puerto Rican patients.  Radiation 
therapy induces damage to the cell DNA that results in a cascade of events involving a network 
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of signal transduction and transcriptional regulation.164  This event stimulates a cellular stress 
response, including DNA damage recognition and cell cycle arrest, that leads to either DNA 
repair or apoptosis.164  In our study, we used microarray technology to conduct a genome wide 
study focused on the identification of transcriptional changes resulting from the radiotherapy 
insult from baseline to midpoint of EBRT.  The 20 most up- and down-regulated genes include 
p53-dependent genes, oxidative stress, and immune modulation related genes.  To identify key 
functional categories and diseases within the differentially expressed genes we performed a 
review of literature using the Gene Ontology Consortium and Pubmed searches.  In vivo and ex 
vivo studies have shown that differential expression of genes activating several physiological 
pathways may explain the mechanisms behind CRF.15,165  These results suggest that the 
activation of these genes may have played an important role in the RT-related fatigue experience 
of this clinical population.  These gene expression changes and the associated canonical 
pathways identified are in concordance with previous studies as described below. 
During EBRT, there is active cellular apoptosis.16  Consistent with this, the present study 
findings showed that apoptosis-related genes including ferredoxin reductase (FDRX) and sestrin 
3 (SESN3) were up-regulated during EBRT.  Ferredoxin reductase FDXR was the most up-
regulated observed in this study.  FDXR is regulated by the p53 family by DNA damaging agents 
in a p53-dependent manner, and by a mutated form of p53 that is involved in inducing 
apoptosis.166  A previous study demonstrated that over-expression of the ferredoxin reductase 
protein increased the sensitivity of  colorectal carcinoma cells to reactive oxygen species (ROS) 
5-FU, and doxorubicin-induced cell death.166  Specifically, the mechanism by which FDXR 
regulates ROS induced apoptosis is by hindering ROS from being detoxified by an antioxidant 
system.166  ROS production is a critical process linked to RT-related fatigue.16  It has been 
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suggested that since ROS is mainly produced in the mitochondria, it may have an effect on 
oxidizing the mitochondrial pores resulting in disruption of the mitochondrial membrane 
potential that can consequently lead to cytochrome c release and apoptosis.16,166   
Another study supported this hypothesis by reporting that ferredoxin reductase to be up-
regulated following irradiation of  lymphoblastoid cells at 3 Gy and 10 Gy doses, respectively, 
from 10 unrelated individuals.164  In addition, FDRX also was observed to be up-regulated 
related to UV radiation damage stress response.167  This observation was not only reported in 
radiation but also in chemotherapy where FDXR was one of the genes significantly induced by 
p53-mediated apoptosis after treatment with 5-FU through generation of oxidative stress in the 
mitochondria of colon cancer cells.168  The current study findings and the supporting evidence 
strengthens our hypothesis that FDXR up-regulation accelerates ROS-induced apoptosis, which 
may contribute to the experience of fatigue in this clinical population. 
The current study also revealed that the SESN3 gene was significantly up-regulated 
during EBRT.  Recent information establishes that all members of the Sestrin family are induced 
by oxidative stress linked to the metabolism of ROS and other reactive metabolites.169 The gene 
SESN3 is known for being involved in the maintenance of physiological concentrations of 
intracellular ROS.169  Intracellular ROS can influence cellular processes such as cell growth.169-
170   The accumulation of ROS in the mitochondria has been linked as an apoptotic stimulus170  
and to RT-related fatigue.16  Nonetheless, SESN3 has been found to be activated by Forkhead 
box (FOXO) transcriptional factors.169,170   In one study, it was observed that induction of 
SESN3 by Forkhead box O3 caused a transitory decline in ROS production and delayed 
Forkhead box O3-induced apoptosis of neuronal cell lines.170  Similarly, Kopnin et al.171 found 
that down-regulation of SESN3 in human Li-Fraumeni fibroblast cell line (MDAH041) cells 
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caused increased ROS levels and chromosomal instability in cells expressing oncogenic RAS.  
Deregulation of intracellular ROS homeostasis has being found to play a role in the development 
of many diseases such as cancer, rheumatoid arthritis, and diabetes.172  However, Sestrins can 
inhibit cancer cell growth through their role as suppressors of mTORC1 activity.171  An earlier 
study demonstrated support for sestrin-2-related DNA damage upon irradiation and genotoxic 
drugs treatments on breast cancer cells through a poorly understood mechanism that may be 
related to the inhibition of mTORC1.173   
Another gene of the Sestrin family, sestrin 1 (SENS1), have been found to be a potential 
fatigue-relevant gene.  Broderick et al.174 using the partial least squares methodology found that 
SENS1 was the top influential gene from the microarray experiment that was significantly 
associated and influential to the symptom space composed of fatigue, depression, and sleep 
disturbance.  Symptoms were measured with the Multidimensional Fatigue Inventory, Centers 
for Disease Control and Prevention Symptom Inventory, and the Medical Outcome Short Form-
36 questionnaires.  Specifically, SENS1 was able to discriminate fatigued (n = 75) from non-
fatigued females (n = 37) providing support for the oxidative stress involvement in chronic 
fatigue syndrome.174  It is noteworthy that the up-regulation of SESN3 observed in the present 
study could contribute to ROS accumulation contributing to the development of RT-related 
fatigue.  
Kruppel-like factor 1 (KLFLF1), intelectin 1 (ITLN1), and dolichyl-phosphate 
mannosyltransferase polypeptide (DPM2) also were up-regulated in this study.  KLF1 has been 
identified as a transcription factor involved in the regulation of erythroid differentiation.175  
Under homeostatic conditions, the expression of erythropoietin facilitates the production of 
erythrocytes.176  However, under hypoxic conditions resulting from acute RT exposure, 
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overexpression of erythropoietin maintains erythroid populations by the facilitation of 
proliferation and survival of erythroid progenitor cells.  Voorhees et al.165 proposed that since 
sustained glucocorticoid exposure stimulates proliferation of erythroid progenitor cells, and 
ligand-bound glucocorticoid receptor in conjunction with the transcription factor KLFI promotes 
erythroid differentiation, it is possible that sustained elevations in glucocorticoids levels in 
response to psychological stress contributed to erythropoiesis through erythroid progenitor 
proliferation.  Expression of pro-erythroid transcription factor KLF1 is restricted to erythroid 
cells and their precursors.  Evidence from animal studies has demonstrated that mouse restraint 
stress has been useful in studying behavioral and biological symptoms associated with fatigue 
and depressive disorders.165   Indeed, Voorhees et al.165 found overexpression of KLF1 at day 21 
in mice exposed to chronic restraint stress.  Sustained elevations in stress response also were 
evidenced by the elevation in stress markers, such as corticosterone levels, diminished body 
weight, diminished spleen and diminished thymic mass.165   
The association between fatigue, psychological stress (e.g. stress, sleep disturbance, 
depression, and anxiety) and pain has been established.158  Investigators have proposed that 
combining information from fatigue, psychological disturbance, and pain measurements, with 
gene expression data, will expand our ability to discover significant genes that might contribute 
to the understanding of the underlying etiology of this cluster of symptoms.177  Thus, Voorhees 
et al.165 results align with the present study finding that Kruppel-like factor 1 (KLF1) also was 
up-regulated.  With this information in mind, it is possible that in the present study sustained 
elevations in glucocorticoid levels evoked by RT-related-fatigue and psychological stress might 
have occurred that consequently might have triggered a positive influence on erythropoiesis 
evidenced by over-expression of KLF1.      
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Of particular interest was the finding that ITLN1 was overexpressed in the present study.  
Overexpression of the ITLN1 was observed on resected malignant pleural mesothelioma tissue 
and on adenoma of the colon.178  That study implicated ITLN1,  a human galactose-binding 
lectin, in cell differentiation, apoptosis, and recognition of tumor antigens, although the 
mechanism is not fully understood.178  A link between ITLN1 and fatigue resides in the potential 
role that adipokines (the secretory hormones released from adipose tissue) might play regulating 
multiple biological processes such as energy homeostasis and inflammation.  Omentin is an 
adipokine that is codified by the genes ITLN1 and ITLN2.177  RT-related fatigue it is a symptom 
triggered by inflammation and ATP dysregulation.16-17  Omentin has been found to be 
differentially expressed in patients with nonspecific inflammation such as osteoarthritis177 and 
obstructive sleep apnea.179  Fatigue, similarly to obstructive sleep apnea, has been found to be 
associated with sleep disturbance and daytime sleepiness.158  Although the underlying 
mechanism about this association remains to be elucidated, inflammation might be an etiological 
common factor.  Indeed, Kurt et al.179 found that plasma levels of omentin were found to be 
significantly higher in sleep apnea syndrome patients compared to the control group, although 
there was no significant correlation among sleepiness measured by the Epworth Sleepiness Scale 
and omentin levels in osteoarthritis patients.  Kurt et al.179 reported a small sample size as a 
possible limitation of the study.   
Similarly, Gang-Li et al.177found no significant associations between serum omentin-1 
concentrations and the Western Ontario McMaster University Osteoarthritis Index Scores in 
osteoarthritis patients.   Gang-Li et al.177 also acknowledged that the cross-sectional design and a 
relatively small sample size as a limitation.  They concluded that further studies are needed to 
assess the anti-inflammatory effect of omentin-1 since there were no significant differences in 
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serum omentin-1 concentrations between osteoarthritis patients and controls.  Other investigators 
have reported that omentin had an anti-inflammatory role by preventing tumor necrosis factor-
induced cyclooxygenase expression.177,180  Thus, there is a great potential that overexpression of  
ITLN1 in the present study represented an effort of the cells to release adipokines that mediate 
the inflammation process associated to RT-related fatigue.   
The involvement of the immune system, and particularly T cells, in the fatigue 
experience of prostate cancer patients receiving EBRT has been proposed.15  The list of the top 
20 up-regulated and down-regulated differentially expressed genes of the present study (see 
Table 19 p.101 ) showed that, of the top 10 down-regulated differentially expressed genes, most 
were involved in immune system processes.  The majority of these genes contains B cell-related 
annotations and/or is associated with B cell functions.  Those involved in B cell-related 
annotations are: (a) BACH2,  a B-cell-specific transcription repressor that has been shown to be a 
tumor suppressor in B-cell malignancy by enhancing apoptosis in response to oxidative stress;181 
(b) BANK1, an adaptor protein only expressed in B-cells that regulates calcium mobilization in 
response to B-cell receptor triggering and preventing hyperactive B-cell responses by attenuation 
of CD40-mediated;182; (c) IGHM, which encodes a B cell specific immunoglobulin, which is a 
trans-membrane receptor that has an important role in B cell development and signaling; (d) 
TCL1A (T-cell leukemia/lymphoma 1A), a proto-oncogene member of a multigene family that 
includes TCL1B and MTCP1, which is expressed in B cells.  Those associated with B cell 
functions include: (a) PAX5, a B-cell-specific transcription factor that plays an essential role in 
B-cell development.183  In the absence of PAX5, B-cells differentiate to other cell types such as 
T-lymphocyte or natural killer cells183 reduction in PAX 5 expression has been linked to B-cells 
senesce (tumorigenesis) of a variety of cancers such as astrocytoma, B-cell-ALL, 
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medulloblastoma, lymphomas and Wilm’s tumors;183 (b) MS4A1, the top down-regulated gene in 
both the present and the Caucasian studies; S4A1 is a member of the membrane-spanning 4A 
gene family, and encodes a B-cell surface molecule that functions in the differentiation of B-cells 
into plasma cells;182 (c) POU2AF1, a B cell-specific transcriptional factor essential for B-cell 
maturation and germinal center formation that has been reported to contribute to susceptibility 
for Primary Biliary Cirrhosis among the Japanese Population184 and for Multiple sclerosis among 
Europeans;185 and (d) Fc receptor-like A  encoded protein, selectively expressed in B cells, and 
which may be involved in their development.   
The down-regulation of these genes, including the B cell specific immunoglobulin IGHM 
and regulators of B cell differentiation and activation, suggest a decrease in the B cell population 
among prostate cancer patients receiving EBRT.  Commonly observed down-regulated genes 
from the current study and the previous Caucasian study17 include FCRLA, IGHM, PAX 5, 
BACH2, MS4A1, and POU2AF1.   Taken together, these results suggest that the expression 
levels of these B cell-related genes are affected by the disease and treatment status, regardless of 
ethnicity.  Changes in differentially expressed genes related to B and T lymphocytes also were  
described among fatigued breast cancer patients.84  These results might suggest that the observed 
changes in B cell related genes are specific to cancer-related fatigue.  Evidence suggests that B-
cell mediated inflammatory process might underline fatigue.15,84 
The etiology of RT-related fatigue remains unclear.  However, recent studies suggest that 
immune and inflammatory response trigger the fatigue experience.  The involvement of the 
immune system, and particularly T cells, in RT-related fatigue has been reviewed by Saligan et 
al.15  Expression analysis from the present study as well as from the Caucasian study showed that 
the most prominent group of differentially expressed genes were those involved in immune 
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system processes.  Such changes in gene expression, particularly altered functional B cell in 
fatigued patients and the role of the immune system, were described in detail by Myers,186 and by 
Bradley, Ford and Bansal.187  Myers 186 explains that, in the event of the body exposition to a 
pathogen, the antigens probably stimulate the response of the immune system.  Specifically, 
macrophages (antigen-presenting cells) destroy the pathogen, evoking that antigens are moved to 
the cell surfaces of the macrophages to be recognized by circulating specific T cells (a type of 
white blood cells also known as leukocytes).186  T -cells then bind to the macrophages and 
produce more T cells that recognize the particular antigens.186  Among the different type of T 
cells, cytotoxic T cells play a role killing some types of antigens directly, while T-helper cells 
stimulate production of B cells (another type of white blood cell) that play an important role 
secreting an antibody that can destroy antigens.186  Thus, the importance of B-cells resides in 
having multiple immune functions, such as antibody production, antigen presentation and 
regulation of the function and activity of other immune cells, (i.e., T-regulatory cells, NK cells 
and macrophages).188  
These results suggest the involvement of B cells in the pathology of RT-related fatigue.  
Although the participants of the present study did not report experiencing bacterial infections 
that might have triggered a fatigue experience, it is possible that RT caused defects of B cell 
function that might underlie fatigue.  Specifically, B cells play a role in producing antibodies and 
are potent antigen presenting cells.187  Thus, impairment of B cell function or development can 
lead to recurrent infections, or a propensity to autoimmunity or allergy.187  Other RT- related 
immune abnormalities also have been suggested.15  For example, Landmark et al.84found that 
two of the gene sets that were expressed lower in fatigued breast cancer patients were involved in 
multiple myeloma and a diffuse large B-cell lymphoma.  Landmark et al. 84speculated that 
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fatigue might engage some of the same pathways that are down-regulated in those type of B-cell 
disorders.  Bradley et al.187 further explains that B cell development in the bone marrow is an 
antigen independent tightly regulated process.  After several rounds of B cell expansion take 
place, the functional light chains of the antibodies replace the surrogate light chains and pair up 
with the (mu) heavy chains, resulting in cell surface IgM expression eventually forming the B 
cell receptor (BCR).187   BCR expression allows the negative selection of autoreactive B cells for 
elimination by apoptosis.187   Deficiency of these processes may allow the later development of 
systemic autoimmunity.187   
It is also possible that RT causes increased numbers of transitional B cells and naïve B 
cells that might overwhelm the B cell maturation process, which may consequently become 
suboptimal.187   Alternatively, T cell help provided by cytokines may not support naïve B cells to 
develop into plasmablasts.187  In addition, it is possible that RT caused one or more alterations in 
B cell maturation that may lead to an increased tendency to autoimmunity and a subtle humoral 
immune dysfunction, an active process by which the dysfunctional B cell maturation process 
contributes to symptomatology.  Thus, if B-cell thresholds for cellular signaling, activation or 
proliferation are altered, this will increase the risk of self-reactive B-cells escaping and the 
potential of autoimmune disease.187  Indeed, Bradley et al.187 found that patients with moderate 
chronic fatigue had increased proportions of transitional and naïve B cells and reduced 
plasmablasts by which the dysfunctional B-cell maturation process might have contributed to the 
fatigue symptomatology.    
In addition, Landmark’s84 study found that fatigued breast cancer survivors had an 
increased risk of B-cell lymphoma type cells expression that may indicate chronic immune 
activation or infection.  Specifically, plasma cells develop from B cells in response to antigen 
131 
 
presentation and T-cell activation.  However, each plasma cell synthetizes and secretes one type 
of antibody that targets and binds to an antigen for destruction.187 Thus, if RT causes changes in 
B-cell function, and if changes in B-cell function can be related to fatigue symptomatology 
somehow, then there may be a connection between RT and fatigue symptomatology.15,17 
In the event of repression of B cell and T cells, if cancerous cells build up in the bone 
marrow, it might leave too little room for the production of red blood cells, white blood cells and 
platelets, which might make patients more susceptible to fatigue.84  Landmak et al.84 study on 
gene expression and fatigue among breast cancer survivors found that genes involved in multiple 
myeloma, B-cell lymphoma, B-cell recognition of a specific antigen and the B cells subsequent 
activation to mature B cells, also were down-regulated.   In repression of genes related to B- and 
T-cell functions, RT can cause some defect of B cell memory or T cell dysfunction.187  However, 
the total effects of B-cell depletion on the immune system are likely to be complex and time-
dependent.188  Cytokines that coordinate and stimulate the cellular process necessary for the 
production of antibodies are secreted by macrophages, T-helper cells, and B cells.186 
Dysregulation of B cells by RT can cause a differentiation of B cells into an increasing natural 
killer (NK) cell numbers and activation, reduced macrophage maturation and increasing tumor 
necrosis factor (TNF)—a secretion and decreased the suppressive function of T regulatory 
cells.188   Our findings suggest that B cells might in fact be an additional tissue involved in RT-
related fatigue that recently has been identified as multi-etiological, involving the dysregulation 
of several physiological and biochemical systems.78 
One study showed that behavioral symptoms can be linked to altered gene expression of 
IGHM.189  As in other studies,158 the present study showed that RT-related fatigue was found to 
be associated with sleep disturbance.  Earlier research has suggested that higher levels of fatigue 
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during RT also were associated with pain.158  Data from investigations with individuals with 
chronic abdominal pain have resulted in the recognition that sleep disturbance is the consequence 
of a complex cascade of biological events including inflammation.189  Importantly, a number of 
genes pathways also have been implicated in other manifestations of side-effects of RT such as 
fatigue, depression and pain.189  Studies examining changes in gene expression and changes in 
sleep disturbance suggest some common aspects to RT-related-fatigue etiology.189  Based on 
expression analysis of data on 26 individuals with chronic abdominal pain, it was found that 
IGHM was one of the five genes that overlap between the pain and poor sleep quality group 
using the Pittsburgh Sleep Quality Index.189  Similar to the present study, the majority of the 
differentially expressed genes comparing poor sleep quality to good sleep quality were down-
regulated.189  Consistency in microarray results suggests that down-regulation of IGHM  may be 
related to the etiology of fatigue, poor sleep quality and pain.  The hypothesis that changes in 
expression of genes related to B-cell function can echo some of the changes related to RT-related 
fatigue also might be supported by the results of the present study.  Thus, further studies should 
investigate if prostate cancer men under EBRT with down-regulation of B cell-related genes are 
more prone to develop RT-related fatigue, and conversely, if men with a higher expression of B 
cell-related genes possibly might be carrying a protective effect against fatigue or if it is the 
disease process itself that decreases the expression of B cell-related genes in prostate cancer 
men.   
XK and RHD genes are both transcription factors and are both observed to be up-
regulated in this study and the previous study of Caucasian men.17 The XK and the RHD genes 
belong to a family of genes called blood group (blood group antigens).190  Recent evidence 
demonstrates that XK  might play a role in transporting substances into and out of cells, 
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maintaining cell structure, attaching to other cells and molecules, and participating in chemical 
reactions.190  On red blood cells, the XK protein attaches to another blood group protein, the Kell 
protein.190  Clinicians have  reported the occurrence of decrease in hemoglobin during RT.191  In 
the present study, differences in hemoglobin levels between baseline and midpoint of EBRT 
were not studied, nor differences in hemoglobin levels between fatigued and non-fatigued 
participants.  Previous studies on prostate cancer patients during EBRT have found significant 
associations between fatigue and overexpression of genes related to hemoglobin synthesis.16  
Similar findings have been found by Landmark et al.84 among  fatigued breast cancer survivors.  
Since XK and the RHD genes are present within the cell membrane of red blood cells, 
overexpression of these genes offer support for a possible linkage between fatigue and the 
hemoglobin synthesis.     
The mechanism involved in our Puerto Rican sample attenuation of RT-related fatigue 
fully may not be understood.  However, a proposed hypothesis of RT-related fatigue etiology 
may involve ROS accumulation.  As discussed above, several genes may play a role in this 
proposed mechanism.  SESN3 is known to suppress oxidative damage.169  Accumulation of ROS 
in the mitochondria serves as an apoptotic stimulus of the intrinsic death pathway.170  Extrinsic 
factors such as EBRT can lead to oxidative stress.27  Oxidative stress is the reflection of an 
imbalance of  ROS and reactive nitrogen species (RNS) metabolism and inability of the cells 
(mitochondria) to detoxify ROS and RNS and other reactive metabolic intermediates.169  While 
all members of the sestrin family are induced by oxidative stress by different induction 
mechanism,169 SESN3, which is highly up-regulated in the present study, is stimulated by 
oxidative damage via activation of FOXO transcription factors.170  FOXO3 also was up-
regulated  (adjusted p value <.02, log fold change 0.20) in this study.  SESN3 knockdown caused 
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an increase of FOXO3 inducing ROS and accelerating apoptosis.170  SESN3, a FOX-inducible 
protein, has been shown to suppress oxidative stress-induced  mTORCH 1 (target of rapamycin) 
activities, thus maintaining cellular energy during oxidative stress.169-170  Although it is not clear 
that FOXO3 activated SESN3 in our study, it is plausible that the antioxidant, AMPK-activating, 
and MTORC1 suppressing capabilities of the sestrin family contributed to the attenuation of RT-
related fatigue in this clinical population.   
Because the expression of 646 genes was found to be differentially expressed (p <.00001) 
between midpoint and baseline of EBRT, we further explored the functional networks and 
canonical pathways in which these genes may be involved.  The functional networks of the 646 
differentially expressed genes in this study suggest that cellular processes (cellular development, 
function and maintenance, growth and proliferation,  protein synthesis, and, cell death and 
survival) and especially immune response (including hematological system development) were 
the most active biologic pathway at midpoint of EBRT, which may be related to RT-induced 
cellular injury.    
The top three identified functional pathways--phospholipase c signaling, role of NFAT in 
regulation of the immune response, and Gαq signaling--play an important role in intracellular 
and second messenger signaling, as well as in cellular immune response.192  These pathways 
have been demonstrated in previous research to be involved in immune regulation and the 
complex signaling pathway that regulates cell dynamics.192  However, since most of the genes 
from the top three pathways except GNAS, were down-regulated, this finding supports the idea 
that induction of RT in our sample may has been  balanced by suppression of these genes based 
on the intensity of the damage.   
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As shown in Figure 13 p. 106, the canonical pathway is composed of 21 differentially 
expressed genes observed in this study.  The canonical pathway is predominantly composed 
down-regulated genes; however, this is probably due to the fact that, although statistically 
significant, many of the up-regulated genes did not achieve the cutoff of 2-fold change (see 
Appendix R).  Among the three top pathways, GNAS, CAMK4, and ITPR1 were co-expressed in 
all three pathways.  CAMK4 and ITPR1 are associated with calmodulin-dependent protein 
kinase activity, calcium-dependent protein serine/threonine kinase activity, intracellular signal 
transduction, ATP binding and inflammatory response.193  Specifically, CAMK4 mediates 
calcium-dependent stimulation of dendritial growth, which is dependent on CAMK4-stimulated 
phosphorylation and activation of the transcription factor cAMP response element-binding 
protein (CREB).193  CAMK4 is a multifunctional enzyme, which stimulates calcium-dependent, 
CREB mediated stimulation of dendritic growth and cell survival.193  It has been reported that the 
CAMK4-CREB signaling cascade also inhibits apoptosis and promotes neuron and dendritic cell 
survival against various stresses.  Bo Liu et al.194 found a significant increase in apoptosis in cells 
repressing CAMK4 on mouse MIN6 B cells model.  Therefore, the importance of repression of 
CAMK4 in the present study resides in the fact that apoptosis is the pathway necessary to make 
RT effective.  Bo Liu et al.194 provided evidence that overexpression of the constitutively active 
form of CAMK4 (DCaMK4) resulted in significant reductions in caspase-3/7 activities (whereas 
apoptosis was minimal) and stimulation of MIN6 B-cell division (promoted B-cell proliferation).  
Caspase-3/7 activity is universally increased during apoptosis.194   
A possible link of CAMK4 with fatigue further was investigated by Wu et al.193  in 
transgenic mouse lines overexpressing constitutively active CAMK4 in skeletal muscles. Indeed, 
they found that skeletal muscles from these mice showed augmented mitochondrial DNA 
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replication and mitochondrial biogenesis, up-regulation of mitochondrial enzymes involved in 
fatty acid metabolism and electron transport, and reduced susceptibility to fatigue during 
repetitive contractions.193 Therefore, these previous reports on animals suggest that repression of 
CAMK4 might be a common contributor to RT-related fatigue.   
Dysregulated apoptosis caused by RT is a critical failure associated with RT-related 
fatigue.   Bradford et at.195 found that induction of apoptosis in G-292 human osteoblastic cells 
by exposure to etoposide or the inflammatory cytokine TNF-alpha  promoted acute caspase-3/7 
activity.195  ITPR1, encodes the type 1 InsP3R.195   InsP3Rs are intracellular calcium channels 
and key proapoptotic mediators.195  The link of IRTP1 in our study lies in the possibility that 
exposure to RT probably also repressed transcription of the ITPR1 gene that encodes the 
intracellular calcium release channel implicated as a critical regulator of early apoptosis or 
programmed cell death.   
GNAS was the only up-regulated gene common in the top three pathways.  GNAS is likely 
to play a central role in regulating the biological process of signaling transduction.  G proteins 
are known to trigger a complex network of signaling pathways such as the Gαq Signaling 
pathway.192  In addition, GNAS have  been linked to the regulation  of  activity of hormones by 
stimulating the activity of the enzyme adenylate cyclase.192  Of the three genes of interest, more 
has been published on the relationship of GNAS and behavioral symptoms.  GNAS was 
previously identified as a fatigue-associated gene among 112 female subjects with unexplained 
fatigue measured by the Multidimensional Fatigue Inventory.196  Interestingly, GNAS have also 
been identified as differentially expressed in depressive patients with chronic fatigue syndrome 
measured by the Somatic and Psychological Health Report.197  In summary, the relationship of 
GNAS with the development of behavioral symptoms relies on GNAS encoding the stimulatory 
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G-protein subunit alfa, which is involved in the generation of intracellular cAMP and plays a 
crucial role in energy expenditure and metabolism by mediating sympathetic.198-199  
One of the most highly ranked pathways was Role of NFAT in Regulation of the 
Immune, which is predominantly marked by the up-regulation of GNAS and the down-regulation 
of BCR and the down-regulation of 8 genes (IP3R, CSP, BCR, SLP65, LCK, FYN, CALM, 
P13K).  NFAT are a family of transcription factors expressed in several cell types of the immune 
system, therefore playing  an important role in immune responses process.192  NFAT are 
activated by stimulation of receptors coupled to Calcium-Calcineurin signals from various 
kinases.192  The current study findings showed that the ATM serine/threonine kinase (log fold 
change= -0.510, p = .000043), calcium/calmodulin dependent protein kinase IVPIK3R1, PRKCA 
and PRKCH were significantly down-regulated, suggesting that the NFAT transcription factors 
are not activated during EBRT.  Inflammation as a result of RT involves the activation and 
recruitment of phagocytes (macrophages, neutrophils), NK cells, complement system and 
secretion of cytokines like IL-1b, IL-6, TNF-a by activated cells that are essential for the host 
defense system210.  None of these cytokines were differentially expressed in our study (p > .05).  
However, it also has been suggested that NFATc signaling pathway plays a role in dysregulation 
of inflammation.200  The activation of the NFATc signaling pathway in macrophages leads to a 
hyperinflammatory effect with immune-pathologic consequences.200  The acute inflammation 
during RT has been associated with fatigue.15,17  Since NFATc isoforms actively and negatively 
are regulated in macrophages during acute inflammatory responses,200 it is possible that any 
deregulation leading to NFATc activation (e.g. RT) might lead to excessive pro-inflammatory 
cytokine production and to the development to RT-related fatigue.  NFATc activation in 
macrophages also has been found in pathologic disorders characterized by chronic TNF-α 
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production, including rheumatoid arthritis.200   In agreement with this supposition, fatigue has 
been found to be associated with TNF-mediated inflammatory state.  
Another ranked pathway was the Gαq Signaling pathway.  Similar to the previous 
pathways discussed above, GNAS was the only up-regulated gene (expression value 0.573); 
while the other genes associated with these pathways are down-regulated (ATM, CAMK4, 
FNBPI, ITPR1, NAPEPLD, PIK3R1, PRKA, PRKCH, and RHOH).  After activation, the G-
proteins route the signal molecules from cell surfaces receptors that are activated by ligands such 
as hormones, neurotransmitters and chemokines to regulate diverse physiological functions.192 
Whistler et al.196 identified 839 fatigue-associated genes among 112 female subjects with 
unexplained fatigue.  Unexplained fatigue was measured with the Multidimensional Fatigue 
Inventory.  The authors did not provide the entire list of genes associated with fatigue; however, 
they provided the results of mapping fatigue-associated genes to pathways.  These associated 
genes implicated six different signaling pathways including the G-protein signaling pathway.  
This similarity to the present study suggests that Gαq Signaling pathway might have played a 
role in fatigue development.  Cell signaling pathways interacts with and regulates nearly all 
biological process associated with RT-related fatigue, such as cell growth, proliferation and 
apoptosis.196  Apoptotic extrinsic pathway is triggered by activation of tumor necrosis factor 
receptor family, and the intrinsic pathway is triggered by various forms of stress such as 
radiation.   Moreover, it has been postulated that the stimulatory G proteins modulate apoptosis 
induced by irradiation by regulating BCL-2 family expression in cancer cells treatment, and thus 
modulation of ROS-induced apoptosis.201  A previous study also found dysregulation of BCL-2 
expression to be associated with significant change in fatigue during EBRT in Caucasian men 
with non-metastatic prostate cancer.21 These findings suggest that G proteins can protect various 
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cells from apoptosis.202  It is likely that during RT, the body uses apoptosis for eliminating 
unwanted cells and damaged cells to preserve homeostasis.202  Thus, it is plausible that in our 
study at the midpoint of EBRT, the majority of our participants who did not experience RT-
related fatigue may have better apoptosis-activating mechanisms to get reduce damaged cells 
from irradiation, compared to participants with significant change in fatigue.    
The overall picture emerging from the findings of the present study supports the 
hypothesis that the etiology of CRF probably involves the dysregulation of several physiological 
and biochemical systems, such as oxidative stress, inflammation, immune modulation and 
hematopoietic dysfunction.  Significant changes in expression of genes related to B-cell 
functions (FCRLA, IGHM, PAX 5, BACH2, MS4A1, and POU2AF1), inflammation (ITLN1, 
CCR7), hemoglobin synthesis (XK and RHD), and induced by oxidative stress (Sestrin family), 
in the same direction (up-/down-regulation) were demonstrated both in the present study with 
Puerto Rican patients and previously in the Caucasian study.  Further studies will be needed to 
elucidate the possible roles of the B cell down-regulation and probably the oxidation 
phosphorylation process in these patients, i.e. ATP production in RT-related fatigue 
pathogenesis.  Another approach will be to explore/confirm if the remaining differentially 
expressed genes from the top 20 (FGFR1OP2, DPM2, DPCD, BANK1, BACH2, TCL1a, 
LINC00926, and ZER1) might be related to fatigue development specifically among the Puerto 
Rican population.  No study was located that reported a link between those genes and cancer-
related symptoms or that reported that those genes are ethnicity specific.  However, the concept 
of heterogeneity in people responses to RT is a possible explanation.  Previous research among 
the Puerto Rican population has found heterogeneity-related differences in the field of 
pharmacogenetics.203  Thus, ethno-geographic origin should be taken into consideration when 
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conducting genomic studies.203  For example, admixture is a type of gene flow among human 
population that may occur when individuals from two or more parental populations form a new 
hybrid population.203  Most likely, the gene flow among Puerto Ricans islanders is a 
representation of the admixture among Amerindians, Spaniard, and West-African individuals as 
is gathered from history.203  In support of this, Ruano et al.203 study on 32,536 genotype assays 
from 332 SNPs in 196 cardiometabolic and neuroendocrine genes in 98 Puerto Rican islanders 
confirmed this trichotomous origin of Puerto Rican islanders with three approximately evenly 
divided clusters.  In another study, Zuniga et al.204 found that allelic frequencies of 15 autosomal 
short tandem repeat marker among 205 PR living in Massachusetts showed a 76.4 % genetic 
contribution of European, African 17%, and Amerindian genes 6.6%. Therefore, the PI 
speculates that the phenomenon of admixture may have played a role and may explain the 
possibility that the remaining differentially expressed genes from the top 20 (FGFR1OP2, 
DPM2, DPCD, BANK1, BACH2, TCL1a, LINC00926, and ZER1) are ethnicity specific. 
Interestingly, in addition to similarities in gene expression observed in the present study 
and the Caucasian study, those genes that regulate the pathways and proteins thought to be 
underlying RT-related fatigue also are shared with studies of other psycho-neurological 
symptoms.178-179,189  This evidence supports the hypothesis that common biological pathways 
(e.g. inflammation, immune dysfunction) might explain the cluster of symptoms cancer patients 
experience during and after treatment, such as fatigue, decreased activity, sleep disturbance, pain 
and stress.  These symptoms are commonly named “sickness behavior.”186  Thus, in response to 
infectious diseases, animals and humans might exhibit similar patterns, including lethargy, 
depression, anorexia, and reduction in grooming representing an adaptive response to illness.186  
It is believed that this response is driven to conserve energy and resources.186  This pattern of 
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sickness behavior also may demonstrate weakness, inability to concentrate, decreased interest in 
surroundings, decreased social and sexual interactions, anhedonia (inability to experience 
pleasure from normally pleasured life events), enhanced perception of pain and impaired 
learning.186  In response to these characteristics, animals and individuals respond with an 
adaptive response to illness such as a pattern of increasing sleep, seeking warmth, and reducing 
energy devoted to seeking and grooming.186  For example, Voorhees et al.’s165 animal study 
reported that mice exposed to extended restraint stress protocols demonstrate similar biological 
symptoms as individuals experiencing psychological stress.  These findings suggest that a new 
translational pathway 205 is needed specifically related to symptom-focused therapies. Also, the 
development of safe and effective treatments will be challenging.  Challenges to be addressed 
may include the complex biochemical pathways underling the etiology of symptom cluster, and 
how to assess and manage the individual variability in symptom reporting in the trajectory of 
fatigue during and after cancer treatment.205  However, the contribution of gene expression 
studies in developing personalized therapies seems promising.  It will contribute to making use 
of individual differences in symptom experience to identify genetic and epigenetic risk factors 
for developing symptom trajectories.205   
Summary 
In summary, the results obtained in the present study clearly illustrate significant 
differences in gene expression between mid-point and baseline of EBRT.  While these 
differences in gene expression may offer a molecular explanation for the RT-related changes 
during EBRT, it suggests a biologic explanation behind the development of RT-related fatigue.  
Although RNA microarray results do not confirm definitive causation of change in genetic 
expression and behavior, the study findings are an important first step towards the goal of 
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identifying a gene expression-based classifier able to discriminate fatigued versus non-fatigued 
Puerto Rican Hispanic prostate cancer patients using a simple blood test, could lead to improve 
treatment outcomes in this understudied population.   Further, these study findings should 
stimulate nurses to better understand the mechanisms underlying fatigue intensification during 
cancer therapy. These data will provide nurses and other clinicians information to educate our 
patients about their symptoms so we can develop an optimal plan to manage their symptoms. 
Well informed oncology patients have better treatment outcomes, plan sound decisions for 
improved symptom management, and have enhance QOL following treatment.   
Although it is unclear from our study whether the changes in gene expression we found 
in our study were specifically associated with fatigue, future research will be directed at 
providing direction toward the identified genes and pathways that may contribute to our 
understanding of the complexity of RT-related fatigue. This is particularly important for the 
Puerto Rican prostate cancer population because of the potential disabling symptom during and 
after EBRT.  
Limitations 
Limitations of this study include the relatively small sample size (despite its 
appropriateness for our power analysis) and the unusual lack of change in fatigue over the course 
of EBRT that preventing addressing Aim 3.  A larger sample would have permitted a subset 
analysis of those participants for whom fatigue worsened, something we were unable to do due 
to the small sample size.  A limitation of this study may have been the use of a unidimensional 
measure of fatigue.  As fatigue is multi-dimensional, (i.e. mental, physiological, and 
neuromuscular) it is possible our measure did not capture that part of fatigue that might have 
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increased over the course of EBRT for more study participants.   Another limitation of the 
current study was not having complete data of the complete blood cell counts as well as of 
urinary tract symptoms that might contribute to possible explanations of no changes of fatigue 
and/or no changes in sleep disturbance among the Puerto Rican prostate cancer patients.  
Findings from this study cannot be generalized to cancer patients with other diagnoses and under 
other types or combinations of treatments. 
 
Clinical implications   
The use of EBRT in prostate cancer in Puerto Rico is a popular treatment option, and 
findings from this study suggest it may have a less detrimental effect on fatigue than in the 
Caucasian population.  Physical activity has been shown to lessen fatigue severity among cancer 
patients during treatment.  A good physical condition and maintenance of physical activity prior 
and during EBRT among the men of this sample may have contributed to no significant changes 
in fatigue.  In the future, an exercise intervention may be reasonable approach for exploring how 
to reduce fatigue among those for whom fatigue worsens during EBRT.  Also healthy diets 
consumed by participants may have increased the serum antioxidant levels, thus potentially 
reducing ROS formation leading to mitochondrial dysfunction that can lead to fatigue.  Given the 
high association of sleep disturbance and depression with fatigue, health professionals should 
assess sleep disturbance and depression as well as fatigue and treat these as needed. 
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Appendix A 
Recruitment Facility Support Letter 
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Appendix B 
Study Flyer 
If you are a Prostate cancer survivor, over 40  years of age, who are about to start radiotherapy, 
you are eligible to participate in a study.  If you are interested in more information, or would like 
to participate in the study, please call the co-investigator. 
 
 
Velda J. Gonzalez 
Co- Investigator 
PhD. Nursing student/University of Kansas 
University of Puerto Rico Cancer Center 
(787) 457-8508 
(787) 772-8300 x 11290 
Velda.gonzalez@upr.edu 
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Appendix C 
 
University of Puerto Rico Institutional Review Board Approval Letter 
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Appendix D 
 
 
University of Kansas Institutional Review Board Approval Letter 
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Appendix E: Inclusion criteria check-List 
 
Screening Sheet (to be filled by the co-Investigator) 
 
Are you… 
 
YES NO 1.     >21 years of age 
YES NO 1.     Anon-metastatic PC patient scheduled to receive EBRT 
YES NO 2. Concurrently receiving androgen deprivation therapy 
 
Have you ever had… 
YES NO 1.     Major depression, bi-polar disorder, psychosis, within the past 5 years (e.g., 
Have you ever received a diagnosis from a psychiatrist, psychologist, or other mental health 
professional? 
YES NO 1.     Alcohol dependence/abuses, within the past 5 years 
YES NO 2. Clinically significant fatigue (e.g. You may have been short of breath and 
the doctor may have told you that you had fluid in your lungs or that your heart was not pumping 
well.) 
YES NO 2. Progressive or unstable disease of any body system (e.g. Heart failure, 
active hepatitis) 
YES NO 3. Uncorrected hypothyroidism or anemia 
YES NO 4. Second malignancies (e.g. has your cancer spread or metastasized to other 
parts of your body?) 
YES NO 5. Concurrent chemotherapy with their EBRT? 
YES NO 6. Chronic inflammatory disease (e.g. Osteoarthritis, rheumatoid arthritis) 
YES NO 7. Are you on sedatives, steroids, or non-steroidal anti-inflammatory agents 
YES NO 8.  Lung problems such as asthma, emphysema, or chronic bronchitis 
YES NO 10.  Kidney problems 
 
  a. If yes, do you require hemodialysis or peritoneal dialysis?  
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Appendix H 
 
Demographic Form (English version) 
 
Age: ______years  
 
Marital Status: 
 
   Married  ______ (1) Number of Children:_______ 
   Single   ______ (2) 
   Widowed  ______ (3) 
   Divorced  ______ (4) 
  Living with Partner ______  (5) 
  Other   ______ (6) 
 
Religion:  
  
  Protestant ______ (0) 
  Catholic ______ (1) 
  Jewish  ______ (2) 
  Buddhist ______ (3) 
  Other  ______ (4) 
 
Ethnic Background (check all that apply): 
  
  White    ______ (1) 
  African American/Black ______ (2) 
  Mix of races   ______ (3) 
    
 
Occupation or Job: _____________________________________________ 
 
Place of Employment (if employed): _______________________________ 
 
 Full Time  Part Time  
 
Highest Education Completed by [Respondent] 
 Not attended school 
 Elementary or middle school 
 Some high school 
 High school diploma or equivalent (GED) 
 Some higher education, no degree 
 Technical or vocational school 
 Associate degree 
 BS/BA 
 Graduate degree 
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Also, give number of years in school: ______years 
Primary caregiver at home and relationship: ________________________________ 
 
If married, spouse’s age: ________ years. 
 
Spouse: Highest Education Completed  
 Not attended school 
 Elementary or middle school 
 Some high school 
 High school diploma or equivalent (GED) 
 Some higher education, no degree 
 Technical or vocational school 
 Associate degree 
 BS/BA 
 Graduate degree 
 
 
THANK YOU VERY MUCH FOR COMPLETING THE QUESTIONNAIRE 
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Appendix I 
 
Demographic Form (Spanish version) 
 
Edad: ______años  
 
Estatus Marital: 
 
   Casado  ______ (1) Número de hijos:_______ 
   Soltero  ______ (2) 
  Viudo   ______ (3) 
   Divorciado  ______ (4) 
  Convive  ______  (5) 
  Otro   ______ (6) 
 
Religión:  
  
  Protestante ______ (0) 
  Católico ______ (1) 
  Judío  ______ (2) 
  Budista ______ (3) 
  Otra  ______ (4) 
 
RaícesÉtnicas: 
  
  Blanco    ______ (1) 
  Afro Americano/Negro ______ (2) 
  Mescla de razas  ______ (3) 
    
 
Ocupación: _____________________________________________ 
 
Lugar de Trabajo: _______________________________ 
 
 Tiempo Completo  Tiempo Parcial  
 
Grado másalto completado 
 No atendió escuela 
 Elemental o intermedia 
 Algo de superior 
 Escuela Superior o equivalente (GED) 
 Mayoreducación pero sin grado 
 Técnica o vocacional  
 Grado Asociado 
 Bachillerato 
 Maestría o doctorado 
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Total de número de años en escuela: ______años 
Cuidador principal: ________________________________ 
 
Si casado, edad de conyugue: ________ años. 
 
Esposa: Grado másalto Completado 
 No atendió escuela 
 Elemental o intermedia 
 Algo de superior 
 Escuela Superior o equivalente (GED) 
 Mayoreducación pero sin grado 
 Técnica o vocacional  
 Grado Asociado 
 Bachillerato 
 Maestría o doctorado 
 
Total de número de años en escuela: ______años 
 
GRACIAS POR COMPLETAR EL CUESTIONARIO 
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Appendix J 
 
FACIT Fatigue Scale (Version 4) 
English (Universal) 16 November 2007 
Copyright 1987, 1997 
Page 1 of 1 
Below is a list of statements that other people with your illness have said are 
important. Please circle or mark one number per line to indicate your response 
as it applies to the past 7 days.  
 
   
 
Not at 
all 
A 
little 
bit 
Somewhat 
Quite 
a bit 
Very 
much 
I feel fatigued………….................................... 0 1 2 3 4 
I feel weak all over............................................    0 1 2 3 4 
I feel listless (“washed out”)….......................... 0 1 2 3 4 
I feel tired........................................................... 0 1 2 3 4 
I have trouble starting things because I am 
tired..................................................................... 
0 1 2 3 4 
I have trouble finishing things because I am 
tired...................................................................... 
0 1 2 3 4 
I have energy....................................................... 0 1 2 3 4 
I am able to do my usual activities...................... 0 1 2 3 4 
I need to sleep during the day.............................. 0 1 2 3 4 
I am too tired to eat............................................. 0 1 2 3 4 
I need help doing my usual activities.................. 0 1 2 3 4 
I am frustrated by being too tired to do the 
things I want to do............................................... 
0 1 2 3 4 
I have to limit my social activity because I am 
tired...................................................................... 
0 1 2 3 4 
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Appendix K 
 
FACIT-F (4a Versión) 
Spanish (Universal) 18 June 2012 
Copyright 1987, 1997  
Página 1de 1 
Marque un solo número por línea para indicar la respuesta que corresponde a los últimos 7 
días. 
 
 
Nada 
Un 
poco 
Algo Mucho Muchísimo 
Me siento agotado................................................ 0 1 2 3 4 
Siento debilidad en todo el cuerpo....................... 0 1 2 3 4 
Me siento decaído................................................ 0 1 2 3 4 
Me siento cansado................................................ 0 1 2 3 4 
Tengo dificultad para comenzar las cosas porque 
estoycansado....................................................... 
0 1 2 3 4 
Tengo dificultad para terminar las cosas porque 
estoycansado....................................................... 
0 1 2 3 4 
Tengo energía....................................................... 0 1 2 3 4 
Soy capaz de hacer mis actividades habituales 
(ej. trabajar, ir a la escuela, hacer compras)......... 
0 1 2 3 4 
Necesito dormir durante el día............................. 0 1 2 3 4 
Estoy demasiado cansado para comer.................. 0 1 2 3 4 
Necesito ayuda para hacer mis actividades 
habituales.............................................................. 
0 1 2 3 4 
Estoy frustrado porque estoy demasiado cansado 
para hacer las cosas que quiero hacer.................. 
0 1 2 3 4 
Tengo que limitar mis actividades sociales 
debido al cansancio.............................................. 
0 1 2 3 4 
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Appendix L 
 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
INSTRINSTRUCTIONS:  We are interested in finding out about the kinds of physical activities that 
people do as part of their dally everyday lives. The questions will ask you about the time you spent 
being physically active in the last 7 days. Please answer each question even if you do not consider 
yourself to be an active person. Please think about the activities you do at work, as part of your 
house and yard work, to get from place to place, and in your spare time for recreation, exercise or 
sport. 
 
Think about all the vigorous activities that you did in the last 7 days. Vigorous physical activities 
refer to activities that take hard physical effort and make you breathe much harder than normal. 
Think only about those physical activities that you did for at least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling? 
_____ days per week 
No vigorous physical activities Skip to question 3 
2. How much time did you usually spend doing vigorous physical activities on one of those days? 
_____ hours per day 
_____ minutes per day _____Don’t know/Not sure 
Think about all the moderate activities that you did in the last 7 days. Moderate 
activities refer to activities that take moderate physical effort and make you breathe somewhat harder 
than normal. Think only about those physical activities that you did for at least 10 minutes at a time. 
3. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace or double tennis? 
Do not include walking. 
_____ days per week 
No moderate physical activities Skip to question 5 
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4. How much time did you usually spend doing moderate physical activities on one of those days? 
_____ hours per day 
_____ minutes per day 
______Don’t know/Not sure 
Think about the time you spent walking in the last 7 days. This includes at work and at home, 
walking to travel from place to place, and any other walking that you might do solely for recreation, 
sport, exercise, or leisure. 
5. During the last 7 days, on how many days did you walk for at least 10 minutes at a time? 
_____ days per week 
No walking Skip to question 7 
6. How much time did you usually spend walking on one of those days? 
_____ hours per day 
_____ minutes per day 
______Don’t know/Not sure 
The last question is about the time you spent sitting on weekdays during the last 7 days. Include 
time spent at work, at home, while doing course work and during leisure time. This may include time 
spent sitting at a desk, visiting friends, reading, or sitting or lying down to watch television. 
7. During the last 7 days, how much time did you spend sitting on a week day? 
_____ hours per day 
_____ minutes per day 
_____ Don’t know/Not sure 
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Appendix M 
 
IPAQ 
CUESTIONARIO INTERNACIONAL DE ACTIVIDAD FÍSICA 
 
Instrucciones: Estamos interesados en saber acerca de la clase de actividad física que la gente 
hace como parte de su vida diaria. Las preguntas se referirán acerca del tiempo que usted utilizó 
siendo físicamente activo(a) en los últimos 7 días. Por favor responda cada pregunta aún si usted 
no se considera una persona activa. Por favor piense en aquellas actividades que usted hace como 
parte del trabajo, en el jardín y en la casa, para ir de un sitio a otro, y en su tiempo libre de 
descanso, ejercicio o deporte. 
 
Piense acerca de todas aquellas actividades vigorosas que usted realizó en los últimos 7 días. 
Actividades vigorosas son las que requieren un esfuerzo físico fuerte y le hacen respirar mucho 
más fuerte que lo normal. Piense solamente en esas actividades que usted hizo por lo menos 10 
minutos continuos. 
 
Durante los últimos 7 días, ¿Cuántos días realizó usted actividades físicas vigorosas como 
levantar objetos pesados, excavar, aeróbicos, o pedalear rápido en bicicleta? 
 
_____ días por semana  
 
  Ninguna actividad física vigorosa  Pase a la pregunta 3 
 
¿Cuánto tiempo en total usualmente le tomó realizar actividades físicas vigorosas en uno de esos 
días que las realizó? 
 
_____ horas por día  
_____ minutos por día  
  ______ No sabe/No está seguro(a)  
 
Piense acerca de todas aquellas actividades moderadas que usted realizo en los últimos 7 días.  
Actividades moderadas son aquellas que requieren un esfuerzo físico moderado y le hace respirar 
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algo más fuerte que lo normal. Piense solamente en esas actividades que usted hizo por lo menos 
10 minutos continuos.  
 
Durante los últimos 7 días, ¿Cuántos días hizo usted actividades físicas moderadas tal como 
cargar objetos livianos,  pedalear en bicicleta a paso regular, o  jugar dobles de tenis? No 
incluyacaminatas. 
 
_____ díasporsemana 
 
  Ninguna actvidad física  moderada Pase a la pregunta 5 
Usualmente, ¿Cuánto tiempo dedica usted en uno de esos días haciendo actividades físicas 
moderadas? 
 
_____ horas por día 
_____ minutos por día 
 
  No sabe/No está seguro(a)  
Piense acerca del tiempo que usted dedicó a caminar en los últimos 7 días.  Esto incluye trabajo en 
la casa, caminatas para ir de un sitio a otro, o cualquier otra caminata que usted hizo únicamente 
por recreación, deporte, ejercicio, o placer. 
 
5. Durante los últimos 7 días, ¿Cuántos días caminó usted por al menos 10 minutos 
continuos?   
 
_____ días por semana 
  
  No caminó  Pase a la pregunta 7 
Usualmente, ¿Cuánto tiempo gastó usted en uno de esos días caminando? 
 
_____ horas por día 
_____ minutos por día  
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  No sabe/No está seguro(a)  
 
 
La última pregunta se refiere al tiempo que usted permanenciósentado(a) en la semana en los 
últimos 7 días. Incluya el tiempo sentado(a) en el trabajo, la casa, estudiando, y en su tiempo libre. 
Esto puede incluir tiempo sentado(a) en un escritorio, visitando amigos(as), leyendo o permanecer 
sentado(a) o acostado(a) mirando televisión. 
 
Durante los últimos 7 días, ¿Cuánto tiempo permaneció sentado(a) en un día en la semana? 
 
_____ horas por día  
_____ minutos por día  
 
  No sabe/No está seguro(a)  
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Appendix N 
 
PROMIS Item Bank v. 1.0 – Sleep Disturbance – Short Form 8b  
Spanish (Universal) 15 August 2012 © 2008-2012 PROMIS Health Organization 
and PROMIS Cooperative Group Page 1 of 1 
 
Responda a cada enunciado marcando una casilla por línea.  
 
 
En los últimos 7 días... Nada 
Un 
Poco 
Algo Mucho Muchísimo 
Tuve el sueño inquieto................................ 
 
1 
 
2 
 
3 
 
4 
 
5 
Me sentí satisfecho/a con mi sueño............ 
 
1 
 
2 
 
3 
 
4 
 
5 
Mi sueño fuereparador............................... 
 
1 
 
2 
 
3 
 
4 
 
5 
Tuve dificultad para dormirme.................... 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
En los últimos 7 días... Nada 
Un 
Poco 
Algo Mucho Muchísimo 
Tuve problemas para permanecer dormido..... 
 
1 
 
2 
 
3 
 
4 
 
5 
Dormí mal....................................................... 
 
1 
 
2 
 
3 
 
4 
 
5 
Dormí suficiente.............................................. 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
En los últimos 7 días... 
Muy 
mala  
Mala Pasable Buena  Muybuena 
La calidad de mi sueño fue.......................... 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
Spanish (Universal) 15 August 2012 © 2008-2012 PROMIS Health Organization and PROMIS  
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Appendix O 
PROMIS Item Bank v. 1.0 – Sleep Disturbance – Short Form 8b  
(Universal) 15 August 2012 © 2008-2012 PROMIS Health Organization and 
PROMIS Cooperative Group Page 1 of 1 
 
 
Please respond to each item by marking one box per now. 
 
 
In the past 7 days... 
Not at 
all  
A little 
bit 
Somewhat  
Quite a 
bit  
Very 
much 
My sleep was restless................................. 
 
1 
 
2 
 
3 
 
4 
 
5 
I was satisfied with my sleep...................... 
 
1 
 
2 
 
3 
 
4 
 
5 
My sleep was refreshing............................. 
 
1 
 
2 
 
3 
 
4 
 
5 
I had difficulty falling asleep...................... 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
In the past 7 days... 
Not at 
all  
A little 
bit 
Somewhat  
Quite a 
bit  
Very 
much 
I had trouble staying asleep.......................... 
 
1 
 
2 
 
3 
 
4 
 
5 
I had trouble sleeping.................................... 
 
1 
 
2 
 
3 
 
4 
 
5 
I got enough sleep.......................................... 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
In the past 7 days... 
Very 
poor  
Poor Fair  Good 
Very 
good 
My sleep quality was.................................... 
 
1 
 
2 
 
3 
 
4 
 
5 
 
(Universal) 15 August 2012 © 2008-2012 PROMIS Health Organization and PROMIS  
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Appendix P 
The Hamilton Rating Scale for Depression 
Item Value 
 
DEPRESSED MOOD 
(Sadness, hopeless, helpless, 
worthless) 
 
Absent 
These feelings are indicated only on questioning 
These feelings are spontaneously reported verbally 
Communicates feelings non-verbally i.e., through facial expression, posture, voice, 
and tendency to weep 
Patient reports VIRTUALLY ONLY these feelings in his spontaneous verbal and 
non-verbal communication 
 
FEELINGS OF GUILT 
 
Absent 
Self-reproach, feels he has let people down 
Ideas of guilt or rumination over past errors or sinful deed 
Present illness is a punishment. Delusions of guilt 
Hears accusatory or denunciatory voices and/or experiences threatening visual 
hallucinations 
 
SUICIDE Absent 
Feels life is not worth living 
Wishes he were dead or any thoughts of possible death to self 
Suicide ideas or gesture 
Attempts at suicide (any serious attempt rates) 
 
INSOMNIA EARLY No difficulty falling asleep 
Complains of occasional difficulty falling asleep - more than 1/2 hour 
Complains of nightly difficulty falling asleep 
 
INSOMNIA MIDDLE No difficulty 
Patient complains of being restless and disturbed during the night 
Waking during the night - any getting out of bed (except for purposes of voiding) 
 
INSOMNIA LATE No difficulty 
Waking in early hours of the morning but goes back to sleep 
Unable to fall asleep again if he gets out of bed 
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WORK AND ACTIVITIES 
No difficulty 
Thoughts and feelings of incapacity, fatigue or weakness related to activities 
(work or hobbies) 
Loss of interest in activities (hobbies or work) - either directly reported by patient, 
or indirectly in listlessness, indecision and vacillation (feels he has to push himself 
to work or do activities) 
Decrease in actual time spent in activities or decrease in productivity. 
In hospital, if patient does not spend at least three hours a day in activities 
(hospital job or hobbies) exclusive of ward chores 
Stopped working because of present illness. In hospital, if patient engages in no 
activities except ward chores, or if patient fails to perform ward chores unassisted 
RETARDATION: 
PSYCHOMOTOR (Slowness 
of thought and speech; 
impaired ability to 
concentrate; decreased motor 
activity) 
Normal speech and thought1. 
Slight retardation at interview 
Obvious retardation at interview 
Interview difficult 
Complete stupor 
 
AGITATION None 
Fidgetiness 
Playing with hands, hair, etc. 
Moving about, can't sit still 
Hand wringing, nail biting, hair-pulling, biting of lips 
 
ANXIETY:  
PSYCHIC 
No difficulty 
Subjective tension and irritability 
Worrying about minor matters 
Apprehensive attitude apparent in face or speech 
Fears expressed without questioning 
 
ANXIETY: SOMATIC 
(Physiological concomitants of 
anxiety, such as - Gastro-
intestinal: dry mouth, wind, 
indigestion, diarrhea, cramps, 
belching. - Cardio-vascular: 
palpitations, headaches. - 
Respiratory: hyperventilation, 
sighing. - Urinary frequency - 
Sweating) 
Absent 
Mild 
Moderate 
Severe 
Incapacitating 
 
SOMATIC SYMPTOMS: 
GASTROINTESTINAL  
 
None 
Loss of appetite but eating without staff encouragement. Heavy feelings in 
abdomen 
Difficulty eating without staff urging. Requests or requires laxatives or medication 
for bowels or medication for gastro-intestinal symptoms 
Appendix O Appendix P 
Appendix O 
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SOMATIC SYMPTOMS: 
GENERAL 
None 
Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of 
energy and fatigability 
Any clear-cut symptom 
 
GENITAL SYMPTOMS 
(loss of libido, menstrual 
disturbances) 
Absent 
Mild 
Severe 
 
HYPOCHONDRIASIS Not present 
Self-absorption (bodily) 
Preoccupation with health 
Frequent complaints, requests for help, etc... 
Hypochondriacal delusions 
 
LOSS OF WEIGHT No weight loss 
Probable weight loss associated with present illness (>500g/week) 
Definite weight loss(>1kg/week) 
 
INSIGHT Not depressed (based on above items) OR Acknowledges being depressed and ill 
Acknowledges illness but attributes cause to bad food, climate, overwork, virus, 
need for rest, etc. 
Denies being ill at all 
 
 
 
 
 
 
 
 
 
Total ___________ 
197 
 
Appendix Q. Health Form 
  
   
 ID# _______________  Age: _______________ Evaluation Date: _______________ 
 
RT Simulation Date: 
_____________________________________ 
STAGE OF DISEASE:______ 
 Gleason score:________ 
 Type of ADT, _______ and duration __________ 
 # of RT fractions _______ # of RT fields_________ 
 Pelvic RT, yes or no: _______ 
 Weight __________ Height______________ 
 
_________________________________________________ 
COMORBID CONDITIONS:  
 
Current medications: 
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________ 
.  
Check if it applies:   Baseline Midpoint EOT 
HTN  PSA    
Diabetes  Hgb    
Anemia  Albumin    
Heart Attack  Thyroxine    
Depression  Interruption of RT    
Anxiety  Hx. of infection    
Thyroid problems  ER visits    
Other:  Hospital Admission    
 Weight    
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Appendix R. Genes with a FDR <0.01 
ID Symbol Name Log(Fold-
Change) 
P.Value adj.P.Val 
201737_s_at 6-Mar membrane-associated ring finger 
(C3HC4) 6, E3 ubiquitin protein 
ligase 
-0.416483365 4.14E-05 0.00803564
8 
213666_at 6-Sep septin 6 -0.541015854 8.23E-06 0.00643964
7 
214298_x_at 6-Sep septin 6 -0.547234599 1.97E-05 0.00679128
8 
1555526_a_
at 
6-Sep septin 6 -0.41827274 4.01E-05 0.00793218
5 
200965_s_at ABLIM1 actin binding LIM protein 1 -0.675395949 3.74E-06 0.00544715
7 
210461_s_at ABLIM1 actin binding LIM protein 1 -0.422225223 0.00010305
9 
0.01051422
6 
205213_at ACAP1 ArfGAP with coiled-coil, ankyrin 
repeat and PH domains 1 
-0.355740857 0.00010865
7 
0.01070418
5 
205377_s_at ACHE acetylcholinesterase (Yt blood 
group) 
0.246436535 4.09E-05 0.00797084
6 
205997_at ADAM28 ADAM metallopeptidase domain 
28 
-0.568128942 6.47E-05 0.00916657
9 
1553427_at ADAMTS15 ADAM metallopeptidase with 
thrombospondin type 1 motif, 15 
0.263574775 5.36E-05 0.00849720
4 
203865_s_at ADARB1 adenosine deaminase, RNA-
specific, B1 
-0.594770997 3.20E-06 0.00544715
7 
209979_at ADARB1 adenosine deaminase, RNA-
specific, B1 
0.41613665 2.00E-05 0.00679128
8 
201752_s_at ADD3 adducin 3 (gamma) -0.437491737 9.06E-05 0.01013273
9 
220606_s_at ADPRM ADP-ribose/CDP-alcohol 
diphosphatase, manganese-
dependent 
-0.477460006 1.62E-05 0.00652388
8 
219361_s_at AEN apoptosis enhancing nuclease 0.330497035 7.99E-07 0.00364212
1 
217729_s_at AES amino-terminal enhancer of split -0.410526942 0.00011413
1 
0.01085116
4 
227198_at AFF3 AF4/FMR2 family, member 3 -0.822274258 4.92E-05 0.00833877 
1552287_s_a
t 
AFG3L1P AFG3-like AAA ATPase 1, 
pseudogene 
-0.555411818 5.01E-05 0.00834844
2 
235926_at ANAPC5 anaphase promoting complex 
subunit 5 
-0.605493188 5.64E-05 0.00873569
3 
212583_at AQR aquarius intron-binding 
spliceosomal factor 
-0.218554687 6.11E-05 0.00902189
9 
213039_at ARHGEF18 Rho/Rac guanine nucleotide 
exchange factor (GEF) 18 
-0.412735266 7.51E-05 0.00943974 
242239_at ARL5B-AS1 ARL5B antisense RNA 1 -0.531037765 0.00011639
7 
0.01097238
3 
205047_s_at ASNS asparagine synthetase (glutamine-
hydrolyzing) 
-0.676695703 1.70E-05 0.00652388
8 
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209693_at ASTN2 astrotactin 2 0.237321784 7.82E-05 0.00957385
3 
232838_at ASXL3 additional sex combs like 3 
(Drosophila) 
0.280291969 4.55E-05 0.00817169
5 
227365_at ATCAY ataxia, cerebellar, Cayman type 0.275145014 9.27E-05 0.01020214
3 
231825_x_at ATF7IP activating transcription factor 7 
interacting protein 
-0.407397447 2.39E-05 0.00722109
4 
210858_x_at ATM ataxia telangiectasia mutated -0.472514912 1.96E-05 0.00679128
8 
208442_s_at ATM ataxia telangiectasia mutated -0.510325909 4.31E-05 0.00815159
8 
223339_at ATPIF1 ATPase inhibitory factor 1 -0.273887652 8.61E-05 0.00984667
9 
204516_at ATXN7 ataxin 7 -0.412712592 0.00010138
3 
0.01051422
6 
221234_s_at BACH2 BTB and CNC homology 1, basic 
leucine zipper transcription factor 
2 
-0.989631763 4.86E-07 0.00363219
8 
227173_s_at BACH2 BTB and CNC homology 1, basic 
leucine zipper transcription factor 
2 
-0.468213388 5.53E-06 0.00592514 
219667_s_at BANK1 B-cell scaffold protein with ankyrin 
repeats 1 
-1.039378218 3.81E-05 0.00793218
5 
1558662_s_a
t 
BANK1 B-cell scaffold protein with ankyrin 
repeats 1 
-0.702967876 4.96E-05 0.00833877 
223134_at BBX bobby sox homolog (Drosophila) -0.457352353 9.91E-05 0.01046160
6 
222891_s_at BCL11A B-cell CLL/lymphoma 11A (zinc 
finger protein) 
-0.60307787 5.55E-05 0.00866317
8 
222895_s_at BCL11B B-cell CLL/lymphoma 11B (zinc 
finger protein) 
-0.68569958 1.59E-05 0.00652388
8 
219528_s_at BCL11B B-cell CLL/lymphoma 11B (zinc 
finger protein) 
-0.695201346 3.33E-05 0.00784405
3 
201261_x_at BGN biglycan 0.305545609 7.26E-05 0.00925507
9 
202931_x_at BIN1 bridging integrator 1 -0.294464341 3.78E-05 0.00793218
5 
214439_x_at BIN1 bridging integrator 1 -0.327577901 4.56E-05 0.00817169
5 
207655_s_at BLNK B-cell linker -0.844816248 3.74E-05 0.00793218
5 
207186_s_at BPTF bromodomain PHD finger 
transcription factor 
-0.458313139 3.50E-06 0.00544715
7 
208685_x_at BRD2 bromodomain containing 2 -0.376609434 9.81E-05 0.01043482
3 
215010_s_at BRSK2 BR serine/threonine kinase 2 0.371996264 3.85E-05 0.00793218
5 
229827_at BUB3 BUB3 mitotic checkpoint protein 0.246540068 8.21E-05 0.00976116
4 
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238593_at C11orf80 chromosome 11 open reading 
frame 80 
-0.58521126 8.08E-05 0.00969849
9 
1559097_at C14orf64 chromosome 14 open reading 
frame 64 
-0.486999329 6.36E-06 0.00603407
8 
228666_at C15orf38 chromosome 15 open reading 
frame 38 
0.264286308 4.10E-05 0.00797084
6 
231153_at C16orf86 chromosome 16 open reading 
frame 86 
0.277535825 9.00E-05 0.01012350
1 
1557828_a_
at 
C5orf28 chromosome 5 open reading frame 
28 
-0.564640857 7.12E-05 0.00921266
3 
215954_s_at CACTIN cactin, spliceosome C complex 
subunit 
-0.289637725 0.00011299
4 
0.01083497
1 
219896_at CALY calcyon neuron-specific vesicular 
protein 
0.265848172 9.06E-05 0.01013273
9 
229029_at CAMK4 calcium/calmodulin-dependent 
protein kinase IV 
-0.569849314 3.68E-05 0.00793218
5 
231710_at CAPS calcyphosine 0.400140237 9.53E-05 0.01031292
4 
231862_at CBX5 chromobox homolog 5 -0.336978513 4.69E-05 0.00823489
7 
239014_at CCAR1 cell division cycle and apoptosis 
regulator 1 
-0.490146901 1.57E-05 0.00652388
8 
237475_x_at CCDC152 coiled-coil domain containing 152 -0.40267085 5.48E-05 0.00860224 
206337_at CCR7 chemokine (C-C motif) receptor 7 -0.855626052 1.27E-05 0.00649251
9 
206508_at CD70 CD70 molecule 0.288242775 8.66E-06 0.00649251
9 
215925_s_at CD72 CD72 molecule -0.587775424 5.68E-05 0.00873569
3 
1555779_a_
at 
CD79A CD79a molecule, immunoglobulin-
associated alpha 
-0.648004243 7.94E-07 0.00364212
1 
205049_s_at CD79A CD79a molecule, immunoglobulin-
associated alpha 
-0.768059007 3.12E-05 0.00776252
7 
205297_s_at CD79B CD79b molecule, immunoglobulin-
associated beta 
-0.446891887 0.00011349
4 
0.01083497
1 
203794_at CDC42BPA CDC42 binding protein kinase alpha 
(DMPK-like) 
0.215974634 0.00010241 0.01051422
6 
215181_at CDH22 cadherin 22, type 2 0.340165492 1.66E-05 0.00652388
8 
206575_at CDKL5 cyclin-dependent kinase-like 5 0.319115759 6.97E-05 0.00919527
9 
240889_at CDRT15L2 CMT1A duplicated region transcript 
15-like 2 
0.316506378 4.38E-05 0.00817169
5 
228868_x_at CDT1 chromatin licensing and DNA 
replication factor 1 
0.365857616 3.98E-05 0.00793218
5 
209489_at CELF1 CUGBP, Elav-like family member 1 -0.297604956 7.04E-05 0.00921266
3 
207331_at CENPF centromere protein F, 350/400kDa 0.170722501 8.02E-05 0.00969425
4 
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239442_at CEP68 centrosomal protein 68kDa -0.332895351 0.00011161
1 
0.01078976
3 
206824_at CES1P1 carboxylesterase 1 pseudogene 1 0.350463495 8.40E-05 0.00978649
3 
234706_x_at CFTR cystic fibrosis transmembrane 
conductance regulator (ATP-
binding cassette sub-family C, 
member 7) 
0.126591832 0.00010284
3 
0.01051422
6 
225026_at CHD6 chromodomain helicase DNA 
binding protein 6 
-0.38228634 4.03E-05 0.00793218
5 
212313_at CHMP7 charged multivesicular body 
protein 7 
-0.407111494 1.18E-06 0.00427675
7 
213628_at CLCC1 chloride channel CLIC-like 1 -0.329268827 1.70E-05 0.00652388
8 
234443_at CLSTN2-AS1 CLSTN2 antisense RNA 1 0.257562281 3.81E-05 0.00793218
5 
231884_at CNTROB centrobin, centrosomal BRCA2 
interacting protein 
0.326559424 1.50E-05 0.00652388
8 
232733_s_at COL20A1 collagen, type XX, alpha 1 0.267559014 3.20E-05 0.00777537
2 
217484_at CR1 complement component (3b/4b) 
receptor 1 (Knops blood group) 
0.2406621 0.00010980
9 
0.01077882
3 
218648_at CRTC3 CREB regulated transcription 
coactivator 3 
-0.402085296 1.43E-05 0.00649251
9 
207030_s_at CSRP2 cysteine and glycine-rich protein 2 0.227633344 1.76E-06 0.00457613
1 
235523_at CTC1 CTS telomere maintenance 
complex component 1 
-0.357302929 2.06E-05 0.00679952
9 
222819_at CTPS2 CTP synthase 2 -0.290947316 1.62E-05 0.00652388
8 
200838_at CTSB cathepsin B 0.317453237 9.17E-05 0.01015928
2 
224703_at DCAF5 DDB1 and CUL4 associated factor 5 -0.307448623 6.65E-05 0.00918738
1 
203409_at DDB2 damage-specific DNA binding 
protein 2, 48kDa 
0.350384304 3.20E-05 0.00777537
2 
200694_s_at DDX24 DEAD (Asp-Glu-Ala-Asp) box 
helicase 24 
-0.369252469 7.14E-05 0.00921266
3 
1568815_a_
at 
DDX50 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 50 
-0.524185446 1.52E-05 0.00652388
8 
221081_s_at DENND2D DENN/MADD domain containing 
2D 
-0.500251911 0.00010152
8 
0.01051422
6 
226116_at DFFA DNA fragmentation factor, 45kDa, 
alpha polypeptide 
-0.399748384 8.10E-05 0.00969849
9 
215003_at DGCR9 DiGeorge syndrome critical region 
gene 9 
0.261777148 1.14E-05 0.00649251
9 
203385_at DGKA diacylglycerol kinase, alpha 80kDa -0.388542741 1.07E-05 0.00649251
9 
211272_s_at DGKA diacylglycerol kinase, alpha 80kDa -0.41120375 1.16E-05 0.00649251
9 
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214193_s_at DIEXF digestive organ expansion factor 
homolog (zebrafish) 
-0.499589308 0.00011209
1 
0.01078976
3 
215529_x_at DIP2A DIP2 disco-interacting protein 2 
homolog A (Drosophila) 
-0.364417667 0.00010900
6 
0.01071920
2 
244725_at DMRTA1 DMRT-like family A1 0.313519975 4.48E-05 0.00817169
5 
1554078_s_a
t 
DNAJA3 DnaJ (Hsp40) homolog, subfamily 
A, member 3 
-0.312312494 8.89E-05 0.01005862
6 
232874_at DOCK9 dedicator of cytokinesis 9 -0.452709825 4.00E-05 0.00793218
5 
226009_at DPCD deleted in primary ciliary 
dyskinesia homolog (mouse) 
0.441423673 1.32E-05 0.00649251
9 
209391_at DPM2 dolichyl-phosphate 
mannosyltransferase polypeptide 
2, regulatory subunit 
0.457599025 0.00010045
1 
0.01051422
6 
217671_at DSERG1 Down syndrome encephalopathy 
related protein 1 
-0.231796963 6.17E-05 0.00905041
5 
239733_at DYDC2 DPY30 domain containing 2 0.188935599 4.98E-05 0.00834844
2 
221586_s_at E2F5 E2F transcription factor 5, p130-
binding 
-0.424440392 6.52E-05 0.00917319
8 
233261_at EBF1 early B-cell factor 1 -0.4289617 8.10E-06 0.00643964
7 
227646_at EBF1 early B-cell factor 1 -0.846448213 2.56E-05 0.00737922
3 
238761_at ELK4 ELK4, ETS-domain protein (SRF 
accessory protein 1) 
-0.476826864 1.34E-05 0.00649251
9 
228674_s_at EML4 echinoderm microtubule 
associated protein like 4 
-0.351981709 0.00011139
5 
0.01078976
3 
219912_s_at ENPP3 ectonucleotide 
pyrophosphatase/phosphodiestera
se 3 
0.273238975 7.00E-05 0.00919527
9 
212375_at EP400 E1A binding protein p400 -0.41526683 5.27E-05 0.00848110
9 
204718_at EPHB6 EPH receptor B6 -0.237230285 2.81E-05 0.00754910
1 
211603_s_at ETV4 ets variant 4 0.367180598 1.58E-05 0.00652388
8 
244500_s_at EVI5L ecotropic viral integration site 5-
like 
0.28410611 0.00011247
5 
0.01080765
6 
207541_s_at EXOSC10 exosome component 10 -0.35911111 8.56E-05 0.00983175 
217234_s_at EZR ezrin -0.438680772 8.30E-05 0.00978649
3 
208623_s_at EZR ezrin -0.497262521 9.61E-05 0.01034221
3 
202862_at FAH fumarylacetoacetate hydrolase 
(fumarylacetoacetase) 
0.30366866 4.55E-05 0.00817169
5 
221602_s_at FAIM3 Fas apoptotic inhibitory molecule 3 -0.649478155 5.25E-07 0.00363219
8 
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221601_s_at FAIM3 Fas apoptotic inhibitory molecule 3 -0.762837321 2.20E-06 0.00501417
8 
1553369_at FAM129C family with sequence similarity 
129, member C 
-0.394493652 9.69E-06 0.00649251
9 
230983_at FAM129C family with sequence similarity 
129, member C 
-0.60016683 6.69E-05 0.00919527
9 
218510_x_at FAM134B family with sequence similarity 
134, member B 
-0.306567395 6.04E-05 0.00898360
7 
218464_s_at FAM222B family with sequence similarity 
222, member B 
-0.299139145 6.88E-05 0.00919527
9 
229289_at FAM71E1 family with sequence similarity 71, 
member E1 
0.289799963 2.51E-05 0.00735058
3 
212229_s_at FBXO21 F-box protein 21 -0.429140649 8.40E-05 0.00978649
3 
205310_at FBXO46 F-box protein 46 -0.312595015 6.43E-05 0.00916657
9 
235401_s_at FCRLA Fc receptor-like A -1.074147189 1.58E-06 0.00457243
6 
235372_at FCRLA Fc receptor-like A -0.419492859 1.16E-05 0.00649251
9 
207813_s_at FDXR ferredoxin reductase 0.496086285 7.42E-11 4.06E-06 
1556283_s_a
t 
FGFR1OP2 FGFR1 oncogene partner 2 0.851956179 6.53E-05 0.00917319
8 
230389_at FNBP1 formin binding protein 1 -0.410003097 5.84E-05 0.00881771 
202723_s_at FOXO1 forkhead box O1 -0.365678555 6.84E-05 0.00919527
9 
223287_s_at FOXP1 forkhead box P1 -0.493719018 4.04E-07 0.00363219
8 
224838_at FOXP1 forkhead box P1 -0.548101469 1.70E-06 0.00457613
1 
224837_at FOXP1 forkhead box P1 -0.525866739 2.70E-06 0.00544715
7 
235444_at FOXP1 forkhead box P1 -0.481176266 6.04E-06 0.00600751
2 
1558996_at FOXP1 forkhead box P1 -0.365210444 1.21E-05 0.00649251
9 
229844_at FOXP1 forkhead box P1 -0.346616329 6.76E-05 0.00919527
9 
238076_at GATAD2B GATA zinc finger domain containing 
2B 
-0.293824643 7.47E-05 0.00940549
7 
214711_at GATC glutamyl-tRNA(Gln) 
amidotransferase, subunit C 
-0.385907352 7.56E-05 0.00946429
9 
210565_at GCGR glucagon receptor 0.347833617 1.47E-05 0.00652388
8 
219508_at GCNT3 glucosaminyl (N-acetyl) transferase 
3, mucin type 
0.298715293 2.63E-05 0.00738187
7 
228173_at GNAS GNAS complex locus -0.427370044 1.26E-05 0.00649251
9 
214157_at GNAS GNAS complex locus 0.572823182 0.00010718 0.01063539
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1 4 
205042_at GNE glucosamine (UDP-N-acetyl)-2-
epimerase/N-acetylmannosamine 
kinase 
-0.372407682 0.00011686
5 
0.01099154
2 
218873_at GON4L gon-4-like (C. elegans) -0.300561751 8.47E-05 0.00978649
3 
226429_at GPALPP1 GPALPP motifs containing 1 -0.401653898 5.29E-05 0.00848110
9 
212487_at GPATCH8 G patch domain containing 8 -0.262831591 2.95E-05 0.00774683
2 
214510_at GPR20 G protein-coupled receptor 20 0.271282071 2.96E-05 0.00774683
2 
210411_s_at GRIN2B glutamate receptor, ionotropic, N-
methyl D-aspartate 2B 
0.308973172 7.98E-05 0.00969364
5 
243985_at GTF2A2 general transcription factor IIA, 2, 
12kDa 
-0.336767326 6.62E-05 0.00917319
8 
229343_at GTSE1 G-2 and S-phase expressed 1 0.327675443 2.39E-05 0.00722109
4 
220577_at GVINP1 GTPase, very large interferon 
inducible pseudogene 1 
-0.466920453 2.65E-05 0.00740014
3 
207592_s_at HCN2 hyperpolarization activated cyclic 
nucleotide-gated potassium 
channel 2 
0.363436439 6.01E-05 0.00898360
7 
201209_at HDAC1 histone deacetylase 1 -0.408992606 2.82E-05 0.00754910
1 
218595_s_at HEATR1 HEAT repeat containing 1 -0.439724396 3.21E-05 0.00777537
2 
212642_s_at HIVEP2 human immunodeficiency virus 
type I enhancer binding protein 2 
-0.304928914 5.92E-05 0.00889172
5 
212873_at HMHA1 histocompatibility (minor) HA-1 -0.44566097 0.00011526
9 
0.01092262
3 
211930_at HNRNPA3 heterogeneous nuclear 
ribonucleoprotein A3 
-0.466998425 9.67E-05 0.01036225
8 
209068_at HNRNPDL heterogeneous nuclear 
ribonucleoprotein D-like 
-0.411190162 2.83E-05 0.00755393
3 
213472_at HNRNPH1 heterogeneous nuclear 
ribonucleoprotein H1 (H) 
-0.251006256 0.00011141
7 
0.01078976
3 
235603_at HNRNPU heterogeneous nuclear 
ribonucleoprotein U (scaffold 
attachment factor A) 
-0.434544484 4.69E-05 0.00823489
7 
205580_s_at HRH1 histamine receptor H1 0.204827226 2.42E-05 0.00722109
4 
200064_at HSP90AB1 heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
-0.526683057 3.82E-06 0.00544715
7 
214359_s_at HSP90AB1 heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
-0.58161724 6.98E-06 0.00606328
8 
1557910_at HSP90AB1 heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
-0.624542656 5.34E-05 0.00849720
4 
211728_s_at HYAL3 hyaluronoglucosaminidase 3 0.275685263 4.61E-05 0.00818619
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5 
211693_at IGH immunoglobulin heavy locus 0.330791865 6.18E-05 0.00905041
5 
209374_s_at IGHM immunoglobulin heavy constant 
mu 
-0.999878579 4.50E-06 0.00558624
8 
212827_at IGHM immunoglobulin heavy constant 
mu 
-1.326467867 9.48E-06 0.00649251
9 
227344_at IKZF1 IKAROS family zinc finger 1 (Ikaros) -0.306860047 2.61E-05 0.00738187
7 
205039_s_at IKZF1 IKAROS family zinc finger 1 (Ikaros) -0.416138023 6.32E-05 0.00914249 
227030_at IKZF3 IKAROS family zinc finger 3 (Aiolos) -0.519285046 2.18E-05 0.00698565
1 
220663_at IL1RAPL1 interleukin 1 receptor accessory 
protein-like 1 
0.378538632 2.93E-05 0.00774683
2 
230966_at IL4I1 interleukin 4 induced 1 0.317913382 5.69E-05 0.00873569
3 
204863_s_at IL6ST interleukin 6 signal transducer 
(gp130, oncostatin M receptor) 
-0.556447548 2.63E-05 0.00738187
7 
217805_at ILF3 interleukin enhancer binding factor 
3, 90kDa 
-0.543051101 8.06E-06 0.00643964
7 
214705_at INADL InaD-like (Drosophila) -0.493182156 0.00011142
7 
0.01078976
3 
202781_s_at INPP5K inositol polyphosphate-5-
phosphatase K 
0.220926284 5.22E-05 0.00844074
5 
217885_at IPO9 importin 9 -0.379001483 2.21E-05 0.00698565
1 
236767_at IQCF2 IQ motif containing F2 0.317469991 1.78E-05 0.00657219
8 
223597_at ITLN1 intelectin 1 (galactofuranose 
binding) 
0.533194227 3.60E-05 0.00793218
5 
203723_at ITPKB inositol-trisphosphate 3-kinase B -0.362102492 1.07E-05 0.00649251
9 
235213_at ITPKB inositol-trisphosphate 3-kinase B -0.466134069 6.05E-05 0.00898360
7 
240052_at ITPR1 inositol 1,4,5-trisphosphate 
receptor, type 1 
-0.617995157 5.44E-07 0.00363219
8 
228074_at ITPRIPL2 inositol 1,4,5-trisphosphate 
receptor interacting protein-like 2 
0.257475032 4.56E-05 0.00817169
5 
212660_at JADE2 jade family PHD finger 2 -0.56361616 7.73E-07 0.00364212
1 
232279_at JADE2 jade family PHD finger 2 -0.482609317 4.15E-06 0.00544715
7 
209097_s_at JAG1 jagged 1 0.333511904 2.61E-05 0.00738187
7 
221068_at KANK2 KN motif and ankyrin repeat 
domains 2 
0.335290445 7.87E-05 0.00960196
8 
208560_at KCNA10 potassium voltage-gated channel, 
shaker-related subfamily, member 
10 
0.302816681 5.36E-05 0.00849720
4 
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205968_at KCNS3 potassium voltage-gated channel, 
delayed-rectifier, subfamily S, 
member 3 
0.260977878 3.56E-05 0.00793218
5 
214861_at KDM4C lysine (K)-specific demethylase 4C -0.314236669 9.58E-05 0.01033473
3 
223161_at KIAA1147 KIAA1147 -0.356506618 6.97E-05 0.00919527
9 
235956_at KIAA1377 KIAA1377 -0.294197572 3.49E-05 0.00793218
5 
210504_at KLF1 Kruppel-like factor 1 (erythroid) 0.692994359 9.09E-05 0.01014370
3 
209254_at KLHDC10 kelch domain containing 10 0.380661547 4.77E-05 0.00824477
7 
221221_s_at KLHL3 kelch-like family member 3 -0.380996345 3.01E-05 0.00776252
7 
219692_at KREMEN2 kringle containing transmembrane 
protein 2 
0.213821988 8.47E-05 0.00978649
3 
222427_s_at LARS leucyl-tRNA synthetase -0.458020559 1.50E-05 0.00652388
8 
222428_s_at LARS leucyl-tRNA synthetase -0.484242977 4.82E-05 0.00829227
7 
57082_at LDLRAP1 low density lipoprotein receptor 
adaptor protein 1 
-0.485918345 3.39E-06 0.00544715
7 
221790_s_at LDLRAP1 low density lipoprotein receptor 
adaptor protein 1 
-0.400002032 6.74E-05 0.00919527
9 
221558_s_at LEF1 lymphoid enhancer-binding factor 
1 
-0.705786773 3.60E-05 0.00793218
5 
231760_at LINC00029 long intergenic non-protein coding 
RNA 29 
0.255109118 8.21E-05 0.00976116
4 
230245_s_at LINC00926 long intergenic non-protein coding 
RNA 926 
-0.95766674 2.37E-05 0.00722109
4 
227933_at LINGO1 leucine rich repeat and Ig domain 
containing 1 
0.282439379 1.40E-05 0.00649251
9 
243703_x_at LIPE-AS1 LIPE antisense RNA 1 0.196463345 4.85E-05 0.00829227
7 
243523_at LOC10012864
4 
LMNE6487 0.318268467 7.00E-05 0.00919527
9 
1558569_at LOC10013154
1 
uncharacterized LOC100131541 -0.514351109 5.78E-05 0.00879596
5 
237977_at LOC10099634
9 
testis expressed 264 pseudogene 0.296979507 2.19E-05 0.00698565
1 
228808_s_at LOXL2 lysyl oxidase-like 2 0.304366291 4.55E-05 0.00817169
5 
230252_at LPAR5 lysophosphatidic acid receptor 5 -0.415732602 4.66E-05 0.00823489
7 
219922_s_at LTBP3 latent transforming growth factor 
beta binding protein 3 
-0.513151377 5.48E-06 0.00592514 
206480_at LTC4S leukotriene C4 synthase 0.217934899 0.00010185
2 
0.01051422
6 
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1557067_s_a
t 
LUC7L LUC7-like (S. cerevisiae) -0.360993579 4.93E-05 0.00833877 
231840_x_at LYRM7 LYR motif containing 7 -0.398090127 0.00010321
9 
0.01051422
6 
235457_at MAML2 mastermind-like 2 (Drosophila) -0.415702498 7.91E-05 0.00962763
6 
238993_at MATR3 matrin 3 0.30822919 1.30E-05 0.00649251
9 
205655_at MDM4 MDM4, p53 regulator -0.544074949 2.79E-05 0.00754910
1 
236814_at MDM4 MDM4, p53 regulator -0.475153913 0.00011021
8 
0.01078022
5 
212693_at MDN1 MDN1, midasin homolog (yeast) -0.429456993 8.85E-06 0.00649251
9 
1569484_s_a
t 
MDN1 MDN1, midasin homolog (yeast) -0.435067498 9.46E-05 0.01029788
7 
203496_s_at MED1 mediator complex subunit 1 -0.282987039 3.03E-05 0.00776252
7 
225452_at MED1 mediator complex subunit 1 -0.364159712 4.42E-05 0.00817169
5 
203497_at MED1 mediator complex subunit 1 -0.469369383 0.00010153
1 
0.01051422
6 
226744_at METTL16 methyltransferase like 16 -0.422281378 1.34E-05 0.00649251
9 
222042_x_at MEX3D mex-3 RNA binding family member 
D 
0.285693523 8.05E-05 0.00969425
4 
235409_at MGA MGA, MAX dimerization protein -0.441315705 3.83E-05 0.00793218
5 
231283_at MGAT4A mannosyl (alpha-1,3-)-glycoprotein 
beta-1,4-N-
acetylglucosaminyltransferase, 
isozyme A 
-0.296731093 0.00011431
7 
0.01085116
4 
212098_at MGAT5 mannosyl (alpha-1,6-)-glycoprotein 
beta-1,6-N-acetyl-
glucosaminyltransferase 
-0.286738537 6.89E-05 0.00919527
9 
1569652_at MLLT3 myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog, Drosophila); translocated 
to, 3 
-0.496122852 8.58E-05 0.00983175 
202167_s_at MMS19 MMS19 nucleotide excision repair 
homolog (S. cerevisiae) 
-0.327500445 9.12E-06 0.00649251
9 
203956_at MORC2 MORC family CW-type zinc finger 2 -0.39617249 1.33E-05 0.00649251
9 
225041_at MPHOSPH8 M-phase phosphoprotein 8 -0.519073965 8.00E-05 0.00969425
4 
243801_x_at MRPL30 mitochondrial ribosomal protein 
L30 
-0.430521081 7.35E-05 0.00935076
1 
217418_x_at MS4A1 membrane-spanning 4-domains, 
subfamily A, member 1 
-1.112188072 5.98E-06 0.00600751
2 
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210356_x_at MS4A1 membrane-spanning 4-domains, 
subfamily A, member 1 
-1.092374741 1.14E-05 0.00649251
9 
231418_at MS4A1 membrane-spanning 4-domains, 
subfamily A, member 1 
-0.800582465 1.90E-05 0.00678133
4 
228592_at MS4A1 membrane-spanning 4-domains, 
subfamily A, member 1 
-1.423438894 6.41E-05 0.00916657
9 
225240_s_at MSI2 musashi RNA-binding protein 2 -0.533898671 4.58E-05 0.00818619
5 
202431_s_at MYC v-myc avian myelocytomatosis viral 
oncogene homolog 
-0.592490345 4.92E-07 0.00363219
8 
201959_s_at MYCBP2 MYC binding protein 2, E3 ubiquitin 
protein ligase 
-0.486500503 3.80E-06 0.00544715
7 
201960_s_at MYCBP2 MYC binding protein 2, E3 ubiquitin 
protein ligase 
-0.436992278 4.41E-05 0.00817169
5 
213613_s_at NADK NAD kinase 0.274914967 3.58E-05 0.00793218
5 
238722_x_at NAPEPLD N-acyl phosphatidylethanolamine 
phospholipase D 
-0.576017953 3.42E-06 0.00544715
7 
212854_x_at NBPF1 neuroblastoma breakpoint family, 
member 1 
-0.353971714 9.94E-05 0.01046860
4 
242191_at NBPF10 neuroblastoma breakpoint family, 
member 10 
-0.591032863 9.05E-06 0.00649251
9 
211105_s_at NFATC1 nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 
1 
-0.347685471 4.24E-06 0.00544715
7 
225876_at NIPAL3 NIPA-like domain containing 3 -0.487868543 9.48E-06 0.00649251
9 
234762_x_at NLN neurolysin (metallopeptidase M3 
family) 
-0.52211926 7.81E-05 0.00957385
3 
231798_at NOG noggin -0.590006121 2.25E-05 0.00702334
1 
211951_at NOLC1 nucleolar and coiled-body 
phosphoprotein 1 
-0.37959983 9.47E-05 0.01029788
7 
229220_x_at NOM1 nucleolar protein with MIF4G 
domain 1 
-0.362244923 8.39E-05 0.00978649
3 
214427_at NOP2 NOP2 nucleolar protein -0.339299058 3.86E-05 0.00793218
5 
210808_s_at NOX1 NADPH oxidase 1 0.250506077 5.14E-05 0.00841445
3 
204538_x_at NPIPA1 nuclear pore complex interacting 
protein family, member A1 
-0.38699399 2.74E-05 0.00748157
3 
215921_at NPIPB3 nuclear pore complex interacting 
protein family, member B3 
-0.431076797 0.00010335
5 
0.01051422
6 
229122_x_at NPRL3 nitrogen permease regulator-like 3 
(S. cerevisiae) 
0.306761196 8.63E-05 0.00984667
9 
209261_s_at NR2F6 nuclear receptor subfamily 2, 
group F, member 6 
0.229121513 9.75E-05 0.01041378
7 
226499_at NRARP NOTCH-regulated ankyrin repeat 
protein 
0.28415589 8.45E-05 0.00978649
3 
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203802_x_at NSUN5 NOP2/Sun domain family, member 
5 
-0.313367587 6.04E-06 0.00600751
2 
213670_x_at NSUN5P1 NOP2/Sun domain family, member 
5 pseudogene 1 
-0.38727319 3.11E-05 0.00776252
7 
234496_x_at NYX nyctalopin 0.360611808 8.39E-05 0.00978649
3 
239748_x_at OCIAD1 OCIA domain containing 1 -0.401248072 9.27E-05 0.01020214
3 
1565065_at OFCC1 orofacial cleft 1 candidate 1 0.243983021 0.00011117
3 
0.01078976
3 
241751_at OFD1 oral-facial-digital syndrome 1 -0.608050623 3.03E-05 0.00776252
7 
225106_s_at OGFOD1 2-oxoglutarate and iron-dependent 
oxygenase domain containing 1 
-0.393230181 2.20E-05 0.00698565
1 
1569617_at OSBP2 oxysterol binding protein 2 0.288132635 6.47E-05 0.00916657
9 
219073_s_at OSBPL10 oxysterol binding protein-like 10 -0.813152852 4.27E-05 0.00815159
8 
221209_s_at OTOR otoraplin 0.314067788 0.00010698
4 
0.01063539
4 
227686_at OXNAD1 oxidoreductase NAD-binding 
domain containing 1 
-0.440066938 1.12E-05 0.00649251
9 
210448_s_at P2RX5 purinergic receptor P2X, ligand-
gated ion channel, 5 
-0.72013783 1.57E-06 0.00457243
6 
232683_s_at PARP6 poly (ADP-ribose) polymerase 
family, member 6 
-0.312101792 5.66E-05 0.00873569
3 
221969_at PAX5 paired box 5 -0.952108039 3.84E-06 0.00544715
7 
235482_at PCBP1-AS1 PCBP1 antisense RNA 1 -0.482781755 2.73E-05 0.00748157
3 
222380_s_at PDCD6 programmed cell death 6 -0.393322931 6.45E-05 0.00916657
9 
1552343_s_a
t 
PDE7A phosphodiesterase 7A -0.346973621 7.63E-05 0.00948145
4 
223619_x_at PECR peroxisomal trans-2-enoyl-CoA 
reductase 
-0.339891001 9.30E-05 0.01021157
1 
209346_s_at PI4K2A phosphatidylinositol 4-kinase type 
2 alpha 
0.261239358 6.75E-05 0.00919527
9 
209018_s_at PINK1 PTEN induced putative kinase 1 0.364308832 8.45E-05 0.00978649
3 
227419_x_at PLAC9 placenta-specific 9 0.261871268 7.08E-05 0.00921266
3 
1557126_a_
at 
PLD1 phospholipase D1, 
phosphatidylcholine-specific 
0.233744872 3.12E-05 0.00776252
7 
226122_at PLEKHG1 pleckstrin homology domain 
containing, family G (with RhoGef 
domain) member 1 
-0.328136583 1.25E-05 0.00649251
9 
216843_x_at PMS2P1 postmeiotic segregation increased 
2 pseudogene 1 
-0.37162667 2.49E-05 0.00735058
3 
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217485_x_at PMS2P1 postmeiotic segregation increased 
2 pseudogene 1 
-0.283501796 3.40E-05 0.00788573
7 
212177_at PNISR PNN-interacting serine/arginine-
rich protein 
-0.475076915 4.61E-05 0.00818619
5 
225507_at PNISR PNN-interacting serine/arginine-
rich protein 
-0.341568865 6.97E-05 0.00919527
9 
205267_at POU2AF1 POU class 2 associating factor 1 -1.04247299 3.89E-05 0.00793218
5 
37152_at PPARD peroxisome proliferator-activated 
receptor delta 
-0.297888757 6.96E-05 0.00919527
9 
226773_at PPM1K protein phosphatase, Mg2+/Mn2+ 
dependent, 1K 
-0.511916974 2.08E-05 0.00681065
8 
235061_at PPM1K protein phosphatase, Mg2+/Mn2+ 
dependent, 1K 
-0.726983464 0.00010606
6 
0.01062351 
229001_at PPP1R3E protein phosphatase 1, regulatory 
subunit 3E 
-0.432051845 3.55E-06 0.00544715
7 
227412_at PPP1R3E protein phosphatase 1, regulatory 
subunit 3E 
-0.372991128 1.21E-05 0.00649251
9 
213093_at PRKCA protein kinase C, alpha -0.512082012 2.73E-05 0.00748157
3 
212068_s_at PRRC2B proline-rich coiled-coil 2B -0.276950594 4.16E-06 0.00544715
7 
214055_x_at PRRC2C proline-rich coiled-coil 2C -0.430957432 6.26E-05 0.00909641
6 
211948_x_at PRRC2C proline-rich coiled-coil 2C -0.400712638 9.18E-05 0.01015928
2 
226491_x_at PTBP1 polypyrimidine tract binding 
protein 1 
0.210336454 9.26E-05 0.01020214
3 
238754_at PTCH1 patched 1 0.38726248 2.61E-05 0.00738187
7 
234000_s_at PTPLAD1 protein tyrosine phosphatase-like A 
domain containing 1 
-0.496474236 7.83E-05 0.00957385
3 
239526_x_at PTPN1 protein tyrosine phosphatase, non-
receptor type 1 
0.262946747 1.04E-05 0.00649251
9 
201164_s_at PUM1 pumilio RNA-binding family 
member 1 
-0.321931161 0.00011700
2 
0.01099154
2 
218949_s_at QRSL1 glutaminyl-tRNA synthase 
(glutamine-hydrolyzing)-like 1 
-0.442270284 7.09E-05 0.00921266
3 
1556122_at RAB11B-AS1 RAB11B antisense RNA 1 0.23101354 4.50E-05 0.00817169
5 
229072_at RAB30 RAB30, member RAS oncogene 
family 
-0.665492593 4.23E-06 0.00544715
7 
228390_at RAB30 RAB30, member RAS oncogene 
family 
-0.725204554 3.60E-05 0.00793218
5 
74694_s_at RABEP2 rabaptin, RAB GTPase binding 
effector protein 2 
-0.587874223 7.38E-05 0.00935500
8 
226090_x_at RABL3 RAB, member of RAS oncogene 
family-like 3 
-0.359080371 8.05E-06 0.00643964
7 
202482_x_at RANBP1 RAN binding protein 1 0.333432015 3.94E-05 0.00793218
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5 
208206_s_at RASGRP2 RAS guanyl releasing protein 2 
(calcium and DAG-regulated) 
-0.410068928 1.07E-05 0.00649251
9 
205801_s_at RASGRP3 RAS guanyl releasing protein 3 
(calcium and DAG-regulated) 
-0.469693555 3.51E-05 0.00793218
5 
205178_s_at RBBP6 retinoblastoma binding protein 6 -0.379184711 8.27E-06 0.00643964
7 
212783_at RBBP6 retinoblastoma binding protein 6 -0.421076872 1.44E-05 0.00649251
9 
216153_x_at RECK reversion-inducing-cysteine-rich 
protein with kazal motifs 
-0.238139538 9.99E-05 0.01050092
1 
236690_at RHBDD1 rhomboid domain containing 1 0.314583324 7.76E-05 0.00957385
3 
220510_at RHBG Rh family, B glycoprotein 
(gene/pseudogene) 
0.295950502 6.62E-05 0.00917319
8 
210430_x_at RHD Rh blood group, D antigen 0.408141193 2.34E-05 0.00719300
1 
236293_at RHOH ras homolog family member H -0.639756696 4.48E-05 0.00817169
5 
205211_s_at RIN1 Ras and Rab interactor 1 0.343377143 5.20E-06 0.00592514 
207735_at RNF125 ring finger protein 125, E3 ubiquitin 
protein ligase 
-0.353981086 7.14E-05 0.00921266
3 
238055_at RP11-35G9.3 uncharacterized LOC100505549 -0.382736444 3.05E-05 0.00776252
7 
1560337_at RP11-
579E24.1 
uncharacterized LOC286184 0.255707843 9.84E-05 0.01043785
6 
200003_s_at RPL28 ribosomal protein L28 -0.491367012 7.82E-05 0.00957385
3 
226078_at RPUSD1 RNA pseudouridylate synthase 
domain containing 1 
0.243727986 9.79E-05 0.01043470
2 
213495_s_at RRBP1 ribosome binding protein 1 0.251436629 8.19E-05 0.00976116
4 
209773_s_at RRM2 ribonucleotide reductase M2 0.302760075 5.13E-05 0.00841445
3 
212846_at RRP1B ribosomal RNA processing 1B -0.587984837 3.36E-05 0.00784970
6 
222789_at RSBN1 round spermatid basic protein 1 -0.431389282 2.93E-06 0.00544715
7 
230700_at RTN4RL1 reticulon 4 receptor-like 1 0.368751512 3.70E-05 0.00793218
5 
218677_at S100A14 S100 calcium binding protein A14 0.302917519 1.41E-05 0.00649251
9 
203408_s_at SATB1 SATB homeobox 1 -0.425846308 3.08E-05 0.00776252
7 
232992_at SAYSD1 SAYSVFN motif domain containing 
1 
0.251863532 1.92E-05 0.00679128
8 
1569225_a_
at 
SCML4 sex comb on midleg-like 4 
(Drosophila) 
-0.653984768 3.59E-05 0.00793218
5 
224029_x_at SCN11A sodium channel, voltage-gated, -0.151498324 0.00010473 0.01060070
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type XI, alpha subunit 4 3 
212314_at SEL1L3 sel-1 suppressor of lin-12-like 3 (C. 
elegans) 
-0.682941456 6.04E-05 0.00898360
7 
235684_s_at SESN3 sestrin 3 0.649850264 8.38E-05 0.00978649
3 
221806_s_at SETD5 SET domain containing 5 -0.334765544 0.00010510
2 
0.01060227
7 
208313_s_at SF1 splicing factor 1 -0.393656849 3.79E-05 0.00793218
5 
215454_x_at SFTPC surfactant protein C 0.356717469 0.00010695
9 
0.01063539
4 
219734_at SIDT1 SID1 transmembrane family, 
member 1 
-0.485749263 0.00010489
2 
0.01060070
3 
52940_at SIGIRR single immunoglobulin and toll-
interleukin 1 receptor (TIR) domain 
-0.395139839 3.37E-05 0.00784970
6 
1563498_s_a
t 
SLC25A45 solute carrier family 25, member 
45 
-0.424836621 2.01E-05 0.00679128
8 
207560_at SLC28A1 solute carrier family 28 
(concentrative nucleoside 
transporter), member 1 
0.316246373 5.98E-07 0.00363219
8 
218237_s_at SLC38A1 solute carrier family 38, member 1 -0.637173145 1.20E-05 0.00649251
9 
222935_x_at SLC39A8 solute carrier family 39 (zinc 
transporter), member 8 
0.250769992 0.00010346 0.01051422
6 
234291_s_at SLC6A20 solute carrier family 6 (proline 
IMINO transporter), member 20 
0.374834393 1.71E-05 0.00652388
8 
206565_x_at SMA4 glucuronidase, beta pseudogene -0.398084569 7.43E-05 0.00938252
4 
214728_x_at SMARCA4 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, subfamily 
a, member 4 
-0.238489293 0.00010539
1 
0.01061189
4 
215383_x_at SPG21 spastic paraplegia 21 (autosomal 
recessive, Mast syndrome) 
-0.247742114 6.89E-05 0.00919527
9 
205861_at SPIB Spi-B transcription factor (Spi-
1/PU.1 related) 
-0.471726559 3.27E-05 0.00783497
4 
202524_s_at SPOCK2 sparc/osteonectin, cwcv and kazal-
like domains proteoglycan 
(testican) 2 
-0.522745927 8.04E-05 0.00969425
4 
212071_s_at SPTBN1 spectrin, beta, non-erythrocytic 1 -0.600229037 4.54E-05 0.00817169
5 
224145_s_at SPTBN4 spectrin, beta, non-erythrocytic 4 0.327763039 7.26E-05 0.00925507
9 
222047_s_at SRRT serrate RNA effector molecule 
homolog (Arabidopsis) 
-0.396830354 8.11E-05 0.00969849
9 
201680_x_at SRRT serrate RNA effector molecule 
homolog (Arabidopsis) 
-0.346178403 9.52E-05 0.01031292
4 
213649_at SRSF7 serine/arginine-rich splicing factor 
7 
-0.561980049 3.70E-05 0.00793218
5 
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211670_x_at SSX3 synovial sarcoma, X breakpoint 3 0.297606746 6.99E-05 0.00919527
9 
220059_at STAP1 signal transducing adaptor family 
member 1 
-0.760330756 2.95E-05 0.00774683
2 
233252_s_at STRBP spermatid perinuclear RNA binding 
protein 
-0.625885419 4.72E-06 0.00573092
9 
233251_at STRBP spermatid perinuclear RNA binding 
protein 
-0.427149645 1.14E-05 0.00649251
9 
229513_at STRBP spermatid perinuclear RNA binding 
protein 
-0.87095208 1.98E-05 0.00679128
8 
223548_at SWT1 SWT1 RNA endoribonuclease 
homolog (S. cerevisiae) 
0.277938209 8.30E-05 0.00978649
3 
222715_s_at SYNRG synergin, gamma -0.530678994 3.71E-05 0.00793218
5 
64418_at SYNRG synergin, gamma -0.417960808 3.72E-05 0.00793218
5 
201259_s_at SYPL1 synaptophysin-like 1 -0.420077785 0.00010172
7 
0.01051422
6 
1562255_at SYTL3 synaptotagmin-like 3 -0.494659965 1.74E-05 0.00656668
7 
237091_at TBC1D9 TBC1 domain family, member 9 
(with GRAM domain) 
0.332708125 9.65E-05 0.01036225
8 
220634_at TBX4 T-box 4 0.319121387 6.70E-05 0.00919527
9 
212386_at TCF4 transcription factor 4 -0.594537057 4.74E-05 0.00824477
7 
205254_x_at TCF7 transcription factor 7 (T-cell 
specific, HMG-box) 
-0.498578743 2.02E-06 0.00480480
4 
205255_x_at TCF7 transcription factor 7 (T-cell 
specific, HMG-box) 
-0.662699679 3.23E-05 0.00778273
9 
39318_at TCL1A T-cell leukemia/lymphoma 1A -0.977364696 4.52E-05 0.00817169
5 
209995_s_at TCL1A T-cell leukemia/lymphoma 1A -0.912314963 0.00010317
5 
0.01051422
6 
1553007_a_
at 
TENM1 teneurin transmembrane protein 1 0.284576884 5.35E-05 0.00849720
4 
207883_s_at TFR2 transferrin receptor 2 0.299146671 8.56E-05 0.00983175 
217567_at TGM4 transglutaminase 4 0.314926017 9.38E-05 0.01025384
6 
222122_s_at THOC2 THO complex 2 -0.428635026 4.07E-05 0.00797084
6 
215168_at TIMM17A translocase of inner mitochondrial 
membrane 17 homolog A (yeast) 
0.175341251 2.03E-05 0.00679128
8 
222904_s_at TMC5 transmembrane channel-like 5 0.246635076 8.30E-05 0.00978649
3 
227353_at TMC8 transmembrane channel-like 8 -0.466475369 0.00010787
1 
0.01066522
5 
224493_x_at TMEM241 transmembrane protein 241 -0.291964579 4.42E-05 0.00817169
5 
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Change) 
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214833_at TMEM63A transmembrane protein 63A -0.469887613 6.77E-06 0.00606328
8 
231775_at TNFRSF10A tumor necrosis factor receptor 
superfamily, member 10a 
-0.521556159 4.47E-05 0.00817169
5 
209225_x_at TNPO1 transportin 1 -0.302582222 0.00011198
6 
0.01078976
3 
221829_s_at TNPO1 transportin 1 -0.395480058 0.00011592
5 
0.01096576 
238468_at TNRC6B trinucleotide repeat containing 6B -0.378292168 1.66E-05 0.00652388
8 
230779_at TNRC6B trinucleotide repeat containing 6B -0.424240404 4.00E-05 0.00793218
5 
222820_at TNRC6C trinucleotide repeat containing 6C -0.486061295 6.90E-05 0.00919527
9 
242364_x_at TNRC6C-AS1 TNRC6C antisense RNA 1 -0.354561084 2.34E-05 0.00719300
1 
215275_at TRAF3IP3 TRAF3 interacting protein 3 -0.423073431 4.83E-05 0.00829227
7 
240265_at TRAF3IP3 TRAF3 interacting protein 3 -0.618139183 6.12E-05 0.00902189
9 
205804_s_at TRAF3IP3 TRAF3 interacting protein 3 -0.404212455 0.00010438
1 
0.01058815
6 
200990_at TRIM28 tripartite motif containing 28 -0.367754296 3.69E-05 0.00793218
5 
217759_at TRIM44 tripartite motif containing 44 -0.429987772 1.52E-05 0.00652388
8 
217760_at TRIM44 tripartite motif containing 44 -0.284441617 6.91E-05 0.00919527
9 
219405_at TRIM68 tripartite motif containing 68 -0.337082154 3.94E-05 0.00793218
5 
1554250_s_a
t 
TRIM73 tripartite motif containing 73 -0.620773737 4.96E-05 0.00833877 
232489_at TRMT13 tRNA methyltransferase 13 
homolog (S. cerevisiae) 
-0.63902291 3.95E-05 0.00793218
5 
233617_at TSPY26P testis specific protein, Y-linked 26, 
pseudogene 
0.264522948 5.54E-05 0.00866317
8 
232323_s_at TTC17 tetratricopeptide repeat domain 17 -0.440262054 6.51E-06 0.00603407
8 
210389_x_at TUBD1 tubulin, delta 1 -0.28335485 5.83E-05 0.00881771 
212337_at TUG1 taurine up-regulated 1 (non-
protein coding) 
-0.333775066 5.38E-05 0.00850505
6 
244199_at TWF1 twinfilin actin-binding protein 1 0.366021401 0.00010150
7 
0.01051422
6 
210065_s_at UPK1B uroplakin 1B 0.300377871 1.64E-05 0.00652388
8 
208723_at USP11 ubiquitin specific peptidase 11 -0.317653056 3.76E-05 0.00793218
5 
226477_at VPRBP Vpr (HIV-1) binding protein -0.389907839 3.51E-05 0.00793218
5 
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1560059_at VPS37C vacuolar protein sorting 37 
homolog C (S. cerevisiae) 
0.322119039 9.13E-05 0.01015928
2 
242211_x_at WDR90 WD repeat domain 90 0.294756164 9.32E-05 0.01021297
3 
206698_at XK X-linked Kx blood group (McLeod 
syndrome) 
0.982140408 0.00011635
9 
0.01097238
3 
221939_at YIPF2 Yip1 domain family, member 2 0.255451089 5.72E-05 0.00874109
6 
219075_at YIPF2 Yip1 domain family, member 2 0.344417961 9.47E-05 0.01029788
7 
212340_at YIPF6 Yip1 domain family, member 6 0.378058588 1.59E-06 0.00457243
6 
1557065_at YLPM1 YLP motif containing 1 -0.455025125 1.17E-05 0.00649251
9 
212787_at YLPM1 YLP motif containing 1 -0.390242172 0.00010848
6 
0.01070418
5 
235308_at ZBTB20 zinc finger and BTB domain 
containing 20 
-0.511911858 4.54E-07 0.00363219
8 
205383_s_at ZBTB20 zinc finger and BTB domain 
containing 20 
-0.418530764 1.82E-05 0.00661945
1 
222357_at ZBTB20 zinc finger and BTB domain 
containing 20 
-0.544804149 4.29E-05 0.00815159
8 
213051_at ZC3HAV1 zinc finger CCCH-type, antiviral 1 -0.438161238 0.00011397
7 
0.01085116
4 
230332_at ZCCHC7 zinc finger, CCHC domain 
containing 7 
-0.592734231 1.37E-05 0.00649251
9 
218077_s_at ZDHHC3 zinc finger, DHHC-type containing 3 0.26795685 3.05E-05 0.00776252
7 
202456_s_at ZER1 zyg-11 related, cell cycle regulator 0.406221836 3.20E-05 0.00777537
2 
214142_at ZG16 zymogen granule protein 16 0.335494741 2.78E-05 0.00754910
1 
209049_s_at ZMYND8 zinc finger, MYND-type containing 
8 
-0.376690366 4.32E-05 0.00815159
8 
239231_at ZNF101 zinc finger protein 101 -0.531112138 4.19E-05 0.00810037
8 
217403_s_at ZNF227 zinc finger protein 227 -0.326091382 7.17E-05 0.00922432
1 
239145_at ZNF414 zinc finger protein 414 0.40571468 3.76E-05 0.00793218
5 
217627_at ZNF573 zinc finger protein 573 -0.642804494 1.13E-05 0.00649251
9 
223366_at ZNF704 zinc finger protein 704 0.267992843 1.97E-05 0.00679128
8 
227734_s_at ZNHIT2 zinc finger, HIT-type containing 2 0.285455678 0.00010742
9 
0.01064077
4 
      
 
